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Abstract 
 
Stroke is a common disorder with dire consequences for the patient and for society and will 
increase  in  prevalence  over  the  coming  years.  Following  stroke,  many  patients 
unfortunately suffer a further stroke, and recurrent strokes account for approximately 25% 
of the total. Considerable scope therefore exists to improve both primary and secondary 
stroke prevention.  This thesis has addressed several areas at key stages in the prevention of 
stroke by developing strategies to better identify those at highest risk, attempting to better 
target pre-existing anti-platelet therapy and by beginning the evaluation of xanthine oxidase 
reduction and uric acid lowering therapy in the prevention of stroke. 
 
A clinical scoring system to aid diagnostic recognition in those with suspected transient 
ischaemic attack (TIA) was successfully developed and has the ability to reduce the referral 
of those without cerebrovascular disease to busy TIA clinics. The score was developed on 
data  from  3216  patients  and  included  9  clinically  useful  predictive  variables.  After 
adjustment to reflect the greater seriousness of missing true TIA patients, 97% of TIA and 
22% of non-TIA patients were accurately identified. The results were confirmed during 
prospective validation. Use of the score could have a substantial effect on waiting times for 
assessment; there is potential double the numbers seen within the timeframe recommended 
by guidelines with no other change to services. This would be an important advance given 
the recent evidence that rapid assessment and treatment of those with TIA greatly reduces 
stroke risk.  
 
Aspirin  resistance  was  found  to  be  higher  in  those  with  cerebrovascular  microembolic 
signals (MES) and carotid disease compared to those with equivalent carotid disease and no   - 23 - 
MES. This study included sixty-two patients who mostly had symptomatic carotid disease. 
Approximately a quarter had MES. The rate of aspirin resistance on at least one test was 
25.8%  (16  patients),  with  13  (21%)  resistant  on  PFA-100  testing,  8  (12.9%)  using  the 
Verify-Now system and 5 (8.1%) resistant on both. Aspirin resistance was more common in 
patients with MES (50% compared to 17.4% without, p=0.018 on Fishers exact test). This 
provides a link to a well established and robust surrogate marker of outcome and thus a 
useful  model  to  further  study  the  benefits  of  guided  anti-platelet  strategies.  An 
interventional  clinical  anti-platelet  trial  based  upon  individual  aspirin  responsiveness  in 
high risk individuals such as those with MES is now warranted. Aspirin resistance was also 
confirmed to be a common phenomenon in a case-control study of 180 patients. It was 
present in 34% of those with recent stroke and in 18% of those with risk factors but no 
established disease. However, the role of poor compliance with therapy as a cause in a 
substantial number of cases was established; it accounted for approximately half of those 
labelled resistant in the stroke group. Further, when only those with objective evidence of 
recent aspirin ingestion were considered, the prevalence of aspirin resistance was similar in 
both groups (at 26%). This suggests that objective measures to confirm compliance with 
aspirin therapy should be mandatory in future studies of aspirin resistance.   
 
Increasing  serum  uric  acid  was  found  to  be  a  predictor  of  poor  functional  outcome 
following  acute  stroke  but  not  in  an  independent  fashion.  In  total,  852  patients  were 
included in this study and greater uric acid levels were associated with increased odds of 
poor  outcome  on  univariate  but  not  multivariate  analysis  (OR  1.3,  95%  CI  0.73-2.31). 
However, there was no evidence of an association with favourable outcome as other groups 
have found. Increasing serum uric acid was also shown to be predictive of increased risk of 
stroke,  total,  vascular  and  coronary  mortality  in  treated  hypertensive  patients  but   - 24 - 
interestingly,  the  relationship  between  stroke  mortality  and  serum  uric  acid  appears  J-
shaped and most apparent in females. 
   
A  study  of the  use  of  allopurinol  in those  with  diabetes  showed that  xanthine  oxidase 
inhibition improves cerebral nitric oxide bioavailability suggesting a beneficial effect of 
allopurinol  on  cerebrovascular  health.  This  study  included  14  participants  who  had 
impaired  baseline  cerebrovascular  nitric  oxide  bioavailability.  Allopurinol  led  to  a 
significant  improvement  in  responses  to  NG-monomethyl-L-arginine  (L-NMMA)  when 
compared to placebo (p=0.032, median improvement in ICA flow reduction following L-
NMMA of 3144 (95% CI 375 to 7143)) mls). L-NMMA is an inhibitor of endothelial nitric 
oxide synthase which reduces cerebral blood flow in healthy volunteers; the bigger the 
reduction, the greater the endothelial health. However, a study of the effect of allopurinol 
treatment  on  cerebrovascular  reactivity  (as  measured  by  response  to  acetazolamide 
infusion) in a group of patients with recent subcortical stroke revealed no positive effect.  
Cerebrovascular  reactivity  was  unchanged  by  treatment  with  allopurinol.  This  raises 
interesting questions regarding the longevity of any positive effect of allopurinol as this, 
and other studies of 3 month duration, have revealed no benefit. Further, subjects in this 
study did not, on balance, have elevated serum uric acid and it has recently been suggested 
that only those with significantly elevated levels benefit in the setting of congestive cardiac 
failure.  Whether this is also true in those with stroke also requires to be clarified. A large 
study of the effect of allopurinol on carotid intima-media thickness, a robust and modifiable 
marker of vascular risk, in those with recent stroke is planned to address these questions. 
 
The studies in this thesis therefore include a number of pragmatic findings which could 
improve  care  at  all  stages  in  the  prevention  of  stroke.  The  TIA  scoring  system  could   - 25 - 
improve recognition of the high risk condition TIA, a useful model has been developed in 
which to study a population of patients truly resistant to aspirin and important lessons have 
been learned to aid further evaluation of xanthine oxidase inhibition; a promising therapy 
for the prevention of stroke.   - 26 - 
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A stroke is defined by the World Health Organization (WHO) as a syndrome of “rapidly 
developing  clinical  symptoms  and/or  signs  of  focal  (or  at  times  global)  disturbance  of 
cerebral function lasting more than 24 hours (unless interrupted by surgery or death), with 
no apparent cause other than of vascular origin.” The majority are ischaemic, secondary to 
arterial occlusion by in-situ thrombus or embolus (1), with the remainder being due to 
intracerebral haemorrhage or sub-arachnoid haemorrhage. 
 
1.01  Burden of Stroke / Recurrent Stroke 
 
The WHO estimates that 17 million people die annually from heart disease and stroke. In 
the United Kingdom, stroke remains the single biggest cause of major disability (2) and is 
the third  leading  cause  of  death.    The condition  has a  profound  effect  on  patients and 
relatives and is associated with a vast economic burden (2;3). In the United Kingdom and 
other countries, these costs are on the rise and consistently consume around 5% of health 
care resources (4), costing the NHS and wider economy approximately £7 billion per year 
(5).   
 
The incidence of stroke appears to be similar or perhaps higher in Scotland than in other 
parts of the United Kingdom and in other European and Western countries (6-11). The 
Scottish Borders Stroke Study (11) attempted to ascertain all stroke events in this area over 
a two year period (from 1998-2000). The crude annual incidence rate per 100,000 per year 
was 280 (95% CI 258-304) for all stroke subtypes with 197 (95% CI 179–217) due to 
cerebral infarction, 24 (95% CI 17–31) due to intracerebral haemorrhage, 11 (95% CI 7–
16) due to subarachnoid haemorrhage and 49 (95% CI 40–59) of undetermined subtype. 
Incidence  rates  were  higher  in  males  and  increased  dramatically  with  age,  particularly   - 28 - 
above the age of 65 years, who accounted for 80% of the first ever in a lifetime strokes. In 
total, 790 strokes occurred during the study, 194 (24.7%) of which were recurrent strokes. 
 
The MONICA Project provides further extensive data on stroke incidence, case fatality and 
mortality rates across 16 European countries and China during the period 1985-87. The 
incidences of first-ever and recurrent stroke were greater among men than women in all 
populations. The incidence (age standardized) of stroke was higher in China than in West 
or Central Europe apart from in Finland (for example, incidence was 242 per 100,000 in 
China compared with 361 in Kuopio, Finland and 130 per 100,000 in Göteborg, Sweden) 
(12). Rates were higher in Eastern Europe than in West or central Europe. Approximately 
20%  of  stroke  events  recorded  in  the  MONICA  project  were  recurrent  events.  The 
incidence of recurrent stroke was highest in men and women from Beijing and men in 
Russia (Novosibirsk) but was lowest in Sweden (12). 
 
Stroke is, of course, a global problem and that the incidence and impact of stroke differs 
among ethnic groups (13). The majority of stroke deaths occur in low and middle income 
countries and among non-Western populations (14) and Black, Chinese, South Asian and 
Japanese populations have a higher incidence of stroke compared with Caucasians (2). In 
some Asian populations (excluding India), the burden of cerebrovascular disease exceeds 
that of coronary heart disease (CHD). In China, for example, stroke is the second leading 
cause of death in urban areas (15) and it is estimated that three times as many Asian people 
die from stroke than from CHD (16). 
 
Trends in stroke incidence (age standardised) were also evaluated in the MONICA cohort 
(between  1985  and  1990).  Incidence  fell  in  most  MONICA  centres  except  in  several   - 29 - 
Eastern  European  regions  (17;18).  Other  studies  also  support  the  notion  that  age 
standardised stroke rates and mortality are decreasing (19;20).  However, the age of the 
population  in  most  developed  nations,  including  the  UK  is  projected  to  increase 
considerably in the next half century – the proportion of individuals aged over 65, who 
account for approximately 80% of strokes, is likely to increase by near two-fold (from 20 to 
35%) (21).  It is estimated that the number of individuals in the UK aged over 65 years will 
increase from approximately 9,684,000 to 16,528,000 from 2005 to 2050.  The number of 
stroke events will therefore increase. Even if age standardised rates of stroke remain stable 
or decrease slightly it is projected that the incidence of stroke per annum in the European 
region will rise by over 30% in the next 25 years (10). 
 
It is of interest that those who have suffered stroke have a higher risk of recurrent stroke 
than  of  myocardial  infarction  (MI),  whereas  the  opposite  applies  for  those  who  have 
suffered  MI.  Data  from  large  scale  observational  studies  suggest  that  nearly  80%  of 
recurrent vascular events in those with previous stroke are stroke and that only 20% are MI 
(22).  In the Cardiovascular Health Study, the stroke rate was double that of MI in those 
whose index event was stroke (23), whereas in the CAPRIE study it was 7 times higher 
(24). Approximately 25% of strokes are recurrent events (25) and approximately 25% of 
stroke patients will suffer recurrence within 5 years. The risk of recurrence may be highest 
early, with approximately 4% suffering recurrence within one month and 12% at one year 
(26).  Thereafter, the risk of recurrence after one  year has been estimated at 4-5% per 
annum (27) and while risk may be highest early, the majority of recurrent strokes do of 
course occur after one year (28). 
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It is important also to consider the incidence of transient ischaemic attack (TIA). While 
many  now  regard  stroke  and  TIA  as  one  condition,  they  are  currently  managed  in  a 
different  fashion  in  the  UK  and  beyond.  A  TIA  is  an  episode  of  temporary  and  focal 
neurological symptoms caused by cerebral artery occlusion, with symptom resolution in 
less than 24 hours (29). Patients with a recent transient ischaemic attack (TIA) or minor 
stroke require rapid investigation and treatment initiation to minimize the risk of future 
vascular events, and in particular, the early risk of stroke.  Between 15 and 30% of patients 
with stroke give a history of preceding TIA (30) and the seven day risk of stroke following 
TIA may exceed 30% in high risk groups (31) and risk is highest in the first 48 hours (32).  
These  patients  represent  a  group  at  extremely  high  risk  of  stroke  and  accordingly, 
guidelines recommend that patients are assessed and investigated within 1 week (33;34) 
and that fast track or rapid access neurovascular clinics are established (35).  
 
Data from the Oxford Community Stroke Project suggested a crude annual incidence of 
TIA of 35 per 100,000 population per year in a southern English population, with a slightly 
higher age and sex standardized rate. Other studies have revealed age and sex standardized 
rates of 68 and 83 per 100,000 per year (36;37) and more recent data from Oxfordshire 
showed a higher incidence than previously (38), perhaps reflecting better recognition of 
TIA. 
 
Summary of the Burden of Stroke 
Stroke is clearly a common disorder with dire consequences for the patient and for society 
and will increase in prevalence over the coming years. Following stroke, many suffer a 
further  stroke,  and  recurrent  strokes  account  for  approximately  25%  of  the  total. 
Considerable  scope  therefore  exists  to  improve  both  primary  and  secondary  stroke   - 31 - 
prevention.    TIA  is  also  common  and  represents  a  high  risk  condition  which  must  be 
addressed as an emergency. Those with TIA represent an excellent group in which to study 
new treatments and care strategies given their high risk of events.  
 
1.02  Treatment of Acute Stroke 
 
1.02.1  Therapeutic Targets 
Infarct volume increases in the first few hours after onset of ischaemic stroke, with the 
ischaemic penumbra gradually being subsumed into the area of infarction. The penumbra is 
the region of brain where blood supply is significantly reduced but energy metabolism is 
maintained  because  of  collateral  flow  (39).  Its  viability  depends  on  the  severity  and 
duration of ischaemia and, if blood flow is swiftly restored, some penumbral tissue may be 
saved. However, during the time lag to reperfusion, a physiological cascade occurs which 
places penumbral tissue at further risk. Cellular metabolism becomes anaerobic leading to 
acidosis  and  sodium-potassium  transporters  become  dysfunctional  causing  a  rise  in 
intracellular  osmolarity  and  cytotoxic  oedema.  Intracellular  calcium  increases  and 
ultimately the process becomes self-perpetuating with further rises in intracellular calcium, 
possibly because of release of intracellular glutamate (40). Increased calcium concentration 
within  cells  enhances  injury  through  activation  of  lipase,  protease  and  free  radical 
generation. Blood brain barrier integrity is reduced (41) and if breached, blood components 
can  enter  the  interstitial  space  causing  vasogenic  oedema  and  increasing  the  risk  of 
haemorrhagic transformation of infarcted tissue. Furthermore, even if reperfusion occurs, 
the penumbra is vulnerable to the effects of reperfusion injury (42) as further free radical 
formation and release of harmful neurotransmitters may be provoked.  It has been estimated   - 32 - 
that up to 2 million neurons are lost each minute from stroke onset from this area every 
minute that treatment is delayed (43). 
 
In  the  context  of  intracerebral  haemorrhage,  it  has  recently  been  recognised  that  early 
haemorrhage growth occurs in a significant number of patients (44;45). In a study of 103 
patients, all of whom presented within three hours of onset and underwent serial brain 
imaging with x-ray computed tomography (CT), substantial haemorrhage growth occurred 
in 28% of patients (45). Haemorrhage growth was defined as a 33% increase in volume, 
occurred particularly within the first hour, and was associated with clinical deterioration. 
Haemorrhage growth may be increased in those with hypertension although data do conflict 
(46;47). 
 
Thus, for both ischaemic and haemorrhagic stroke there are therapeutic targets, which are 
likely  to  exist  only  in  the  early  hours  after  stroke.  This  of  course  necessitates  rapid 
assessment and investigation. However, the National Sentinel audit (5) (of England and 
Wales) found that only 30% of those suspected stroke patients who were deemed to require 
urgent brain imaging (within 30 minutes) received a scan on the same day. Also, many 
ambulance  services  do  not  treat  potential  stroke  patients  as  the  highest  category  of 
emergency. Reducing delays to assessment and imaging to increase the numbers presenting 
within the first hours after onset of stroke is therefore crucial and will have a significant 
impact on patient outcomes. Such delays are multi-factorial and will require comprehensive 
strategies to increase public awareness and improve ambulance, emergency medicine and 
radiology services, whilst ensuring all patients have equity of access to stroke unit care. 
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1.02.2  Current Management Strategies 
Once a patient has arrived at hospital and received a diagnosis of acute stroke, management 
serves a dual purpose; to reduce the high risk of recurrent stroke and to reduce the burden 
of disability in established stroke. Secondary preventative measures continue to improve 
and  will  be  outlined  later.  Acute  treatment  of  stroke  involves  control  of  physiological 
variables, strategies to reperfuse the ischaemic area, measures to reduce growth of primary 
intracerebral  haemorrhage  (haemostatic  therapy,  currently  unproven),  protection  of  the 
vulnerable,  yet  salvageable,  ischaemic  penumbra  (neuroprotectant  therapy,  currently 
unproven) and surgery. All patients should be cared for in a dedicated acute stroke unit, 
which  in  itself  saves  lives  and  significantly  improves  functional  outcomes  (48).  By 
definition, a stroke unit is an area and environment of organised and multidisciplinary care 
which ensures access to specialist medical, nursing and allied staff and treatment. 
 
All patients with suspected acute stroke or TIA should undergo emergency brain imaging to 
help confirm the diagnosis, distinguish infarct from haemorrhage and to identify important 
differential diagnoses such as tumour.  The choice of brain imaging modality lies between 
computed tomography (CT) and magnetic resonance imaging (MRI). An urgent brain scan 
enables  rapid  differentiation  of  ischaemic  from  haemorrhagic  stroke  and  there  is  no 
rationale for waiting to image patients – it delays treatment initiation and is the least cost 
effective approach (49). A non-contrast CT brain is the most widely available test and has 
excellent  sensitivity  for  identification  of  haemorrhage  early  after  onset,  while MRI  has 
similar sensitivity for identification of haemorrhage and significantly greater sensitivity for 
detection of ischaemia (50).  Newer CT and MRI based techniques are available which 
have the potential to increase both diagnostic sensitivity and specificity and increase the 
numbers of patients receiving treatments such as thrombolysis (51).    - 34 - 
1.02.3  Control of Physiological Variables 
Arterial hypertension occurs in as many as 80% of patients following acute stroke (52). It is 
associated with a poor outcome (53) but it may represent a protective response - falls in 
blood  pressure  may  lead  to  infarct  extension  because  of  impaired  cerebrovascular 
autoregulation  following  acute  stroke  (54).  There  is  some  evidence  that  a  U-shaped 
relationship exists with arterial hypotension also being associated with a poor outcome (52). 
Such  uncertainty  also  surrounds  intracerebral  haemorrhage  where  hypertension  may 
contribute to haemorrhage growth. Current guidelines suggest lowering blood pressure in 
the presence of hypertensive encephalopathy, aortic dissection, severe cardiac failure and if 
blood pressure is extremely high on repeated measurement (>220 mmHg systolic or > 120 
mmHg diastolic blood pressure) (55). This leaves a great deal of uncertainty in the majority 
of patients and it is unclear whether prior antihypertensive therapy should be discontinued 
in the acute phase and at what thresholds of blood pressure we should intervene and the 
treatment targets that we should aim for.  Fortunately, several large clinical trials are now 
underway  and  should  address  these  issues  (Controlling  Hypertension  and  Hypotension 
Immediately  Post-Stroke  Trial  [CHHIPS  trial]  (56),  Continue  or  Stop  post-Stroke 
Antihypertensives Collaborative Study [COSSACS] (57) and Efficacy of Nitric Oxide in 
Stroke Trial [ENOS trial] (58)).  
 
Elevated blood glucose is common in the acute phase following ischaemic stroke (59) and 
is associated with a poor outcome (60), regardless of the presence of pre-existing diabetes. 
In a recent systematic review of non-diabetic patients, stress hyperglycaemia defined as 
blood glucose of greater than 6 or 7.1 mmol/l was strongly predictive of increased hospital 
mortality (RR 3.28, 95% CI 2.32-4.64) and poor functional outcome (RR 1.41, 95% CI 
1.16-1.73)  (59).  This  may  be  because  elevated  blood  glucose  increases  brain  lactate   - 35 - 
production, which is associated with increased infarct size (61), may reduce the efficacy of 
thrombolytic therapy (62;63) and may increase the risk of haemorrhagic transformation of 
infarcted  tissue.    However,  whether  routine  lowering  of  hyperglycaemia  with  insulin 
improves outcome after acute stroke is as yet unproven.  The recent GIST-UK (Glucose 
Insulin in Stroke) trial (64) enrolled 933 patients and found no evidence of benefit for 
insulin  therapy  in  terms  of  mortality  (OR  1.14,  95%  CI  0.86  to  1.51)  or  secondary 
outcomes. Significantly lower levels of both blood pressure and glucose levels were seen 
following treatment although it is likely the trial was underpowered and further randomized 
controlled trials are required. At present, current guidelines suggest insulin titration in those 
with serum glucose of > 10 mmol/l (55). 
 
Fever has also been associated with a poor outcome following acute stroke (65), possibly 
because  of  a  detrimental  effect  on  intracerebral  metabolism,  increased  free  radical 
production (66) or changes in blood brain barrier function (67). Guidelines suggest the use 
of fanning and paracetamol if temperature rises above 37.5°C and that this should prompt a 
search for infection (55). It is again unclear whether this improves clinical outcome but 
trials are in progress to evaluate this (68). 
 
1.02.4  Reperfusion Strategies for Acute Ischaemic Stroke 
Intravenous Thrombolytic Therapy 
Thrombolytic  therapy  with  tissue  plasminogen  activator  (rt-PA)  is  the  only  licensed 
treatment for acute ischaemic stroke in Europe where it must be administered within three 
hours of symptom onset. First evidence of efficacy was published in 1995 and license was 
granted for use in the United States of America in 1997. In Europe, however, a conditional 
license  was  first  granted  in  2002  and  uptake  has  remained  disappointingly  slow.   - 36 - 
Approximately two thirds of otherwise eligible patients miss out on treatment because of 
delay  in  presentation  and/or  early  misdiagnosis  (69).  The  United  Kingdom  performs 
particularly  badly  and  currently  holds  15th  place  in  the  European  league  table  of 
thrombolysis use; only around 0.2% of stroke patients were treated in 2005 and access to 
treatment across the nation is patchy (70). 
 
Intravenous thrombolytic therapy is clearly beneficial as shown in a recent pooled meta-
analysis  of  the  major  thrombolysis  studies  (71).  The  analysis  considered  2775  patients 
treated within six hours of ictus. The odds of favourable outcome (defined as no disability) 
were 2.8 (95% CI 1.8-9.5) for treatment within 90 minutes and 1.6 (95% CI 1.1-2.2) for 
treatment  between  91  and  180  minutes.  Benefit  was  still  apparent  for  patients  treated 
between 181 and 270 minutes (odds ratio 1.4, 95% CI 1.1-1.9). The rate of significant 
intracerebral haemorrhage was 5.9% in those treated with rt-PA compared to 1.1% in those 
treated with placebo. However, only a small number of these were of clinical significance, 
and  this  risk  of  haemorrhage  is  already  accounted  for  in  the  calculation  of  odds  of 
favourable outcome. Thus, the chance of being free of handicap after stroke is increased 
nearly 3 fold by thrombolytic treatment provided it is administered within 90 minutes of 
onset. Smaller but still significant benefits are seen up to 4.5 hours. The number needed to 
treat (NNT) to achieve an excellent outcome (and avert one case of death or dependency) 
following  treatment  is  approximately  7  (71)  while  the  NNT  to  achieve  a  reduction  in 
disability is approximately 3 (72). The number needed to harm is 30 and these figures 
compare favourably to other interventions such as thrombolysis for acute MI. 
 
A  rigorous  audit  of  outcomes  in  several  thousand  European  patients  (The  Safe 
Implementation of Thrombolysis in Stroke-Monitoring Study (73)) treated within license   - 37 - 
and in routine clinical practice has confirmed that safety is at least as good as in clinical 
trials, with low rates of symptomatic significant haemorrhage. Efficacy also appears to be 
similar (table 1.1). The risk of haemorrhage should not deter use of thrombolytic therapy 
but precautions must be taken to minimise its risk. The factors associated with an increased 
risk of haemorrhage are increasing age, extensive early infarct change on brain imaging, 
diabetes mellitus (DM), elevated blood glucose, DM and a history of previous stroke, and a 
low platelet count (74). Those with higher baseline stroke severity may also have a higher 
risk of haemorrhage but equally, may derive greatest benefit from treatment. Exclusion 
criteria are similar to those for thrombolysis in myocardial infarction, although patients 
with  a  blood  pressure  of  >180/110  mmHg,  or  those  who  require  treatment  to  attain  a 
satisfactory blood pressure, are generally not treated. There are also concerns regarding its 
use in those with DM and a history of previous stroke. Mild systemic bleeding can also 
occur and there is a risk of angio-oedema of approximately 1%, which is typically mild (75). 
 
  Mortality 
(at 3/12) 
Independent 
(at 3/12) 
S-ICH 
(Per SITS-MOST)* 
S-ICH 
† 
Trials  17.3%  49%  N/A  8.6% 
SITS-
MOST 
11.3%  54.8%  1.7%  7.3% 
Placebo  18.4%  30.2%  N/A  1.9% 
*  Bleed  large  enough  to  cause  symptoms  and  accompanying  neurological 
deterioration. †  Any  bleed  with  any  alteration  in  neurological  status  regardless  of 
severity. 
Table 1.1. Summary of outcomes in thrombolysis studies and the SITS register 
 
Very recent data show that intravenous thrombolytic therapy delivered within 3 to 4.5 hours 
of onset but otherwise within the terms of the license is also effective and has a similar   - 38 - 
safety profile to treatment within 3 hours of onset. This was tested in a recent randomized, 
placebo controlled double blind trial, the ECASS III study (76). It included 821 participants 
with  presumed  ischaemic  stroke  and  revealed  an  increase  in  the  odds  of  an  excellent 
outcome  (OR  1.34,  1.02  to  1.76,  p=0.04).  The  rate  of  symptomatic  intracerebral 
haemorrhage was 2.4 % in the treatment and 0.2% in the placebo group (p=0.008). 
 
Intra-arterial Thrombolysis / Mechanical Reperfusion 
These therapies are not widely available in the UK. Intra-arterial thrombolysis involves 
direct catheterisation of an occluded artery and local administration of thrombolytic agents 
(rt-PA or urokinase (not available in UK)). This appears to be an effective therapy for 
confirmed middle cerebral artery (MCA) or basilar artery occlusion. For example, in the 
PROACT II (Prolyse in Acute Cerebral Thromboembolism) trial (77), where treatment was 
initiated within 6 hours of onset, reperfusion rates in those with confirmed MCA occlusion 
were  significantly  higher  following  intra-arterial  thrombolysis  with  urokinase  and 
intravenous heparin (66% compared to 18% in heparin treated controls, p<0.001).  Clinical 
outcomes were also significantly improved with more patients living independently at day 
90 (40% compared to 25% of controls, p=0.043, relative risk reduction 58%).  
 
Basilar artery occlusion carries a grave prognosis with a high mortality rate – perhaps in 
excess of 70%. While randomised controlled trial evidence are lacking, several case series 
have  been  published  which  suggest  reduced  mortality  rate  following  intra-arterial 
thrombolysis (78;79). However, a recent systematic analysis suggested reperfusion rates 
and  clinical  outcomes  were  similar  with  both  intra-arterial  and  intravenous  treatment 
emphasising the need for administration of either form of thrombolysis in this devastating 
condition (79).   - 39 - 
 
Catheter based techniques may allow lower systemic doses of thrombolytic agents to be 
used but also the use of mechanical clot disruption and retrieval. The later approach would 
be a particular advantage in those with a significant haemorrhage risk or in those unsuitable 
for  intravenous  rt-PA.    As  yet,  no  randomized  data  confirm  efficacy  of  mechanical 
embolectomy. However, in a study of 151 patients with ischaemic stroke and any treatable 
intracranial or extracranial artery occlusion who were deemed unsuitable for rt-PA (80;81) 
presenting within 8 hours of onset, a high rate of vascular recanalisation was seen (46% 
compared to 18% in a historical control sample). Those who exhibit recanalisaton also have 
better  outcomes  than  would  be  expected  for  their  baseline  stroke  severity  (81).  These 
strategies  therefore  represent  a  real  alternative  for  those  with  major  stroke  who  are 
unsuitable for rt-PA but the limited availability and need for specialist neuro-radiology staff 
may hinder introduction of these techniques into routine practice. 
 
Trials are ongoing to assess efficacy of thrombolytic therapy in ischaemic stroke up-to 6 
hours after onset of symptoms (82) and to establish whether newer imaging techniques can 
better guide thrombolytic therapy and perhaps allow treatment up to 9 hours after onset in 
selected  patients.    Results  of  small  phase  2  studies  of  this  later  approach  have  been 
conflicting (83-85), although it remains a promising strategy. 
 
1.02.5  Aspirin Treatment 
Patients with ischaemic stroke should be treated with aspirin.  The effect size is modest but 
important; a combined analysis of the CAST (86) and IST (87) revealed 9 fewer deaths or 
fatal strokes for every for every 1000 patients treated with aspirin in the acute phase (88). If   - 40 - 
patients  receive  thrombolytic  treatment,  it  is  generally  advised  that  aspirin  should  be 
deferred for 24 hours. 
 
1.02.6  Anticoagulant Therapy 
Early anticoagulation has not been shown to yield benefit early after stroke. In a meta-
analysis of 22 trials, anticoagulation within 24-48 hours after ischaemic stroke onset led to 
a reduction in early recurrent stroke (OR 0.76, 95% CI 0.65 to 0.88) which was offset by an 
increase (of similar magnitude) in the number of symptomatic intracranial haemorrhages 
(OR 2.52, 95% CI 1.92 to 3.3) (89). Very early treatment with unfractionated heparin has 
been linked with better functional outcome and lower early  recurrence rate (90;91) but 
again  at  the  cost  of  increased  haemorrhagic  complications.  Early  anticoagulation  is 
therefore  not  recommended  as  a  treatment  for  acute  ischaemic  stroke  (55)  although  is 
recommended by some for those with atrial fibrillation (92).  
 
1.02.7  Neuroprotectant Strategies 
Neuroprotectant drugs aim to save ischaemic brain tissue by damping down the potentially 
harmful molecular processes in the penumbra. This may prolong the life of the penumbra, 
maintain blood brain barrier integrity, reduce oedema and haemorrhagic transformation, 
and  reduce  reperfusion  injury.  Such  strategies  may  also  be  of  benefit  in  the  peri-
haemorrhage  region  in  intracerebral  haemorrhage.    Unfortunately,  no  neuroprotectant 
strategy has yet been proven effective in phase III clinical trials or reached clinical practice, 
although at the time of writing several agents are the subject of clinical trials (93).  
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1.02.8  Therapeutic Hypothermia 
Therapeutic hypothermia is arguably the most promising novel therapy for acute stroke (94). 
There  are  several  mechanisms  by  which  hypothermia  may  convey  a  neuroprotectant 
mechanism.  It  will  decrease  cellular  metabolism  (95),  limit  cytotoxic  and  excitatory 
cascades, reduce free radical formation and suppress blood brain barrier breakdown (96). 
Mechanisms of cooling include surface cooling which, while able to attain reductions in 
temperature (97), has disadvantages of patient discomfort and may necessitate sedation and 
paralysis. The preferable, yet more invasive approach, is to use intravascular cooling via a 
central venous heat exchange catheter and infusion of cold saline (98). It also allows greater 
control over rewarming, which may be associated with increases in intracranial pressure if 
performed rapidly (99). 
 
A wealth of data show therapeutic hypothermia is effective in animal models of cerebral 
ischaemia, particularly  with  transient  ischaemia  where  cooling  was initiated within one 
hour  (100-102)  Therefore,  like  thrombolytic  therapy,  it  is  likely  that  therapeutic 
hypothermia will only prove effective if initiated early after onset  and  in patients with 
reperfusion (either spontaneous or iatrogenic).  
 
Evidence of efficacy in humans is lacking, although a recent case report (103) and some 
human feasibility studies (104) provide prima facie evidence of efficacy. Further research is 
required. 
 
1.02.9  Specific Treatment for Intracerebral Haemorrhage 
Supportive treatment is indicated as for all types of stroke. Approximately 15% of cases of 
intracerebral haemorrhage are associated with warfarin. These patients have a higher risk of   - 42 - 
death and disability (105) and require rapid reversal of anticoagulation (106).  No specific 
licensed  treatment  exists  for  the  majority  with  spontaneous  intracerebral  haemorrhage.  
Recombinant  activated  factor  VII  (rFVIIa)  is  a  licensed  treatment  for  bleeding  in 
haemophiliacs who are resistant to factor VIII replacement and is a powerful initiator of 
haemostasis even in patients with normal coagulation. It is also utilized in the setting of 
major  haemorrhage  (107)  and  peri-operative  bleeding  (108).  Adminstration  early  after 
stroke  limits  early haemorrhage  growth  (109;110)  but  has not  been proven  to  improve 
clinical outcome (110).  Initial data in this regard were highly encouraging when, in a study 
of  399  patients  (109),  mortality  was  reduced  in  the  treatment  group  and  the  odds  of 
improvement in disability in survivors was nearly doubled. Unfortunately a larger phase III 
trial did not confirm these benefits (110). This lack of efficacy may relate to randomization 
imbalances in terms of poor prognostic factors such as intraventricular haemorrhage rate 
(111;112)  and  this  does  remain  a  promising  strategy.  A  minimal  increase  in  risk  of 
thromboembolic events was seen in these studies. 
 
1.02.10   Surgical Treatment of Acute Stroke 
Complete MCA infarction is associated with brain oedema, increased intracranial pressure 
and a risk of transtentorial herniation and death. Medical therapy does little to improve 
mortality rates, which may be as high as 80% (113). Decompressive hemicraniectomy has 
recently  been  shown  to  be  effective  in  this  scenario  in  a  pooled  analysis  of  3  recent 
European  trials  (114),  both  in  terms  of  improved  mortality  and  improved  functional 
outcome. Compared to best medical treatment, numbers needed to treat to prevent death, 
severe  disability  or  moderate  disability  are  2;  2  and  4  respectively.  However,  in  these 
studies, participants were relatively young (mean age 43, maximal age 60) and important 
questions remain concerning optimal timing of treatment and patient selection.  Further,   - 43 - 
while this is a viable treatment for the most feared subtype of stroke, this treatment is 
thankfully only relevant for a minority of stroke patients. 
 
Surgery is also a potentially effective therapy for ICH. The recently completed STICH trial 
(115) enrolled 1033 patients with ICH and no benefit was seen from early surgery (OR 0.89, 
95% CI 0.66 to 1.19 for favorable outcome). Pre-specified subgroup analysis suggested 
there may be benefit in lobar ICH located less than 1 cm from the brain surface and a 
further randomized trial is underway to test this hypothesis (116). 
 
Summary of Acute Treatments 
Despite the clear and significant burden of acute stroke, there are depressingly few effective 
treatments. For ischaemic stroke, the only proven effective interventions are stroke unit 
care,  aspirin  and  reperfusion  therapy  with  intravenous  thrombolytic  therapy  and  intra-
arterial thrombolysis in a small subset of patients with proximal middle cerebral artery 
occlusion. No specific licensed treatment exists for ICH (except for stroke unit care). There 
are promising therapies in development but this lack of available treatment, the increasing 
number of strokes due to the ageing population and the burgeoning burden of stroke in the 
developing world makes optimal and cheap preventative therapy vitally important. 
 
1.03  Preventative Treatments for Stroke 
 
Preventative therapies can be considered as either primary (where the individual may be at 
risk of but has no established cardiovascular disease) or secondary (where the individual 
has established cardiovascular disease). Current preventative strategies include anti-platelet 
therapy and lipid lowering therapy to prevent ischaemic stroke, anticoagulant therapy to   - 44 - 
prevent cardioembolic stroke and blood pressure reduction to prevent all stroke subtypes. It 
is  also  recommended  that  patients  undergo  screening  for  and  treatment  of  prevalent 
diabetes mellitus, smoking cessation therapy and lifestyle modification (if required). Many 
of these strategies will also reduce risk of other cardiovascular events such as MI. 
 
1.03.1  Anti-platelet Strategies 
Aspirin is the only licensed strategy for the primary prevention of stroke. There are four 
licensed strategies for anti-platelet therapy to prevent recurrent stroke in the UK. These are 
aspirin,  clopidogrel,  dipyridamole  and  the  combination  of  aspirin  and  extended  release 
dipyridamole.  A summary of the mechanism of action, licensed indication and dosage for 
each of these drugs is shown in table 1.2. Aspirin (acetylsalicylic acid) prevents platelet 
aggregation  by  irreversible  inhibition  of  cyclooxygenase-1  (COX-1).    COX-1  is  a 
constitutive enzyme present in most body cells and is irreversibly acetylatylated by aspirin, 
thereby  reducing  production  of  prostaglandins  and  of  thromboxane  A2  by  platelets.  
Platelets, given their lack of nuclei, are unable to synthesise additional cyclo-oxygenase 
meaning the inhibitory effect of aspirin on thromboxane production will last for the lifespan 
of  the  platelet.  Thromboxane  A2  has  prothrombotic  properties  and  stimulates  platelet 
activation and aggregation. 
 
 
 
 
 
   - 45 - 
Licensed Indications  Drug  Mechanism of Action  Dose* 
PP   SP 
CVD 
SP 
CHD 
SP 
PVD 
Major 
Side 
Effects 
A  Inhibition  of 
cyclooxygenase-1 
75mg   Y  Y  Y  ---  Risk  of 
PUD 
D  Inhibition  of  platelet  re-
uptake  of  adenosine  and 
of  phosphodiesterase  5 
activity 
200mg 
BD  
---  Y  ---  ---  Headache 
GI Upset 
C  Inhibition  of  the 
adenosine  triphosphate 
receptor 
75 mg  ---  Y  Y  Y  GI Upset 
A = aspirin. C = clopidogrel. D = Extended release dipyridamole. * = recommended 
dose in Scotland. PP = primary prevention of stroke and myocardial infarction. SP = 
secondary  prevention.  CVD  =  cerebrovascular  disease.  CHD  =  coronary  heart 
disease.  PVD  =  peripheral  vascular  disease.  PUD  =  peptic  ulcer  disease.  GI  = 
gastrointestinal upset. 
Table 1.2. Anti-platelet drugs available for prevention of stroke and cardiovascular 
disease in the UK. 
 
Several  trials  have  shown  aspirin  to  be  effective  in  reducing  the  risk  of  a  first 
cardiovascular  event  (117-121)  in  apparently  healthy  men  and  men  and  women  with 
adverse  cardiovascular  risk.  Meta-analysis  of  these  trials  (122),  including  over  55000 
patients, of whom 11446 were women, showed a 32% relative risk reduction in risk of first 
MI (RRR 0.68, 95% CI 0.59 to 0.79) and a 15% reduction in risk of any important vascular 
event (RRR 0.85, 95% CI 0.73 to 0.93). However, no reduction in incidence of non-fatal 
stroke was seen (RRR 1.06, 95% CI 0.87 to 1.29). Subgroup analyses in the individual 
trials suggested benefit in females although it did not reach statistical significance in one 
(119;121). The recent Women’s Health Study involved 39876 initially healthy women aged   - 46 - 
> 45  years and evaluated 100 mg aspirin versus placebo (123). No reduction in major 
cardiovascular events, death or MI was seen, although incidence of stroke was reduced (RR 
0.83, 95% CI 0.69 to 0.99). A recent sex specific meta-analysis of primary prevention trials 
(124) including 95456 individuals (51342 women) confirmed a differing effect of aspirin 
between the sexes. It suggested that in women, cardiovascular events and stroke rates (OR 
0.83, 95% CI 0.7 to 0.97) were reduced by aspirin treatment but there was no reduction in 
rate of MI while in men, MI was reduced but there was no reduction in rate of stroke (OR 
1.13, 95% CI 0.96 to 1.33). Current local guidelines recommend that individuals whose 10 
year cardiovascular risk exceeds 20% and those with diabetes who are aged over 40 years 
are given 75 mg of aspirin. However, even this can be questioned given recent data from 
the POPADAD study where no benefit was seen following aspirin use in 1276 individuals 
with  diabetes  (125).  There  is  no  clear  evidence  to  support  any  alternative  anti-platelet 
strategy in the primary prevention setting.  
 
Aspirin is the most commonly prescribed anti-platelet agent for secondary prevention after 
stroke  and  prevents  up  to  a  fifth  of  recurrent  strokes  (126).  Most  studies  suggest  an 
approximate relative risk reduction of 15% in comparison with placebo (86;127;128) for 
both recurrent stroke and composite vascular endpoints. For example, in the UK-TIA study 
(127), 2435 subjects were enrolled and aspirin treatment (either 300mg or 1200 mg per 
day) led to a 15% RRR in a composite endpoint of vascular death, nonfatal MI and nonfatal 
stroke).  It is also effective in reducing death and recurrence in the immediate period after 
stroke (86;87).  
 
At the time of writing, aspirin monotherapy has been compared with placebo, dipyridamole, 
clopidogrel, the combination of aspirin and clopidogrel, the combination of aspirin and   - 47 - 
extended released dipyridamole and with ticlopidine (as well as other drugs that are in 
development or not commonly used). Clopidogrel monotherapy has also been compared to 
the  combination  of  aspirin  and  clopidogrel  and  to  the  combination  of  aspirin  and 
dipyridamole. 
 
Ticlopidine is a member of the thienopyridine family and is an ADP receptor inhibitor. It is 
superior to placebo following stroke in terms of a composite endpoint of stroke, MI or 
vascular  death  (129)  while  studies  have  suggested  marginal  superiority  (130)  over  or 
equivalence (131) to aspirin. It is rarely used and is not licensed in the UK because of a risk 
of severe neutropaenia and thrombotic thrombocytopenia. 
 
The CAPRIE trial (24) compared clopidogrel monotherapy to aspirin in 19195 patients 
with  symptomatic  cardiovascular  disease  (recent  stroke,  MI  or  symptomatic  peripheral 
vascular disease). Overall, clopidogrel use linked with a small but statistically significant 
reduction in the rate of the primary composite endpoint of ischaemic stroke, MI or vascular 
death (5.32% with clopidogrel compared to 5.83% with aspirin, p=0.043). This small 8.7% 
RRR  appeared  predominantly  driven  by  an  effect  in  those  with  PVD  (RRR  23.8%, 
p=0.0028) while in the stroke and MI subgroups, no difference was seen (RRR 7.3%, 95% 
CI -5.7 to 18.7% in those with recent stroke). 
 
Dipyridamole monotherapy is superior to placebo in terms of recurrent stroke prevention, 
but  not  in prevention  of myocardial  infarction  or  vascular  death  and  may  have  similar 
efficacy to aspirin but again without proven benefit in prevention of MI (132;133).  This 
similar efficacy is at the cost of a significantly increased trial drop out rate because of side   - 48 - 
effects such as headache. Aspirin and dipyridamole in combination have also been shown 
to be superior to placebo (134). 
 
The recent  MATCH (135) and CHARISMA trials (136) showed that,  in the secondary 
prevention of stroke, dual therapy with clopidogrel and aspirin is no better than either alone.  
The MATCH trial included 7599 with recent stroke or TIA and additional risk factors for 
recurrence and compared clopidogrel with the combination of aspirin and clopidogrel. The 
combination did not reduce the occurrence of a composite endpoint of ischaemic stroke, MI 
and  vascular  death  (15.7%  vs  16.7%,  RRR  6.4%,  p=0.244)  but  did  lead  to  a  two-fold 
increase in life-threatening bleeding episodes (2.6% vs 1.3%, p<0.0001).  The CHARISMA 
trial compared aspirin and clopidogrel therapy versus aspirin alone amongst 15,603 patients, 
the majority of whom had established cardiovascular disease. In 27% of patients the trial 
entry criterion was previous cerebrovascular disease. Clopidogrel was no more effective 
than  placebo  in  aspirin  treated  patients  in  the  entire  cohort  (occurrence  of  primary 
composite endpoint of 6.8% with combination compared to 7.3%, RRR 7%, p=0.22). In the 
secondary  prevention  cohort  there  was  a  significant  reduction  in  the  primary  endpoint 
(6.9% vs 7.9%, RRR 12%, p=0.046). Trends toward benefit were apparent in those who 
entered the trial on account of stroke, and all-cause stroke appeared lower in the population 
as a whole. However, benefits only bordered on statistical significance before adjustment 
for multiple comparisons and bleeding complications were again increased nearly two-fold 
in  with  combination  therapy  (2.1%  vs  1.3%,  RR  1.62,  p<0.001).    Among  those  with 
multiple risk factors but no established disease, the primary endpoint was non-significantly 
increased on those on dual therapy (RR 1.2, 95% CI 0.91 to 1.59).   
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The CARESS trial compared dual anti-platelet therapy with aspirin and clopidogrel with 
aspirin in patients with recently symptomatic > 50% carotid stenosis and microembolic 
signals (MES). The study was randomized, double blind and the primary endpoint was the 
proportion of patients who were MES positive at seven days and the secondary endpoint 
included recurrent stroke or TIA. The primary endpoint was significantly reduced in those 
who received both aspirin and clopidogrel (43.8% compared to 72.7%, RRR 39.8%, 95% 
CI 13.8 to 50%). There was a strong trend towards a reduction in rate of stroke or TIA 
although numbers were small (4 recurrent strokes and 7 TIAs in the monotherapy group 
compared to 4 TIAs with dual therapy). These promising results suggest that those with 
large vessel atherosclerosis and recent stroke may benefit – in the same way as those with 
recently symptomatic large vessel coronary disease – from early dual anti-platelet therapy 
(137).   
 
The  recent  ESPRIT  trial  (138)  involved  2763  patients  with  recent  stroke  or  TIA  and 
revealed, during a mean follow-up of 3.5 years, that the combination of aspirin and slow-
release dipyridamole afford a 20% relative risk reduction (HR 0.8, 95% CI 0.66 to 0.98, 
ARR 1% per year) in the rate of vascular death or non-fatal stroke or MI compared to 
aspirin  alone.  The  surprising  lack  (and  indeed  reduction)  of  increased  bleeding 
complications is curious and further claims of anti-inflammatory and non-platelet mediated 
benefits of dipyridamole have  emerged (139). The results of ESPRIT  confirm those of 
ESPS 2 (132) and have consolidated the position of aspirin and dipyridamole combination 
therapy as preferable to aspirin alone in the secondary prevention of stroke.   
 
The  recent  PRoFESS  study  compared  aspirin  and  dipyridamole  with  clopidogrel  and 
included  20332  patients  with  recent  stroke  (140).  The  primary  endpoint  was  recurrent   - 50 - 
stroke and there was no difference between the treatment groups (9% following aspirin and 
dipyridamole vs 8.8% following clopidogrel, HR 1.01, 95% CI 0.92 to 1.11). Unlike in 
ESPRIT and ESPS-2, the combination of aspirin and dipyridamole led to an increase in rate 
of  major  haemorrhagic  events  including  haemorrhagic  stroke  in  comparison  to  its 
comparator which offset the slight reduction in ischaemic stroke. 
 
Thus, aspirin, clopidogrel and dipyridamole monotherapy appear to provide similar efficacy 
in the secondary prevention of stroke, although clopidogrel may be slightly superior. The 
combination  of  aspirin  and  clopidogrel  poses  unacceptable  risks  for  little  gain,  except 
perhaps in certain high risk subgroups. Aspirin and extended release dipyridamole has been 
shown to be superior to aspirin in two studies but recent data suggest this strategy offers 
similar yield to clopidogrel monotherapy, which is better tolerated.  In certain high risk 
groups aspirin and clopidogrel combination therapy may be indicated but further study is 
required to confirm efficacy and establish optimal treatment duration.  At present therefore, 
a reasonable strategy would be to employ aspirin and dipyridamole combination therapy as 
first line and, where patients are intolerant to dipyridamole to consider either aspirin or 
preferably clopidogrel monotherapy. For the primary prevention of stroke, aspirin appears 
to be of benefit but perhaps only in women, whereas in men, most evidence suggests a 
reduction in risk of MI. 
  
1.03.2  Anticoagulant Therapy (non-Cardioembolic Stroke) 
The WARSS study enrolled 2206 patients with recent (within 30 days) ischaemic stroke 
without evidence of cardioembolic source. It compared aspirin 325 mg with warfarin with a 
target INR of 1.4 to 2.8 (141). There were no significant differences between the groups in 
terms of efficacy or bleeding risk. The WASID trial (142) compared warfarin and aspirin in   - 51 - 
those  with  recent stroke  and  documented 50 to  99%  intracranial  stenosis  (who had no 
evidence of significant carotid or cardio-embolic disease) and revealed no benefit from 
warfarin in terms of stroke recurrence which was similar in both groups (HR 1.04, 95% CI 
0.73 to 1.48). However, there was significantly worse protection from cardiac events and 
increased haemorrhage rate and increased mortality. The SPIRIT trial was also terminated 
early because of increased bleeding risk, although did involve a high target INR (3 to 4.5) 
(143).  It included 1316 participants with minor stroke or TIA. The ESPRIT trial (144) 
compared  aspirin  with  warfarin  (target  INR  2  –  3)  in  1038  individuals  with  recent 
ischaemic  stroke.  There  was  no  difference  in  rate  of  the  primary  outcome  between 
treatment groups although ischaemic events were lower following warfarin (HR 0.73, 95% 
CI 0.52 to 1.01) but major haemorrhage rate was higher (HR 2.56, 95% CI 1.48 to 4.43). 
Anticoagulation is therefore not recommended for prevention of stroke in those with non-
cardioembolic stroke (55).   
 
1.03.3  Statin / Cholesterol Lowering Therapy 
The link between serum cholesterol levels and coronary artery disease is well established 
and the evidence that cholesterol lowering therapy with HMG-CoA reductase inhibitors 
(statins) reduces coronary morbidity and mortality in those with and without established 
CHD is unequivocal (145). Debate however continues concerning the association between 
serum cholesterol levels and stroke. Such a link would seem likely given the strong link 
between  it  and  CHD,  while  the  heterogeneity  of  stroke  causes  and  epidemiological 
evidence  that  lower  serum  cholesterol  may  link  with  increased  risk  of  intracerebral 
haemorrhage suggests such a link cannot be assumed (146;147). However, statin therapy is 
now an accepted strategy following ischaemic stroke (55).  Further, in a large meta-analysis 
of over 90000 patients (mostly with manifest CHD) who were enrolled in statin trials, statin   - 52 - 
treatment significantly reduced the risk of incident stroke (OR 0.79, 95% CI 0.73-0.85) 
(148). Each 10% reduction in LDL cholesterol appears to afford a 15.6% RRR of stroke 
(95% CI 6.7% to 23.6%). Further compelling evidence arose following the Heart Protection 
Study  which  enrolled  over  20000  patients  with  CHD  or  risk  factors  and  compared 
simvastatin 40 mg with placebo (149). Simvastatin reduced the risk of first stroke by 25% 
(95% CI 15% to 34%, p<0.0001). The ASCOT trial lipid lowering arm (ASCOT-LLA) 
(150), which included those with hypertension, revealed a similar magnitude of stroke risk 
reduction.  Reduction  in  stroke  risk  did  not  accompany  the  modest  reduction  in  serum 
cholesterol seen in the ALLHAT study (151) but, on balance,, the evidence shows that for 
those with and without CHD, statin therapy reduces both risk of MI, mortality and stroke 
risk.  Approximately 16% of patients in the HPS study had suffered previous stroke, just 
over half of whom had no documented CHD.  In this  group  with stroke, statin therapy 
yielded no reduction in recurrent stroke (HR 0.98, 95% CI 0.79 to 1.22).   
 
Until very recently therefore, it was not clear whether statin therapy reduced the risk of 
recurrent  stroke  following  an  index  cerebrovascular  event.    The  SPARCL  trial  (152) 
randomised 4731 patients to high dose (80 mg) atorvastatin or placebo. Treatment led to a 
16% relative risk reduction of recurrent stroke and to reductions in the rates of most other 
vascular complications. These results, subsequently confirmed in a meta-analysis (153), are 
in  contrast  to  those  from  the  HPS,  and  confirm  that  statin  therapy  can  reduce  risk  of 
recurrent stroke. The effect was however less than would be expected in terms of secondary 
prevention of MI. 
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An important consideration is the epidemiological link between low serum cholesterol and 
incidence of haemorrhagic stroke, raising the important possibility that statin therapy may 
increase risk of ICH. Data from randomized controlled trials conflicts but the pivotal  
SPARCL trial (152) did show an increased risk of haemorrhagic stroke in those in the 
treatment arm (HR 1.67, 95% CI 1.09 to 2.56). When these data were combined with those 
from the HPS in a meta-analysis, risk remained elevated in those receiving statin treatment 
(HR 1.73, 95% CI 1.19 to 2.5) (152). However, the same meta-analysis revealed a 20% 
reduction in the risk of the more common recurrent ischaemic stroke (HR 0.8, 95% CI 0.7 
to 0.92) and a smaller but significant reduction in overall recurrent stroke burden (HR 0.88, 
95% CI 0.78 to 0.99). 
 
Thus, statin therapy is clearly indicated and recommended as a preventative strategy in 
those who have suffered ischaemic stroke or who have CHD (55;154). Whether statins 
should be given to those who have suffered ICH and have no other indication for their use 
is at the time of writing unclear. 
 
1.03.4  Blood Pressure Lowering Therapy 
Hypertension is the most significant risk factor for stroke and the relationship between 
increasing blood pressure and increasing stroke  risk even extends to within the normal 
blood pressure range (155;156). Treatment of hypertension is of unequivocal benefit in 
reducing stroke risk in the primary prevention setting (157) and evidence suggests that 
newer  antihypertensive  agents,  such  as  amlodipine  and  angiotensin  receptor  blockers 
(ARBs), offer greater protection than “older” atenolol and diuretic based regimens (158). In 
a recent meta-analysis (158), calcium channel antagonist (except verapamil), angiotensin 
converting enzyme inhibitor (ACEI) and ARB based therapy was superior to diuretic or ß-  - 54 - 
blocker therapy, affording 7% greater protection against stroke (OR 0.93 (95% CI 0.89-
0.98). This may however be due to the small differences in achieved blood pressure control 
rather than specific ancillary properties of any drug (159).  
 
Treatment of hypertension in those who have stroke has now also been shown to reduce 
recurrent stroke risk.  In a recent meta-analysis (158), odds of recurrent stroke were reduced 
by 24% (OR 0.76, 95% CI 0.63-0.92), but interestingly, the strongest evidence exists for 
diuretic based therapies, as opposed to ACE inhibitor or ß blocker based regimens (OR 0.63, 
95% CI 0.55 to 0.73 vs placebo compared to a non-significant 8% reduction in the odds on 
ACEI based therapy).  In the PROGRESS trial (160), which included 6105 patients with 
prior  stroke,  treatment  with  either  perindopril  or  a  combination  of  perindopril  and 
indapamide led to a 26% RRR (95% CI 16 to 34%) in major vascular event rate and a 28% 
RRR (95% CI 17 to 38%) in risk of recurrent stroke during follow up. On sub-analysis, 
combination of perindopril and indapamide led to a 43% (95% CI 30 to 54%) RRR in risk 
of recurrent stroke compared to placebo, a 40% (95% CI 29 to 49%) RRR in the risk of 
major vascular events and a 12/5 mmHg blood pressure reduction. Perindopril monotherapy 
afforded only a 5/3 mmHg reduction in blood pressure and a non-significant 4% RRR in 
stroke risk.  Benefits were similar regardless of history of hypertension and the mean blood 
pressure at trial entry was 147/86 mmHg suggesting that those within the normal blood 
pressure range may also benefit from blood pressure reduction after stroke. 
 
The  MOSES  trial  (161)  suggested  that  an  ARB  based  regimen  using  eprosartan  was 
superior to the calcium channel antagonist nitrendipine. This data supported a new and 
popular  hypotheses  that  drugs  which  increased  angiotensin  II  production  would,  via 
increased  activation  of  the  AT2  receptor,  increase  neuronal  resistance  to  anoxia  via   - 55 - 
recruitment  of  collateral  vessels  and  thus  provide  protection  to  ischaemic  brain  (162).  
However, a number of  issues surround interpretation of the MOSES trial including the 
inclusion  of  multiple  events  and  the  use  of  a  comparatively  low  dose  of  nitrendipine 
(although blood pressure reduction was similar in both treatment arms).  Further against 
this  hypothesis,  the  PRoFESS  trial  (163)  showed  no  significant  reduction  in  recurrent 
stroke,  any  recurrent  vascular  events  or  diabetes  following  telmisartan  use.  The  trial 
involved  20332  patients  with  recent  stroke  and  2.5  years  follow  up.  Benefit  was  not 
apparent despite a 3.8/2 mmHg reduction in blood pressure, although use of concomitant 
blood pressure lowering therapy was higher in the placebo group. 
 
Antihypertensive  therapy  is  therefore  recommended  to  both  reduce  risk  of  first  and 
recurrent  stroke and risk  of  other  vascular  events  following ischaemic stroke,  TIA  and 
intra-parenchymal haemorrhage.  Therapy should be considered in all after stroke, although 
target blood pressure levels are not well defined.  Data support the use of diuretic treatment 
or  a  combination  of  diuretic  and  ACE  inhibitor  therapies  in  the  secondary  prevention 
setting and newer antihypertensive agents such as amlodipine or ACEI / ARB regimens in 
the primary prevention setting. 
 
1.03.5  Diabetes 
Diabetes is a risk factor for stroke (164-166) and is an increasingly prevalent condition 
found in as many 33% of patients with ischaemic stroke (167).  In data from Oxfordshire 
(168), diabetes was shown to be an independent risk factor for recurrent stroke (HR 1.85%, 
95% CI 1.18 to 2.9, p<0.01) and a similar relationship has been found in other analyses 
(169). 
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It is recommended that for the primary prevention of stroke that a lower blood pressure 
target is employed in those with diabetes (130/80 mmHg) and hypertension and this is 
effective in reducing stroke risk (170;171).  In the UKPDS (172), blood pressure control (to 
a mean of 144/82 mmHg) yielded a 44% RRR in risk of stroke and a smaller but similar 
reduction in a combined vascular endpoint.  Additive beneficial effects on progression to 
macroalbuminuria means that ACE inhibitor or ARB based regimens are recommended as 
first-line agents in those with diabetes (173).  
 
Glycaemic control is effective in reducing the risk of microvascular complications, in both 
type 1 and type 2 diabetes (174;175). These include diabetic retinopathy, nephropathy and 
neuropathy. Data  concerning the impact of glycaemic control on risk of macrovascular 
complications  including  stroke  are  less  convincing.  Trends  toward  a  reduction  in 
cardiovascular  event  rates  have  been  seen  but  this  remains  unproven  (176;177).  
Furthermore, data from two recent randomised controlled trials were disappointing. The 
ADVANCE  trial  (178)  included  11,140  patients  and  compared  an intensive strategy  of 
gliclazide ± other drugs with standard treatment and found a 10% reduction in incidence of 
microvascular or macrovascular disease during follow-up (HR 0.9, 95% CI 0.82 to 0.98, 
p=0.1).  This  was  predominantly  due  to  a  reduction  in  rate  of  nephropathy  with  no 
difference  in  macrovascular  event  rate  (HR  0.94,  95%  CI  0.84  to  1.06,  p=0.32).    The 
ACCORD trial (179) was of similar magnitude and included 10,251 patients. It compared 
efficacy of an intensive strategy intended to achieve a glycated haemoglobin level of below 
6% and a standard therapy strategy aiming for a level of 7 to 7.9%. The rate of primary 
outcome of non-fatal MI or stroke or cardiovascular death was similar between the groups 
(HR 0.9, 95% CI 0.78 to 1.04, p=0.16) but mortality was higher (HR 1.22, 95% CI 1.01 to 
1.46, p=0.04) leading to premature termination of the trial. Significant hypoglycaemia and   - 57 - 
weight gain were also more common. Sub-analysis showed no suggestion of benefit with 
specific regard to stroke risk in either of these trials.  
 
Recent European guidelines suggest those with type 2 diabetes who do not require insulin 
and  have  suffered  stroke  be  commenced  on  pioglitazone  therapy  (55).    However,  this 
recommendation is based on data from subgroup analysis from the PROactive trial (180) 
which included 5238 patients with type 2 diabetes and known macrovascular disease and 
compared  pioglitazone  with  placebo.  In  the  cohort  with  previous  stroke  (≈500  in  each 
group) there was  a trend toward a  reduction in major vascular events and death  and a 
significant reduction in both fatal and non-fatal stroke (HR 0.53, 95% CI 0.34 to 0.85) and 
CV death, non-fatal MI and stroke (HR 0.72, 95% CI 0.52 to 1, p=0.0467) (181). 
 
1.03.6  Cardioembolic Stroke / Atrial Fibrillation 
Approximately 20% of strokes are cardioembolic with the majority of cases being due to 
atrial fibrillation.   Left  ventricular mural thrombus and valvular heart disease are other 
important causes (182) with the majority of left ventricular mural thrombi being associated 
with  acute  myocardial  infarction.    Atrial  fibrillation  is  increasingly  common  and  the 
incidence rises dramatically with age. It is estimated that its prevalence roughly doubles 
with each advancing decade from 0.5% at age 50-59 years to nearly 9% in the ninth decade 
of life (183). 
  
Presence of atrial fibrillation predicts both first stroke and recurrent stroke and those with 
concurrent  increased  age,  diabetes,  congestive  cardiac  failure,  previous  stroke  and 
hypertension are at the highest risk. Concurrent increased left atrial size, spontaneous echo 
contrast and left ventricular dysfunction on echocardiography are also predictive factors   - 58 - 
(184). Scoring algorithms are now commonly employed to help predict stroke risk and 
identify those with atrial fibrillation most likely to benefit from anticoagulant treatment. An 
example is the CHADS2 score (185) where the variables presence of recent congestive 
cardiac failure, hypertension, age > 75 years and diabetes mellitus are assigned 1 point and 
history  of  stroke  or  TIA  two  points.  Those  with  a  score  of  2  or  more  (assuming  no 
treatment) have a stroke risk of approximately 4% per annum rising to 8.5% per annum in 
those with a score of 4. The most widely used and studied anticoagulant is warfarin which 
inhibits synthesis of vitamin K dependent clotting factors. 
 
In the primary prevention setting, warfarin is hugely effective. Pooled analysis from the 
major placebo controlled trials reveals a highly beneficial RRR of 68% for ischaemic stroke 
(186) compared to placebo. In absolute terms, the stroke rate fell from 4.5% per annum to 
1.4% with warfarin treatment.  Maximum benefit requires the INR to be above 2 (187;188) 
and the recommended INR range is 2 to 3. 
 
Pooled  analysis  from  large  placebo  controlled  trials  (189)  also  confirms  that  primary 
prevention with aspirin provides a reduction in stroke risk compared to placebo (RRR 21%, 
95% CI 0 to 38%). However, it is clearly an inferior strategy when compared to warfarin 
(190). Meta-analysis revealed a RR of 0.36 (95% CI 0.26 to 0.51) for those treated with 
warfarin compared to aspirin. Similar benefit is also seen in the elderly (191;192). 
 
In the secondary prevention of stroke, warfarin is also highly effective in those with atrial 
fibrillation. In the European Atrial Fibrillation Trial (188), the annual rate of stroke, MI, 
systemic embolism or vascular death was 8% with warfarin in comparison to 15% with 
placebo (HR 0.60, 95% CI 0.41 to 0.87). The timescale of initiation of anticoagulation in   - 59 - 
this setting is unclear. It is clear that early unselected use of anticoagulation (with heparin) 
in those without cardioembolic stroke is ineffective (89-91) but whether it is of benefit in 
those with AF is unclear (92). In the European Atrial Fibrillation Trial (188), nearly one 
half of patients commenced anticoagulation within 14 days, although their neurological 
deficits were minor. Thus, it is generally recommended that anticoagulation be initiated 
within two weeks in those with AF and stroke, although delays of one week are commonly 
employed and guidelines suggest the decision regarding timing be individualised (55). Dual 
anti-platelet therapy with aspirin and clopidogrel was compared to warfarin in the ACTIVE 
W trial (193). This included 6706 patients and suggests that dual anti-platelet therapy offers 
inferior stroke protection at the cost of a similar burden of bleeding complications. 
 
Regarding safety and risk of haemorrhage, warfarin can be considered safe in comparison 
to aspirin, with a major bleeding rate of 1.3% compared to 1% on aspirin or placebo. 
 
There are a number of newer anticoagulant agents in development, many of which are now 
in  phase  3  study.  These  include  direct  thrombin  inhibitors  (such  as  ximelagatran  and 
dabigatran etexilate (194;195) and factor Xa inhibitors such as Rivaroxaban (196;197). The 
potential benefits of these drugs include a lack of requirement for dose adjustment and 
regular monitoring but as yet, none has been shown to be as safe or effective as warfarin for 
the prevention of stroke in those with atrial fibrillation. Ximelagatran was shown to be as 
efficacious as warfarin with a similarly low risk of bleeding complications in both primary 
and secondary prevention in two large trials (198). The drug was however removed from 
the market because of concerns over hepatic toxicity (199).  
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In  the  ACTIVE-A  study,  clopidogrel  was  compared  to  placebo  in  those  with  atrial 
fibrillation taking aspirin who were deemed unsuitable for anticoagulation (200).  The rate 
of vascular events was significantly lower in those treated with clopidogrel and aspirin (RR 
0.89, 95% CI 0.81 to 0.98) and in particular, the risk of stroke was reduced (RR 0.72, 95% 
CI  0.62  to  0.83).  The  risk  of  major  haemorrhage  was  however  increased  with  dual 
antiplatelet therapy (from 1.3% per year to 2% per year, RR 1.57, 95% CI 1.29 to 1.92). 
 
Thus, in summary, anticoagulation with warfarin is the treatment of choice for prevention 
of recurrent stroke in those with cardioembolic stroke. It is also the treatment of choice for 
primary prevention of stroke in those with atrial fibrillation whose risk of stroke exceeds 
the likely risk of haemorrhage. Risk stratification algorithms can be employed to aid this 
decision. In those deemed unsuitable for anticoagulation, aspirin is effective and therapy 
with aspirin and clopidogrel leads to significantly fewer strokes at the cost of increased 
haemorrhage risk. 
 
1.03.7  Carotid Artery Intervention 
Approximately  10-15%  of  ischaemic  strokes  are  thought  to  be  due  to  large  artery 
atherosclerosis  (201),  most  of  which  are  associated  with  a  stenosis  of  the  ipsilateral 
extracranial carotid artery. This stenosis can be remedied by carotid endarterectomy (CEA), 
where, under local or general anaesthesia, the carotid artery is dissected free, opened and 
the  atheromatous  stenosis  removed.  Percutaneous  placement  of  a  stent  via  the  femoral 
artery is an alternative approach. Large randomized controlled trials have shown superiority 
of carotid endarterectomy in comparison to medical therapy (202-204) in those who have 
symptomatic severe carotid stenosis. A pooled analysis of the major symptomatic stenosis 
trials (205) included data on over 6000 patients. In those with symptomatic severe (≥70%)   - 61 - 
stenosis, surgery afforded a 16% absolute risk reduction (ARR) over 5 years and a smaller 
4.5% ARR (p=0.04) in those with moderate (50-69%) stenosis. Surgery slightly increased 
risk (by 2.2%) of stroke in those with less than 30% stenosis (p=0.05) but no effect on risk 
was seen in those with 30-49% stenosis or near occlusion. 
 
Further analysis from a pooled dataset of the largest trials shows that early surgery, despite 
its inherent increased risk, is associated with greater absolute and relative risk reduction 
than  delayed  surgery  (206).  In  those  with  severe  stenosis,  surgery  in  those  who  were 
randomized to treatment within 2 weeks of symptoms afforded an ARR of 23% (95% CI 
13.6 to 32.4%) compared to only 7.4% (95% CI -3.3 to 18.1%) if randomized after 12 
weeks. In those with moderate stenosis randomized there was a 14.8% ARR (95% CI 6.2 to 
23.4%)  following  surgery  if  randomized  within  2  weeks  but  no  significant  benefit  if 
randomized thereafter. 
 
Thus, if treated early, benefit is also apparent for those with a symptomatic 50-69% stenosis. 
It  is  also  possible  to  further  refine  the  risk-benefit  ratio.  Of  those  with  symptomatic 
moderate stenosis, men, those aged over 75, those with evidence of infarction and those 
with hemispheric (rather than retinal) symptoms appear to benefit  most (207-210). Co-
morbidity  must  also  be  considered  as  this  will  increase  peri-operative  risk  and  thus 
adversely refine the risk benefit ratio. Peri-procedural risk is a key factor in determining 
benefit  from  carotid  endarterectomy;  the  lower  the  absolute  benefit  from  carotid 
endarterectomy (such as in younger female patients or asymptomatic disease), the lower the 
surgical complication rate requires to be to ensure benefit. It is generally accepted that this 
must be <6% for those with severe stenosis but < 3% in those with moderate stenosis (55) 
and those with asymptomatic disease.   - 62 - 
 
Carotid artery stenting (CAS) has not yet been proven to be superior or even equivalent to 
carotid  endarterectomy.    Several  trials  have  been  performed,  2  of  which  have  been 
terminated early because of poor results in the stenting arm and 1 of which because of slow 
recruitment. The Wallstent trial (211) involved 219 patients with symptomatic stenosis and 
found a higher peri-procedural stroke rate and a higher rate of major stroke or death at 1 
year  when  compared  to  endarterectomy  (12.1%  vs  4.5%  (p=0.049)  and  3.7%  vs  0.9% 
(p=0.204) respectively). It has since been criticized for allowing relatively inexperienced 
stent operators to participate – a criticism also levied at the recent EVA-3S study (212). 
 
EVA -3S included patients with at least 60% carotid stenosis and ipsilateral stroke within 
120  days.  It  was  terminated  prematurely  after  inclusion  of  527  patients;  the  30  day 
incidence of stroke or death was 3.9% following carotid endarterectomy and 9.6% after 
stenting (RR 2.5, 95% CI 1.2 to 5.1). When only disabling stroke or death were considered, 
it remained more common in the stenting group (3.4% vs 1.5%, RR 2.2, 95% CI 0.7 to 7.2) 
and outcomes were significantly worse at 6 months.  
 
A further recent trial (213) also failed to prove non-inferiority of carotid stenting. The 
SPACE trial included 1200 patients with severe symptomatic (within 6 months) carotid 
stenosis. Outcomes were similar. The rate of death or ipsilateral ischaemic stroke within 30 
days was 6.84% following stenting and 6.34% following endarterectomy (OR 1.09, 95% CI 
0.69 to 1.72). Despite these similar outcomes, the pre-specified non-inferiority margin was 
missed. The reasons for these differing results are not clear but in SPACE, interventional 
radiologists were required to show greater levels of experience than in EVA-3S before 
being included in the study.   - 63 - 
 
Some trials have however showed similar outcomes following stenting. The CAVATAS 
trial  enrolled  504  patients  with  symptomatic  carotid  disease  and  compared  CEA  with 
carotid  angioplasty  (only  ¼  of  patients  received  stents)  (214).  The  trial  also  included 
participants with vertebrobasilar stenotic disease.  The 30 day risk of stroke or death was 
similar (9.9% with CEA and 10% with CAS) with no difference in recurrent stroke rate at 1 
year.  The  peri-surgical  risk  was  however  higher  than  that  suggested  as  the  maximum 
accepted level in consensus guidelines (55). CAVATAS does however provide important 
long-term follow up data in those who have undergone percutaneous carotid intervention 
and while restenosis appears more common in those who underwent angioplasty (215), it 
may not translate into worse clinical outcome and may not afflict those who also received 
stenting (216).  
 
In the SAPPHIRE trial (217), 334 patients deemed at high risk were randomized to either 
CEA or CAS with emboli detection. Patients either had at least 50% symptomatic stenosis 
or asymptomatic 80% stenosis. The endpoint was a composite of death, stroke or MI within 
30 days after the event or ipsilateral stroke between 31 days and 1 year. This was less 
frequent following stenting (12.2% vs 20.1%, absolute difference of 7.9%, 95% CI -0.7 to 
16.4%) and the non-inferiority criteria were met (p=0.004 for non-inferiority). The benefit 
was largely driven by a reduction in MI in those treated with CAS.  Importantly, the peri-
procedural  rate  of  stroke,  MI  or  death  following  CAS  was  only  4.8%  in  this  study  in 
comparison to the higher rates in other trials (212;213). The peri-procedural complication 
rate following endarterectomy was high at 9.9%. However, long-term follow up data are 
now available (218) and further support the authors initial assertions that, in this patient 
group, stenting can afford similar outcomes compared to CEA.    - 64 - 
 
At  the  time  of  writing,  the  Carotid  Revascularization  Endarterectomy vs  Stenting  Trial 
(CREST) (219) is ongoing and aims to recruit 2500 patients with symptomatic stenosis and 
will hopefully clarify the relative benefits or otherwise of carotid stenting. 
 
Carotid  endarterectomy  in  the  primary  prevention  setting  (those  with  asymptomatic 
stenosis)  has  also  been  the  subject  of  large  randomized  controlled  trials  (220-222).  In 
general, these trials support benefit in those with at least moderate stenosis although the 
absolute benefit appears small and thus mandates a low peri-procedural complication rate to 
give benefit.  For example, in the most recent trial, the Asymptomatic Carotid surgery Trial 
(223),  3120  patients  were  randomized  to  either immediate  endarterectomy  or  indefinite 
deferral of endarterectomy. The peri-operative rate of stroke or death was 3.1% following 
CEA. Even when these events were considered, the 5 year risk of stroke or death was lower 
following CEA (6.4% vs 11.8%, ARR 5.4%, 95% CI 3 to 7.8). Similar benefits were seen 
when only fatal events were considered. On subgroup analysis, benefit was not apparent in 
those aged over 75 years.  
 
1.03.8  Utility of Microembolic Signals 
As well as the parameters mentioned, there are further means of risk stratifying individuals 
with carotid disease. Asymptomatic microembolic signals (MES) can be detected using 
transcranial Doppler ultrasound scanning (TCD) (223). The prevalence of MES has varied 
in studies and they are thought to represent thrombi
 and platelet fibrin aggregates (224;225). 
They are found in those with carotid artery disease, and are more common in those with 
recent symptoms (226;227), in those with atrial fibrillation and they arise during cardiac 
and aortic surgery and can be found thereafter in those with cardiac valve prostheses, and in   - 65 - 
particular  those  with  metallic  valves  (228).  In  those  with  recently  symptomatic  carotid 
stenosis, they are typically seen in approximately 40% of individuals (227;229), although 
higher and lower prevalence has been seen. 
 
In  those  with  carotid  disease,  their  occurrence  has  been  shown  to  be  predictive  of  an 
increased stroke risk (226;227;230;231) in a series of small studies.  For example, in one 
study (226) of 64 asymptomatic individuals with unilateral
 70% to 90% internal carotid 
artery stenosis, a microembolic rate of ≥2 per
 hour was associated
 with increased risk of 
suffering ischaemic stroke. However, only five strokes occurred, hence the uncertainty of 
size  of  the  association  (odds  ratio  31,  95%  CI  3  to  302,  p=.005).    In  a  further  study, 
microembolic  signals  at  study  entry  were  predictive  of  TIA  and  stroke  risk  in  both 
symptomatic  and  asymptomatic  patients  with  an  adjusted  combined  odds  ratio  of  8.1, 
although again there  was uncertainty  regarding  the actual  magnitude of  the association 
(95% CI,
 1.58 to 41.5, p=0.01 (231;232).   
 
Microembolic signals (MES) are responsive to anti-platelet therapy; aspirin has some effect 
(233) but more marked effects are seen with addition of clopidogrel (234), with the platelet 
glycoprotein inhibitor tirofibran (235), and with S-Nitrosoglutathione (a nitric oxide donor) 
therapy (236).  The feasibility of using MES as a surrogate endpoint in clinical trials was 
recently studied (234).  As outlined earlier, the CARESS investigators showed that they 
could use MES to detect treatment differences between groups using much smaller numbers 
than trials with traditional clinical endpoints. 
 
Thus, in those with recent stroke or TIA and carotid artery stenosis, carotid endarterectomy 
should be performed if the stenosis is greater than 70% but not sub-totally occluded and if   - 66 - 
the peri-procedural complication rate in that centre is lower than 6% (55). It should also be 
performed in some high risk individuals with moderate stenosis but not in stenosis of less 
than 50% and only if the predicted peri-procedural complication rate is acceptably low. If 
indicated, surgery should be performed as soon as possible and preferably within 2 weeks 
of symptoms. CAS is a viable alternative strategy, particularly if endarterectomy is not 
possible provided the peri-procedural complication rate is in the region of 4-6% (170). In 
those with asymptomatic disease, guidelines therefore suggest that those with high risk of 
stroke such as men with severe stenosis who have a life expectancy of > 5 years can be 
considered for surgery where the peri-operative risk is low at 3% or less (55). Further, 
presence of microembolic signals may help identify a particularly high risk group with 
carotid disease. 
 
1.03.9  Behavioural Risk Factors 
Smoking Cessation 
Cigarette smoking is an independent risk factor for both stroke and recurrent stroke (237).  
In a meta-analysis performed nearly 20 years ago (238), smoking linked with a doubling of 
risk  of  ischaemic  stroke  following  adjustment  for  other  risk  factors.    There  are  no 
randomised controlled trials to evaluate the efficacy of smoking cessation therapy after 
stroke  as  it  is  generally  regarded  as  an  important  strategy  given  compelling  data  from 
observational studies and the other health benefits associated with stopping.  Observational 
data suggest that stopping smoking affords a reduction in stroke risk and that risk returns to 
that of a non-smoker after 5 years (239).  Further, data show that rates of admission for 
acute  coronary  syndrome  fell  significantly  after  the  smoking  ban  in  Scotland  (240), 
although no data are available to show effect on stroke risk. Guidelines currently suggest   - 67 - 
that a combination of pharmacological and behavioural therapy is used, an approach for 
which there is some evidence (241;242).  
 
Excess Alcohol Intake 
The  relationship  between  alcohol  intake  and  stroke  risk  is  complex,  unproven  and 
somewhat controversial. It is generally accepted that the relationship is J-shaped with heavy 
drinkers having an increased risk and likewise those who consume no alcohol (243). Those 
who consume small or moderate amounts of alcohol, have the lowest risk. In a recent meta-
analysis (244), those who consumed more than 5 drinks per day had a RR of 1.69 for stroke 
compared to non-drinkers while those who drink less than one or one to two drinks per day 
had a RR of 0.8 and 0.72 respectively.  The relationship probably holds with regard to the 
risk of recurrent stroke (245).  Guidelines suggest that those who are heavy drinkers should 
be advised to eliminate or reduce their consumption of alcohol. 
 
Weight Reduction / Physical Exercise 
Obesity is also a risk factor for stroke and (246), while it is linked to several major risk 
factors such as blood pressure, presence of diabetes and cholesterol level (247-249), the 
relationship appears independent (248).  The relationship between risk and centri-pedal 
obesity (measured by the waist-hip ratio) may be the strongest with risk tripling in the 
highest quartile of the  distribution (250). As  yet, no data exist to suggest benefit from 
weight  reduction  in  obese  individuals  with  stroke  but  given  the  benefits  on  metabolic 
parameters such as lipid levels and blood pressure, guidelines suggest weight management 
is encouraged through lifestyle measures (154). Pharmacotherapy to aid weight reduction is 
a growing area and several agents are undergoing phase III clinical trials at the time of 
writing, some of which include clinical cardiovascular endpoints.   - 68 - 
 
Moderate intensity physical exercise is also encouraged for those who area able and links 
with improvement in cardiovascular risk parameters (154). No evidence exists to confirm 
clear benefit on stroke risk but in those who have suffered stroke, exercise can improve 
mobility and fitness (251). 
 
There  are  thus  a  number  of  effective  preventative  therapies  for  both  the  primary  and 
secondary prevention of stroke.  Strategies include anti-platelet therapy and lipid lowering 
therapy  to  prevent  ischaemic  stroke,  anticoagulant  therapy  to  prevent  cardioembolic 
ischaemic stroke and blood pressure reduction, treatment of prevalent diabetes, lifestyle 
therapy and behavioural modification to prevent all stroke subtypes.  
 
Summary 
It is difficult to accurately predict the impact of currently available therapies but it is clear 
from recent randomised controlled trials and epidemiological data that first and recurrent 
stroke  remain  common  and  that  they  will  become  increasingly  so.  Using  the  recent 
PRoFESS  trial  as  an  example,  approximately  9%  of  patient  suffered  recurrent  stroke 
despite high uptake of preventative therapies. It is therefore clear that both the optimal and 
rapid use of current strategies and the development of novel therapies are required to ensure 
best possible stroke prevention. 
 
This programme of research and thesis aimed to make improvements in several of these 
areas, with emphasis on improving access to care (chapter 2), improving use of current 
therapies (chapter 3) and the development of new preventative strategies (chapter 4).    - 69 - 
 
 
 
 
 
CHAPTER TWO 
 
 
 
 
A RECOGNITION TOOL FOR TRANSIENT ISCHAEMIC 
ATTACK   - 70 - 
Development of a Recognition Tool for Transient Ischaemic Attack 
 
2.01  Difficulties in Delivering Effective Therapies 
 
Those with TIA represent a high risk group whose risk of stroke is highest in the first 48 
hours  (32).  UK  guidelines  therefore  recommend  that  patients  with  suspected  TIA  are 
assessed as soon as possible (and at least within 1 week) (33;34) in fast track or rapid 
access neurovascular clinics (35). However, at the time of writing the sad reality is that TIA 
is poorly managed in the UK and guideline recommendations are not widely met. Recent 
reports from the UK National Audit Office and the House of Commons Public Accounts 
Committee (5) found that approximately half of patients with suspected TIA were seen 
within 14 days, 58% had a scan outside an effective time window and the majority waited 
12 weeks or more for a carotid ultrasound scan. This must be improved as more rapid 
management  is  effective  in  reducing  stroke  risk  (252).    It  may  even  be  that  current 
guidelines are not stringent enough and that assessment on the day of the event should be 
the aim. The recent EXPRESS study provides compelling evidence (252) that urgent (same 
day) assessment of those with TIA dramatically reduces risk of early stroke. This was a 
very  well  conducted  observational  study,  where  outcomes  in  an  initial  standard 
management phase were compared to those of an urgent same day appointment system. The 
risk of early stroke in the early phase was 10.2% compared to 2.1% in the later phase. 
There are two important points worth mentioning. Firstly, even the initial phase represents 
a significantly more acute and advanced system than exists in most of the UK. Secondly, 
the  main  difference  between  the  study  phases  was  the  time  lag  to  therapy  initiation; 
treatment protocols were similar (although anti-platelet therapy was more aggressive in the   - 71 - 
later phase), the geographical area was identical and the background incidence of stroke 
and TIA was similar throughout.    
 
Such clinics should therefore be the aim but will increase pressure on scare clinical and 
radiology resources, require more frequent availability of specialist staff and are costly to 
implement and run and a number of barriers preclude their effective introduction.  Current 
delays to assessment include delay to presentation by the patient, delay to referral to the 
TIA service by a General Practitioner (G.P), delays to TIA clinic appointments, delay to 
appropriate investigations and a time lag to initiation of appropriate treatment, including 
both medical therapy and therapy for carotid artery stenosis.  Public awareness campaigns 
to improve patient recognition of stroke symptoms are underway, as are programmes to 
improve knowledge of TIA assessment and management among G.Ps. Several strategies 
could be employed to improve hospital TIA services. The number of rapid access out-
patient clinics could be increased and access to imaging services could be improved. For 
example, stroke services could be supported to develop their own imaging services. 
 
All of these strategies will prove costly and it is likely that improvements and streamlining 
of current systems will be most readily achieved. 
 
2.01.1 Strategies to Improve Care of Those with TIA – Rapid Diagnosis 
An  obvious  target  for  improvement  is  to  reduce  the  number  of  non-cerebrovascular 
referrals to TIA clinics, thereby freeing up existing clinic time.  Difficulties in accurate 
diagnosis of patients with suspected TIA are well documented (253-255); inter-observer 
agreement has been shown to be as low as 50% (256), and between 31 and 62% of patients 
referred  with  suspected  TIA  are  deemed  to  have  a  non-cerebrovascular  diagnosis  by  a   - 72 - 
stroke specialist (255;257-259).  This is also a significant problem in Glasgow (257) where 
a recent analysis of referrals over a one year period revealed that just under 50% had an 
alternative diagnosis. Such a large number will make it more difficult for services to meet 
their aim of rapid assessment of those with TIA. 
 
Improvements  in  the  diagnostic  accuracy  during  assessment  of  suspected  TIA  by  non-
specialists  (G.Ps  for  example)  could  be  achieved  if  simple  diagnostic  algorithms  were 
available.  Stroke assessment tools have been developed to aid in the rapid and accurate 
identification of those with stroke and to ensure appropriate ambulance dispatch of the 
patient. Most have been designed for use by paramedical staff and include the Los Angeles 
Pre hospital Stroke Screen (LAPSS) (260), the Cincinnati Pre hospital Stroke Scale (CPSS) 
(261), a combination of the two, the Melbourne Ambulance Stroke Screen (MASS) (262) 
and the Face Arm Speech Test (FAST) (263).  The CPSS and the FAST involve a screen 
for clinical signs commonly seen in stroke, while the LAPSS and MASS encompass both 
components of the history which make stroke less likely and clinical signs commonly seen 
in stroke.  If all the history items are absent and the patient has appropriate signs, stroke is 
deemed to be present.  Use of these scales leads to reasonable diagnostic accuracy - 80% 
diagnostic accuracy for the LAPSS, 84% for the CPSS and 86% for the MASS (262) with 
similar rates likely with FAST (263).  A further study showed that paramedic diagnostic 
accuracy using the  LAPSS improved  after  a period of training (264).  The commonest 
stroke  mimics  with  these  tools  are  cardiac  events,  seizures,  hypoglycaemia,  subdural 
haematoma and fracture.  Missed strokes (10% of 73 using the MASS for example) usually 
occurred because of presence of a history item or where a visual field defect was the only 
clinical  sign  (not  scored  in  scale).    The  more  recently  developed  ROSIER  scale  (265) 
extends the concept of the stroke assessment tool from the field into the emergency room   - 73 - 
and is intended for use by emergency room staff. The clinical skill possessed by emergency 
room  physicians,  in  comparison  to  paramedical  staff,  applied  in  an  environment  more 
conducive to thorough assessment should allow the use of more complex assessments and 
thereby yield better diagnostic accuracy. The main differences between ROSIER and the 
paramedic stroke scales are a specific question regarding syncope (which should increase 
specificity)  and  an  examination  to  identify  visual  field  defects  (which  should  increase 
sensitivity).    Early  use  of  ROSIER  has  yielded  promising  results:  sensitivity  was  93% 
during the prospective validation phase, comparing favourably with the paramedic stroke 
recognition instruments. Specificity was broadly similar to previous scales, although fewer 
stroke  mimics  were  referred  during  the  validation  phase  of  the  study,  suggesting  that 
specificity may improve as experience grows.  
 
Nearly all (6/7) of the missed stroke patients during testing of ROSIER had mild symptoms 
with an NIHSS score of <3, whom the authors would not have considered for thrombolytic 
treatment. This does, however, highlight a potential weakness of the ROSIER scale and 
also, posterior circulation stroke was more likely to be missed.  The authors state that the 
inclusion  of  assessment  of  eye  movements  into  the  ROSIER  scale  would  have  led  to 
detection of 2 more strokes and increased sensitivity further to 95% and this merits further 
consideration. 
 
Lessons from these scales and a recent systematic review of the predictive value of various 
symptoms and clinical signs encountered when evaluating suspected stroke patients (266) 
helps identify those variables likely to be of use in an assessment algorithm for suspected 
TIA.  It is clear that unilateral weakness, in particular of the arm and face, and a language 
disorder strongly suggest that a stroke or TIA has occurred, while the absence of such signs   - 74 - 
and the presence of loss of consciousness or seizure activity point toward an alternative 
diagnosis.  Diplopia, vertigo and sensory loss, while consistent with stroke or TIA, are of 
less value in making a clear clinical diagnosis but may contribute. As yet however, there 
are no such diagnostic algorithms in use for suspected TIA, although clinical prediction 
tools have been developed to aid risk stratification following confirmed TIA. An example is 
the “ABCD” scoring tool and its refinement “ABCD2”, both of which were developed and 
validated  in  cohorts  with  confirmed  TIA.  Using  only  clinical  parameters,  the 
ABCD/ABCD2 scores describe ordinal hierarchical scales from 0 – 6/7 (table 2.1). Those 
with the highest scores have significantly increased risk of early stroke (31;32). 
 
A  Age  ≥ 60 years  1 point 
B  Blood pressure  ≥ 140/90 mmHg  1 point 
C  Clinical features  Unilateral weakness  2 points 
    Speech impairment without weakness  1 point 
D  Duration  ≥ 60 minutes  2 points 
    10-59 minutes  1 point 
D  Diabetes  Presence of Diabetes Mellitus  1 point 
Table 2.1. ABCD2 Scoring Criteria. When using the ABCD score, no point is added 
for prevalent Diabetes Mellitus. 
 
There  remain  some  controversies  regarding  widespread  use  of  these  tools.  Attempts  to 
validate  these  systems  in  independent  populations  have  been  generally  (32),  but  not 
universally successful (267) and some groups have questioned the utility of a score that 
does not incorporate significant carotid disease or other potential cardio-embolic source 
(268).  Most  importantly,  in  the  original  and  subsequent  ABCD  validation  studies, 
presentation with true TIA was assumed. This renders suitability of the tool by referring 
practitioners  (or  using  information  from  them)  on  all  those  referred  to  TIA  services   - 75 - 
unsupported; TIA assessment services consistently see a high rate of non-cerebrovascular 
pathologies (257). Further, given that the majority of studies testing the properties of the 
ABCD system did not utilise brain imaging to support ischaemic brain damage and the 
known difficulties with diagnosis, it is possible the cohorts described included a substantial 
proportion of patients without a true TIA. It could be argued the very low rate of early 
stroke in those with a low ABCD score (32) supports this assertion and that part of the 
utility  of  these  tools  is  to  distinguish  true  TIA  from  other  more  benign  pathologies. 
Regardless, the utility of these scores could be seen to justify attempts to develop better and 
more encompassing diagnostic tools. 
 
Thus,  data  from  the  field  of  acute  stroke  and  from  risk  stratification  instruments  for 
confirmed TIA suggest that development of an algorithm or clinical scoring system for 
diagnosis of TIA should be possible. If it were, and the number of patients referred with 
alternate diagnoses was reduced, this could reduce burden on services and improve care for 
those with genuine TIA.  
 
2.02  Chapter Aim / Hypothesis 
The  hypothesis  was  that  a  diagnostic  algorithm  and  clinical  scoring  system  could  be 
developed to aid accurate diagnosis of TIA and minor stroke in the community, that its use 
would reduce the numbers referred with non-cerebrovascular diagnoses and that this would 
reduce clinic waiting times and facilitate rapid assessment. The aim was to develop and 
rigorously test such a system. 
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2.03  Methods 
 
The algorithm was developed using data contained in the West Glasgow Stroke Registry 
and was tested on an independent prospective data set from the same source. The impact of 
the projected reduction in non-cerebrovascular referral rate was then assessed using real 
data on referral rates and clinic availability during the prospective validation study. 
 
The West Glasgow Stroke Registry 
The Western Infirmary serves a catchment population of approximately 225,000 people and 
receives approximately 500-600 outpatient referrals per year (predominantly (>95%) from 
GPs).  The fast track TIA clinic is held twice weekly. Baseline demographic data, a history 
of  presenting  complaint,  relevant  examination  findings  and  diagnosis  and  management 
plans are prospectively recorded at the time of clinic review. All patients are discussed with 
a Consultant Stroke Physician (with at least 10 years experience). Data are entered into an 
electronic  database  (the  West  Glasgow  Stroke  Registry)  which  currently  includes  all 
patients who attended the Fast Track clinic between March 1992 and January 2005. At a 
follow up visit, data regarding investigation results, final diagnosis and treatment plans are 
gathered.   
 
Development of the Diagnostic Tool 
The  diagnosis  (“cerebrovascular”  versus  “non-cerebrovascular”)  as  determined  at  clinic 
visit was used as the reference standard in the study. This included patients with TIA and 
those with minor stroke symptoms lasting 24 hours who had not been referred to the in-
patient service. Variables felt likely to be useful in the diagnosis of TIA, including those 
thought to be suggestive of an alternative diagnosis (table 2.2) were identified in advance.    - 77 - 
Included  variables  were  symptoms  used  in  stroke  diagnostic  algorithms  and  those 
previously  shown  to  predict  a  stroke  diagnosis  (261-263;265;266).    Logistic  regression 
models were used to identify discriminatory variables and to develop a clinical scoring 
system. 
 
Statistical Analysis 
Analyses were performed using S Plus version 6.2. First, univariate analysis was used to 
identify variables predictive of diagnosis. Logistic regression models were used to identify 
independently discriminatory variables.  Stepwise selection procedures were employed to 
identify significant explanatory variables using Akaike’s Information Criterion (269). In a 
forward stepwise selection procedure, the initial model involves no explanatory variables 
and the most significant variable of all the explanatory variables is added to the model at 
each  step  until  all  significant  variables  are  included.  In  backward  selection,  the  initial 
model  involves  all  possible  explanatory  variables  and  at  each  step the  least  significant 
variable is omitted from the model until the final model selected involved only significant 
variables. Two way interaction variables were also considered. The interactions considered 
were all feasible two way interactions within each subcategory of predictive variables (as 
shown  in  table  2.2).  The  final  model  was  internally  validated  using  three-fold  cross 
validation.  During three-fold cross-validation, the data were split into three groups of equal 
size and the model was fitted to the data of two of the groups to predict the class of the 
remaining group. This was repeated for all group combinations and for two further random 
splits of the data. 
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Variables that showed discriminatory power were considered for inclusion in a clinical 
scoring system. Non-weighted (where explanatory variables were assigned a value of 1), 
weighted and rounded weighted scoring systems (based upon the regression co-efficient) 
were  then  developed.  Receiver  operating  characteristic  curves  were  used  to  determine 
optimal  cut-off  scores;  and  sensitivity,  specificity  and  positive  and  negative  predictive 
values  were  calculated.    Following  this  two  ‘costs  of  misclassification’  models  were 
developed to reflect the presumed greater importance of failing to identify cerebrovascular 
Risk  Factors    / 
Miscellaneous 
Predictive  of 
Cerebrovascular 
Diagnosis 
Predictive  of  Non 
Cerebrovascular 
Diagnosis 
Smoker  Unilateral Face Weakness *  Headache * 
Hypertension *  Unilateral Arm Weakness *  Seizure * 
Diabetes Mellitus *  Unilateral Leg Weakness *  Loss of Consciousness * 
Hyperlipidaemia *  Unilateral  Face  Sensory 
Disturbance * 
Atrial Fibrillation  Unilateral  Arm  Sensory 
Disturbance * 
History of Stroke or TIA *  Unilateral  Leg  Sensory 
Disturbance * 
Other Vascular Disease *  Sudden True Vertigo  
Diplopia * 
Sudden True Ataxia * 
Language Disorder * 
Duration of Symptoms * 
Hemianopic  Visual 
Disturbance * 
Pre-syncope 
Table 2.2.  Pre-identified Variables Felt Likely to be Predictive of Clinic Diagnosis.  
* = variables predictive on univariate analysis, all p<0.001.   - 79 - 
events compared to incorrectly labelling mimics.  A cost of 2:1 is considered when it is 
assumed that the cost of misclassifying a cerebrovascular patient as non-cerebrovascular is 
twice as much as the cost of misclassifying in the opposite direction. Similarly, a cost of 
3:1 is where the cost of misclassifying a cerebrovascular patient as non-cerebrovascular is 
deemed to be three times as great. Essentially it is a penalty assigned for making a mistake, 
taking into account that a failure to treat a life-threatening condition is more serious than 
undertaking unnecessary but generally safe investigations. By raising or lowering the cost 
of a misclassification, decisions are biased in different directions, as if there were more or 
fewer cases in a given class. These ratios were arbitrarily chosen. The Hosmer-Le Cessie 
test (270) was used to evaluate fit of the model. 
 
A formal power calculation was not performed for the multivariable logistic regression 
models;  this  is  notoriously  complex.  However,  the  data  includes  a  large  number  of 
outcomes for each variable included (35 for the least common variable (seizure) with others 
in the hundreds). Further, the small standard errors, small p values and large sample size 
give  further  evidence  that  power  was  sufficient  for  the  plan  to proceed  to  multivariate 
modeling. 
 
Prospective Validation of the Diagnostic Tool 
Data on all referrals to the Fast Track TIA clinic were gathered during the period October 
2005  to  June  2006.  The  clinical  scoring  system  scores  were  not  used  to  aid  clinical 
diagnosis and were later calculated by independent observers who were not involved with 
the patients care or development of the scoring system. 
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Assessment of the Impact of the Tool 
Delays  to  clinic  appointment  during  the  prospective  validation  phase  were  calculated 
(expressed as median and inter-quartile range).  The effect of the projected reduction in 
non-cerebrovascular referral rates was then established via a model based upon the actual 
number of referrals and clinic availability during the study period.  During early modeling 
it was predicted that the scoring system would reduce the number of non-cerebrovascular 
referrals by approximately 50% or 25% with the unadjusted weighted system and 2:1 costs 
model respectively. The median delay to clinic appointment was then recalculated first with 
every second then every fourth non-cerebrovascular patient being removed.  
 
The advice of a Multi-centre Research Ethics Committee was sought and formal ethics 
committee approval and formal informed consent were deemed unnecessary.   
 
2.04  Results 
 
Development of the Scoring System 
The development cohort included 3230 patients. Mean age was 65 years (SD 12.8).  Other 
baseline characteristics are shown in table 2.3.  Sufficient data were available for 3216 
patients, of whom 2215 (69%) had a diagnosis of TIA or minor stroke. 
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Variables predictive of diagnosis on univariate analysis are shown in table 2.2. Three risk 
factors (history of stroke or TIA, hypertension and diabetes) and 17 clinical features were 
significantly predictive of clinician diagnosis on logistic regression analysis. The predictive 
clinical features were headache, vomiting, loss of consciousness, seizure (all predictive of 
non-cerebrovascular diagnosis), age, duration of symptoms, visual loss, diplopia, ataxia, 
speech  disorder,  dysphasia,  unilateral  arm  or  leg  weakness,  unilateral  facial  weakness, 
unilateral  sensory  disturbance,  other  pattern  of  weakness  and  other  pattern  of  sensory 
disturbance  (predictive  of  a  cerebrovascular  diagnosis).    During  stepwise  selection,  8 
variables were rejected from the model leaving twelve explanatory variables. These were 
history of stroke or TIA, headache, diplopia, loss of consciousness, seizure, age, duration of 
symptoms, speech disorder, unilateral leg weakness, unilateral upper motor neuron (UMN) 
facial weakness, unilateral lower motor neuron (LMN) facial weakness and other weakness. 
No interaction terms remained in the model. 
 
Variable  Development Sample 
n=3230 
Validation Sample 
n=237 
Age  65 years (SD 12.8)  65 years (SD 15.7) 
Smoker  1893 (58.6%)  84 (35.45%) 
Hypertension  1484 (45.96%)  111 (46.84%) 
Diabetes  261 (8.08%)  29 (12.24%) 
Hypercholesterolaemia  637 (19.73%)  56 (23.63%) 
Atrial Fibrillation  161 (4.99%)  18 (7.59%) 
Previous Stroke or TIA  937 (29.02%)  55 (22.36%) 
Other Vascular Disease  879 (27.22%)  60 (25.32%) 
Table  2.3  –  Baseline  Characteristics  of  Samples  Used  to  Develop  The  Scoring 
System.   - 82 - 
Three variables were removed as it was felt they would not be useful in the scoring system; 
LMN  facial  weakness  was  removed  as  there  were  few  cases  and  each  occurrence  was 
associated with a diagnosis of Bell’s palsy (a rare occurrence in the TIA clinic). UMN 
facial weakness was then renamed unilateral facial weakness.  Duration of symptoms was 
removed. This was recorded as < 1 hour, 1-24 hours, 1-3 days or > 3 days in the database 
and it was felt none of these boundaries was sensitive enough to influence decision making; 
many TIAs last less than 1 hour, while on the other hand, those lasting longer convey 
greater risk (31;32).  “Other weakness” was also removed. This was essentially defined as 
non unilateral weakness, so was already being accounted for in the model and it was felt 
this may lead to confusion during use of the score.  Unilateral leg weakness was included in 
the final model but unilateral arm weakness was not; this was because the vast majority of 
patients with unilateral arm weakness had unilateral leg weakness and vice versa meaning 
one of these variables was removed during stepwise regression. The variable unilateral leg 
weakness  was  therefore  replaced  by  unilateral  limb  weakness.    This  left  9  predictive 
variables:  6  positive  indicators  of  cerebrovascular  disease  and  3  indicators  of  a  non-
cerebrovascular diagnosis.  The final regression coefficients (when only these 9 variables 
were included and rounded to one decimal place) are shown in table 2.4 and all had p 
values of <0.001. Removal of the unsuitable variables did not affect the performance of the 
final model (assessed using linear discriminant analysis). 
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Explanatory Variable  Coefficient  Standard Error 
History of Stroke (or TIA)  0.51  0.1 (3.5x10
-7) 
Headache  0.46  0.11 (7.1x10
-5) 
Diplopia  1.23  0.28 (2.7x10
-6) 
Loss of Consciousness  1.06  0.21 (1.9x10
-7) 
Seizure  1.58  0.43 (1.4x10
-4) 
Speech Abnormalities  1.29  0.14 (<1x10
-10) 
Unilateral Limb Weakness  1.72  0.10 (<1x10
-10) 
UMN Facial Weakness  0.63  0.15 (9.5x10
-8) 
Age  0.04  0.004 (<1x10
-10) 
Table 2.4. – The final regression co-efficients for variables predictive of clinic 
diagnosis. UMN = upper motor neurone. 
 
The Weighted Scoring System 
The weighted scoring system is shown in table 2.5. Predictive variables were allocated the 
value of the regression coefficient for that variable if the variable was present or absent as 
outlined in the table. ROC curves identified  a  score of >6.1 as the optimal cut-off  for 
prediction  of  cerebrovascular  diagnosis  (figure  2.1).  This  accurately  identified  84%  of 
cerebrovascular  diagnoses  and  60%  of  non-cerebrovascular  diagnoses  with  a  positive 
predictive value (PPV) of 82% and negative predictive value (NPV) of 62% (table 2.6). 
 
With the 2:1 cost ratio, an optimal cut-off score of > 5.4 was used (figure 2.2) and 97% of 
TIA and 24% of non-TIA patients were accurately identified with a positive predictive 
value of 73% and 78% (table 2.7). With a 3:1 cost ratio, an optimal cut-off score of > 5 was 
used and 98% of TIA and 15% of non-TIA patients were accurately identified. With a 5:1 
cost ratio, an optimal cut-off score of > 4 was used and 100% of TIA and 2% of non-TIA   - 84 - 
patients were accurately identified. As these later two scores yielded only minor increases 
in sensitivity with significant falls in specificity, they were not considered further. 
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TIA 
Variable  Score if Yes  Score if No 
History of Stroke or TIA  0.5  0 
Headache  0  0.5 
Diplopia  1.2  0 
LOC / Pre-syncope  0  1.1 
Seizure  0  1.6 
Speech Abnormalities  1.3  0 
Unilateral Limb Weakness  1.7  0 
UMN Facial Weakness  0.6  0 
Age  Multiply by 0.04 
To calculate the score, all values should be summed. If total score >6.1, classify as 
TIA. For “2:1 cost ratio,” if total score >5.4, classify as TIA. 
Table 2.5. – The Weighted TIA scoring system. All values reflect the regression 
coefficients seen. 
Figure 2.1. Receiver Operating Characteristic Curve for Weighted Scoring 
System   - 85 - 
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Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  1852  363  2215 
Non-CVD  397  604  1001 
Column Total  2249  967  3216 
Table 2.6.  2*2 Table for Weighted Scoring System During the Development Phase.  
Calculated sensitivity 84%, specificity 60%, PPV 82%, NPV 62%. 
 
Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  1852  363  2215 
Non-CVD  397  604  1001 
Column Total  2249  967  3216 
Table 2.7.  2*2 Table for Weighted Scoring System with 2:1 Cost Adjustment During 
the Development Phase.  Calculated sensitivity 97%, specificity 24%, PPV 73%, NPV 
78%. 
 
 
Figure 2.2. Receiver Operating Characteristic Curve for Weighted Scoring System 
With 2:1 Cost Ratio   - 86 - 
The Un-weighted Scoring System 
The un-weighted scoring system is shown in table 2.8. Predictive variables were allocated a 
value of one to be added if variable was present or absent as outlined in the table. ROC 
curves identified a score of >5.5 as the optimal cut-off for prediction of cerebrovascular 
diagnosis (figure 2.3).  This accurately identified 82% of cerebrovascular diagnoses and 
60% of non-cerebrovascular diagnoses with a positive predictive value of 82% and NPV of 
60% (table 2.9). 
 
With  the  adjustment  to  reflect  the  greater  seriousness  of  missing  true  cerebrovascular 
patients (the 2:1 cost ratio), an optimal cut-off score of > 4.5 was used (figure 2.4) and 98% 
of TIA and 18% of non-TIA patients were accurately identified (table 2.9).  
 
Variable  Score if Yes  Score if No 
History of Stroke or TIA  1  0 
Headache  0  1 
Diplopia  1  0 
LOC / Pre-syncope  0  1 
Seizure  0  1 
Speech Abnormalities  1  0 
Unilateral Limb Weakness  1  0 
UMN Facial Weakness  1  0 
Age  Multiply by 0.03 
To calculate the score, all values should be summed. If total score >5.5, classify as 
TIA. For “2:1 cost ratio,” if total score >4.5, classify as TIA. 
Table 2.8. – The Un-weighted TIA scoring system.   - 87 - 
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Figure 2.3. Receiver Operating Characteristic Curve for Un-weighted Scoring 
System 
Figure 2.4. Receiver Operating Characteristic Curve for Un-weighted Scoring 
System With 2:1 Cost Ratio.   - 88 - 
Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  1822  393  2215 
Non-CVD  401  600  1001 
Column Total  2223  993  3216 
Table 2.9.  2*2 Table for Un-Weighted Scoring System During the Development Phase.  
Calculated sensitivity 82%, specificity 60%, PPV 82%, NPV 60%. Using the 2:1 Cost 
Adjustment, calculated sensitivity 98% and specificity 18%. 
 
The Rounded Scoring System 
The rounded weighted scoring system is shown in table 2.10. Predictive variables were 
allocated a value of one to be added if variable was present or absent as outlined in the table. 
ROC  curves  identified  a  score  of  >6.6  as  the  optimal  cut-off  for  prediction  of 
cerebrovascular diagnosis (figure 2.5). This accurately identified 85% of cerebrovascular 
diagnoses and 55% of non-cerebrovascular diagnoses with a positive predictive value of 
81% and NPV of 63% (table 2.11). 
 
With the 2:1 cost ratio, an optimal cut-off score of > 5.7 was used (figure 2.5) and 97% of 
TIA and 23% of non-TIA patients were accurately identified.  
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Variable  Score if Yes  Score if No 
History of Stroke or TIA  0.5  0 
Headache  0  0.5 
Diplopia  1  0 
LOC / Pre-syncope  0  2 
Seizure  0  1.5 
Speech Abnormalities  1  0 
Unilateral Limb Weakness  2  0 
UMN Facial Weakness  0.5  0 
Age  Multiply by 0.04 
To calculate the score, all values should be summed. If total score >6.6, classify as 
TIA. For “2:1 cost ratio,” if total score >5.7, classify as TIA. 
Table  2.10.  –  The  Rounded  TIA  scoring  system.  All  values  reflect  the  regression 
coefficients seen rounded to the nearest half integer. 
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Figure 2.5. Receiver Operating Characteristic Curve for Rounded Weighted Scoring 
System.   - 90 - 
Receiver Operating Characteristic Curve for Scoring System
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Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  1891  324  2215 
Non-CVD  450  551  1001 
Column Total  2223  993  3216 
Table  2.11.    2*2  Table  for  the  Rounded  Weighted  Scoring  System  During  the 
Development Phase.  Calculated sensitivity 85%, specificity 55%, PPV 81%, NPV 63%. 
Using the 2:1 Cost Adjustment, calculated sensitivity 97% and specificity 23%. 
 
The Prospective Validation Set 
237 patients were included of whom 143 (60.3%) had a diagnosis of TIA or minor stroke.  
Further baseline characteristics are shown in table 2.3.  
 
The weighted scoring system correctly identified 85% of patients with a cerebrovascular 
diagnosis and 54% of those with a non-cerebrovascular diagnosis with a PPV of 74% and a 
NPV of 70%.  Using the 2:1 misclassification score, 93% of patients with a cerebrovascular 
diagnosis and 34% of those with a non-cerebrovascular diagnosis were correctly identified 
Figure 2.6. Receiver Operating Characteristic Curve for Rounded Weighted 
Scoring System with 2:1 Cost Ratio.   - 91 - 
with  a  PPV  of  68%  and  NPV  of  76%  (table  2.12).  With  the  2:1  cost  adjustment,  the 
rounded weighted scoring system gave a sensitivity of 93% and a specificity of 37% with a 
PPV of 69% and NPV of 78% (table 2.13). Also with the 2:1 cost adjustment, the un-
weighted scoring system gave a sensitivity of 94% and a specificity of 26% with a PPV of 
66% and NPV of 73% (table 2.14). The confidence intervals for all parameters greatly 
overlap those found during the development phase suggesting similar performance of the 
model in each data set. 
 
Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  133  10  143 
Non-CVD  62  32  94 
Column Total  195  42  237 
Table 2.12.  2*2 Table for the Weighted Scoring System with 2:1 Cost Adjustment 
During the Prospective Validation Phase.  Calculated sensitivity 93%, specificity 34%, 
PPV 68%, NPV 76%. 
 
 
Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  133  10  143 
Non-CVD  59  35  94 
Column Total  192  45  237 
Table  2.13.    2*2  Table  for  the  Rounded  Weighted  Scoring  System  with  2:1  Cost 
Adjustment  During  the  Prospective  Validation  Phase.    Calculated  sensitivity  93%, 
specificity 37%, PPV 69%, NPV 78%. 
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Predicted Diagnosis  Clinic Diagnosis 
CVD  Non-CVD 
Row Total 
CVD  134  9  143 
Non-CVD  70  24  94 
Column Total  195  42  237 
Table 2.14.  2*2 Table for the Un-Weighted Scoring System with 2:1 Cost Adjustment 
During the Prospective Validation Phase.  Calculated sensitivity 94%, specificity 26%, 
PPV 66%, NPV 73%. 
 
It was felt that the 2:1 cost adjustment models performed best and that the weighted and 
rounded weighted scoring systems performed equally well but were better than the un-
weighted system. Given that the scores would require formal calculation because age was 
used as a continuous variable, the weighted scoring system with 2:1 cost adjustment was 
chosen as the final model (table 2.5, figure 2.2) as it most closely represents the data and an 
on-line  tool  was  developed  to  allow  automated  calculation  of  the  score 
(http://www.stams.strath.ac.uk/~karenl/tia/). The Hosmer-Le Cessie test gave a p value of 
0.02 for fit of the final chosen model. 
 
Impact on Clinic Waiting Times 
During the period of the prospective validation set the median waiting time from referral 
date to clinic attendance was 15 days (IQR 8-23).  Removal of every fourth and every 
second non-cerebrovascular patient had potential to reduce the median waiting time to 8 
and 7 days respectively. The proportion of those seen within 7 days (and thus within the 
minimum  standard  of  current  guidelines)  was  21.6%.  This  increased  to  42.9  and  50% 
respectively  following  omission  of  every  fourth  and  every  second  non-cerebrovascular   - 93 - 
patient representing a 21.3 and 28.4% increase in those assessed within the framework of 
current guidelines. This is summarized in table 2.15. 
  
 
2.05  Discussion 
 
The results of this study show that a clinical scoring system could be utilized to reduce the 
number of non-cerebrovascular referrals to a fast track TIA service.  A scoring system that 
employs a 2:1 cost of misclassification adjustment would have little adverse impact on 
recognition rates of bona fide TIA and could reduce the number of non-cerebrovascular 
referrals by a clinically meaningful amount. 
 
TIA is poorly managed in many countries, including in the UK as the above data from the 
UK National Audit Office and the House of Commons Public Accounts Committee (5) 
clearly  show.    UK  consensus  guidelines  suggest  that  patients  with  suspected  TIA  are 
assessed and investigated within 1 week (33;34) while European guidelines appropriately 
suggest  assessment  “without  delay”  (55).  Fulfilling  these  aims  will  be  costly  and  will 
present challenges. For example, the clinic at the Western Infirmary was established (and 
was able) to assess patients within days but experienced a progressive increase in non-
  Current  Clinic 
Performance 
25%  ↓  in  Non-TIA 
Referral Rate 
50%  ↓  in  Non-TIA  
Referral Rate 
Median  Delay  to 
Clinic  
15  8  7 
Assessed  Within  7 
Days 
21.6%  42.9%  50% 
Table 2.15. Projected Improvements in Delays to Clinic Presentation   - 94 - 
cerebrovascular referrals to approximately 50% (257). This “overloaded” the system, such 
that the median delay to clinic assessment in the prospective validation period of this study 
was an unsatisfactory 15 days.   Reducing the number of non-cerebrovascular referrals is 
feasible and will free up existing resources and facilitate urgent assessment of those with 
TIA.  
 
However,  accurate  identification  of  stroke  and  TIA  patients  is  notoriously  difficult 
(255;256)  and  a  variety  of  conditions,  such  as  seizure,  migraine  or  systemic  upset can 
mimic TIA (266). Assessment algorithms exist but are rarely employed out with the clinical 
trial setting (271;272) and in practical terms represent little more than descriptions of a 
typical TIA which give little practical guidance to aid decision making by non-specialists.  
A recent systematic review of the predictive value of various symptoms and clinical signs 
(266) and the available stroke assessment tools (260-263;265) show that symptoms such as 
unilateral weakness and a language disorder suggest that stroke has occurred, while loss of 
consciousness or seizure activity point toward an alternative diagnosis.  Diplopia, vertigo 
and sensory loss are also, but more weakly, consistent with stroke.  In this study, similar 
variables were unsurprisingly found to be predictive of TIA. 
 
Unilateral limb weakness, unilateral facial weakness, speech disorder, diplopia, history of 
stroke or TIA and increasing age were predictive of TIA. There are obvious deficiencies of 
a scoring system involving only these variables.  Patients with amaurosis fugax, sensory 
lacunar and some posterior circulation events would be missed.  It is unrealistic, given the 
heterogeneity of TIA symptoms, to expect that a clinical scoring system could detect all 
types of event. Amaurosis fugax for example has an entirely different set of differential 
diagnoses than other types of TIA.  It is imperative that such systems are introduced in   - 95 - 
conjunction with improved user education, with clear direction as to their limitations and 
clear advice that clinician concern and acumen override the score. 
 
The recently developed ABCD and ABCD
2 scores are risk stratification instruments that 
deserve comment (31;32).  They seem able to identify those with a high risk of stroke early 
after TIA but were developed on data from patients with a confirmed diagnosis of TIA and 
are thus unproven as diagnostic instruments. They would also suffer similar, or perhaps 
greater,  weaknesses  as  the  score  developed  in  this  study  in  terms  of  failure  to  detect 
amaurosis fugax, sensory lacunar and posterior circulation events. A recent analysis from 
our unit suggests this may be the case (273)  but whether this score would add further to the 
increasingly used ABCD scores is unclear and under investigation. 
 
There are limitations to this study. The clinic diagnosis, rather than final diagnosis (such as 
that supported by brain imaging) was used as the reference standard. Essentially therefore 
this study has assessed whether a scoring system can distinguish those whom a specialist 
feels require further investigation for cerebrovascular disease from those who do not. This 
is an appropriate aim for a diagnostic tool, in particular one to aid the clinical diagnosis of 
TIA.  However, levels of inter-observer agreement in the unit from which the study data 
arises  have  not  been  assessed  but  hopefully  the  standardized  review  process,  the  large 
number of subjects and limited number of experienced observers used will limit these. 
Further, only three patients with suspected stroke had a final diagnosis which differed from 
the  original  clinic  diagnosis  during  the  prospective  validation  phase.  Although  it  was 
reassuringly  consistent  with  the development sample,  the  prospective  validation  sample 
was small and cannot replace external validation. 
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The Hosmer-Le Cessie test yielded a p value of 0.02 suggesting the favoured model is not a 
good fit to the data (p-values of greater than 0.05 suggest a good fit). The fit of the model 
could perhaps have been improved by selecting different weights for the scores involved in 
the system or by selecting a different cut-off point for the model but this would render the 
tool  less  clinically  useful;  a  greater  importance  was  assigned  to  sensitivity  in  order  to 
ensure the maximum number of true TIA cases would be referred for specialist assessment. 
 
This tool could be used by colleagues in primary care.  However, it was developed using 
data generated during assessment by stroke specialists.  It is not certain that GPs would 
reach the same conclusions regarding what constitutes a particular symptom, for example, 
pre-syncope or unilateral limb weakness.  A sensitivity of 85%, as seen with the weighted 
scoring system, represents a failure rate of TIA detection too great for safe use in clinical 
practice.    The  2:1  misclassification  scoring  system  yielded  a  sensitivity  of  97%  and 
specificity of 24% during the development phase and 93% and 34% during the prospective 
validation  phase.    This  reduction  in  non-cerebrovascular  referral  rate  was  shown  to  be 
clinically  meaningful;  it  would  greatly  reduce  delay  to  assessment  in  this  service.  The 
weighted system performed best, although the non-weighted system would be easiest to use 
in clinical practice. The rounded weighted system may appear easiest to use but age is 
incorporated as a continuous variable so formal calculation would be required so it was 
opted to use the weighted system which most accurately reflects the data as the final model. 
This makes the score seem cumbersome and perhaps too difficult to use but many centers 
are moving toward an electronic referral process which would allow scores to be calculated 
automatically  from  information  given,  without  the  need  for  manual  calculation.  An 
example  of  this  can  be  found  at  http://www.stams.strath.ac.uk/~karenl/tia/.  This  allows   - 97 - 
maximum information and discriminatory ability to be retained, and in particular to avoid 
dichotomizing continuous variables such as age. 
 
The false negatives or “missed TIAs” are of interest.  In the prospective validation phase 
there were 10 patients with a presumed cerebrovascular diagnosis who were not identified 
by the 2:1 costs scoring system.  Of these, three were felt at final clinic review not to have 
had a TIA or minor stroke and only one of the remainder had brain imaging supportive of 
ischaemia in the relevant territory. This patient presented with a pure hemianopic visual 
disturbance. Two had possible transient ataxia, one had a transient language disorder and 
the remainder pure sensory symptoms.  These patients should still be identified if the score 
was used in conjunction with basic clinical acumen; use of the score itself will improve 
knowledge of presentation of stroke and TIA and may thus increase detection of TIA at the 
population level.  
 
Chapter Summary 
 
This study suggests that a reduction in the rate of referral of non-cerebrovascular diagnoses could 
significantly improve performance of TIA services and that a simple clinical scoring system could be 
used to achieve this.  Further work to evaluate use of the score in clinical practice is ongoing. 
Independent external validation and perhaps comparison to the ABCD scores would be of use.   - 98 - 
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CEREBROVASCULAR EVENTS   - 99 - 
Aspirin Resistance and Risk of Cerebrovascular Events  
 
3.01  Potential Significance of Aspirin Resistance 
As outlined in the introduction, aspirin based anti-platelet strategies are the most commonly 
prescribed  and are  likely  to remain  so.  However,  regardless  of the  chosen anti-platelet 
strategy, it is clear that the effect is modest and recurrent event rates remain high. Methods 
to identify the most suitable regimen for individual patients are attractive as recent data 
suggest that intra-individual response to anti-platelet agents differs. 
 
It is increasingly recognised that some have a degree of “aspirin resistance.”  A recently 
published meta-analysis revealed a prevalence of 28% (274) but included studies covering a 
variety of patient groups and study methodologies. In the context of patients with a history 
of acute stroke, a “resistance” rate of 25.5% (and 8.1% to 1300mg aspirin per day) has been 
quoted (275).  Recent meta-analyses have also shown resistant patients to have a near four 
fold  increase  in  risk  of  suffering  a  vascular  event  compared  (274;276)  with  aspirin 
responders. For example, across 20 studies of 2930 individuals, 810 (28%) were classified 
as aspirin resistant and 39% of these suffered a cardiovascular event during follow-up, 
compared to only 16% of those who were aspirin sensitive (OR 3.85, 95% CI 3.08 to 4.8). 
The OR for a new cerebrovascular event in those with aspirin resistance was 3.78 (95% CI 
1.25  to  11.41);  the  wide  confidence  intervals  reflect  the  small  number  of  studies  and 
subjects  included.  A  high  rate  of  aspirin  resistance  has been  seen  in  those  with  stroke 
recurrence despite aspirin (277) and an increase in total vascular events (278) has been seen 
in  aspirin  non-responders  with  documented  cerebrovascular  disease.    A  recent  study 
showed a far higher rate of aspirin resistance in those who suffered a repeat stroke during 
follow up in comparison to those who did not (OR 14.25, 95% CI 8.5 to 23.7) (279). It   - 100 - 
seems therefore that lack of response to aspirin may link to increased stroke risk in both the 
primary and secondary preventative setting. 
 
However, it is important to recognize that a variety of issues beset research in this field; as 
yet no consensus exists concerning the definition of aspirin resistance or its mechanism and 
no evidence exists to suggest that its presence should guide therapy. 
 
3.01.1  Definition of Aspirin Resistance / Measuring Platelet Function 
Aspirin resistance can be defined either clinically (vascular events in patients taking aspirin, 
perhaps better termed treatment failure) or in terms of laboratory measures (such as failure 
to inhibit platelet aggregation or thromboxane A2 production).  The available laboratory 
measures are numerous. 
 
The platelet count is not affected by anti-platelet therapy so is unsuitable as a means of 
assessing  aspirin  responsiveness.    Likewise,  the  bleeding  time,  while  it  is  affected  by 
aspirin (280;281) and can show differences between action of anti-platelets (281), is not 
well-suited to widespread clinical use as it involves a skin incision and is unlikely to be 
well tolerated by patients. 
 
The level of response to aspirin therapy can be determined by measuring the extent by 
which  aspirin  inhibits  platelet  production  of  thromboxane  A2.    Thromboxane  A2  is 
metabolised to various stable thromboxane B2 products which can be detected in the plasma 
or  urine  as  simple  and  inexpensive  indicators  of  platelet  activity.    Thromboxane  A2  is 
metabolised  to  thromboxane  B2 (detectable in  plasma),  and  11-dehydrothromboxane B2 
(detectable in urine).  These metabolites can be measured by ELISA techniques and have   - 101 - 
been  used  in  studies  of  aspirin  resistance  which  have  shown  an  association  between 
resistance  and  increased  cardiovascular  event  rate  (282).  There  are  important  issues 
concerning specificity of these techniques. For example, urinary 11-dehydrothromboxane 
B2 levels reflect thromboxane production, which by in large will be inhibited by aspirin but 
extra-platelet  sources  of  thromboxane  A2  exist  and  may  arise  in  those  with  recently 
symptomatic  cardiovascular  disease  (283)  and  thus  lead  to  overestimates  of  resistance 
levels. 
 
There are a number of other means of measuring thromboxane-dependent platelet function.  
Light  or  optical  aggregation  techniques  have  traditionally  been  used  and  measure  the 
increase in light transmittance through platelet suspensions when platelets are aggregated 
by an agonist such as thromboxane A2, adenosine diphosphate or collagen.  This requires 
the preparation of a suspension of platelet-rich plasma and while often considered the gold 
standard, is time consuming. Other drawbacks include the potential for artificial activation 
of platelets during  centrifugation. Electrical impedance aggregometry (284) is a similar 
technique which measures changes in electrical impedance between two electrodes when 
platelets are aggregated by an agonist.  Conveniently, this method can be performed on 
whole  blood  samples  and  obviates  some  of  the  drawbacks  of  optical  aggregometry. 
However, the accuracy and reproducibility of both techniques is somewhat poor due to the 
impact  on  aggregation  of  factors  such  as  age,  sex  and  race.    Furthermore,  in-vitro 
techniques for measuring platelet function do not reflect the complex in-vivo interactions of 
platelets with other circulating blood elements. 
 
Semi-automated cartridge based analysers are now available and have the advantage of 
being  simple  and  quick  to  use  and  can  be  performed  on  whole  blood  samples.    Two   - 102 - 
commonly used systems are the PFA-100 system (Dade Behring, Leiderbach, Germany) 
and the RPFA system (Verify Now, Accumetrics). The PFA-100 (285) device measures 
platelet function under controlled shear stress.  A citrated blood mix is placed in an analyser 
and is vacuum aspirated through a capillary system with a membrane coated with platelet 
agonists  (collagen  and  epinephrine  or  adenosine  diphosphate  cartridges  are  available). 
Provided levels of von Willebrand factor and platelet glycoprotein receptors are sufficient, 
platelets  will  attach  and  aggregate  upon  contact  with  the  membrane.  Platelet  adhesion, 
activation and aggregation is then expressed as the ‘closure time’ – the time taken for a 
platelet plug to form and occlude the analyser aperture.  Only the collagen and epinephrine 
assay is sensitive to the action of aspirin.  The device has been shown to be more sensitive 
than  traditional  optical  aggregation  techniques  (286)  and  labels  a  higher  proportion  of 
individuals as resistant (274).  The maximum time measured is 300 seconds, after which the 
closure  time  is  given  as >300  seconds.   The  RPFA  system utilizes  a  slightly  different 
method and is a form of whole blood aggregometry.  A citrated blood mix and ‘aspirin 
assay’  are  placed  into  an  analyser  and  platelet  induced  aggregation  is  measured  as  an 
increase in light transmittance.  The aspirin assay contains fibrinogen coated beads and 
arachidonic  acid.  Arachidonic  acid  causes  platelet  aggregation  and  binding  to  the 
fibrinogen beads follows causing platelet agglutination. The extent of this is proportional to 
the  changes  in  light  transmission  and  results  are  expressed  as  the  number  of  aspirin 
response units and percentage inhibition of platelets by aspirin.  The RPFA system can also 
give measures of clopidogrel and platelet-glycoprotein inhibitor responsiveness if different 
assays are used. Anecdotally, results on use of the PFA-100 device are also user dependent 
and a learned effect exists. Specific data are limited, although many laboratories report that 
reproducibility of results and the number of errors reduces with experience. 
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Thromboelastography  can  also  be  performed  using  a  point  of  care  device  (TEG, 
Haemoscope Corp, Niles, IL, USA). The TEG system measures a variety of variables as 
blood is induced to clot under low shear stress conditions. The pattern of changes in visco-
elastic  properties  of  blood  mirror  those  of  clot  formation  and  allow  assessment  of  the 
kinetics of clot formation and growth and strength and stability of the clot. A coagulation 
profile is then displayed and while this is most commonly used to evaluate clot formation 
during cardiopulmonary bypass, it can be used to assess response to anti-platelet therapy. A 
recent  development  is  the  TEG  Platelet  Mapping  assay  (Haemoscope  Corp,  Niles,  IL, 
USA) which eliminates the contribution of thrombin and fibrin to clot strength (via addition 
of heparin, reptilase and factor XIIIa) and thus allows the impact of platelet pathways to be 
studied  by  the  addition  of  relevant  agonists  (287).  Addition  of  arachidonic  acid  allows 
measurement of thromboxane A2 mediated platelet aggregation. 
 
Flow cytometry techniques may also be used to determine levels of platelet inhibition by 
aspirin.    Surface  expression  of  numerous  platelet  activation  markers  such  as  P-selectin 
(288)  and  activated  glycoprotein  IIb/IIIa  receptors (289) on  platelet  membranes  can  be 
induced and measured as indicators of aspirin activity.  However, these techniques require 
expensive equipment, are not widely available and are time-consuming. 
 
There  are  thus  a  variety  of  techniques  to  assess  aspirin  responsiveness  and  there  are 
advantages and drawbacks with each. Most available methods are limited by the need for 
local analysis; whether whole blood or plasma based techniques, transportation to central 
laboratories, a standard feature in most clinical trials, is not possible as transportation of 
samples will increase likelihood of false results. The cartridge based analysers are attractive 
because they could function as point of care devices but have limitations in that they do   - 104 - 
they do not directly measure platelet thromboxane A2 production and agreement between 
them has previously been shown to be poor (290).  On the other hand, there is attraction to 
measuring platelet function as a whole rather than one means of platelet activation. Further, 
it  is  important  to  note  that  approaches  that  more  directly  measure  thromboxane  A2 
production have other drawbacks, such as influence from extra-platelet or COX mediated 
production. 
  
3.01.2  Mechanism of Aspirin Resistance 
The  mechanism  of  aspirin  resistance  is  likely  to  be  multi-factorial,  or  at  least  may  be 
different  in  different  individuals.  It  is  also  true  that  the  presence  of  apparent  aspirin 
resistance in the laboratory setting may signify increased platelet activation which reflects 
more severe atherosclerosis; aspirin resistance may therefore simply be a marker of more 
severe disease which could explain the apparent link with increased cardiovascular events.  
Putative  mechanisms  however  include  lack  of  patient  adherence,  insufficient  dosing, 
reduced absorption, non COX-1 mediated thromboxane A2 synthesis, increased activity of 
alternate platelet activation pathways and interference of aspirin action by other drugs.  
 
Poor compliance is perhaps the most important factor to consider. A flaw of existing work 
is  that  many  studies  have  not  reliably  assessed  recent  aspirin  ingestion  and  patient 
compliance (which may itself be a factor in some of these events (291)). If a patient has not 
taken aspirin, they will appear aspirin resistant and changing an anti-platelet regimen from 
aspirin to a newer anti-platelet may be unnecessary and costly. Approximately 10-40% of 
patients do not take prescribed anti-platelet tablets in the secondary prevention setting (292-
296) and this could confound aspirin resistance work. It is now possible to measure aspirin 
(or  its  salicylate  metabolites)  in  urine  using  high  performance  liquid  chromatography   - 105 - 
techniques,  thus  allowing  objective  determination  of  compliance.  This  has  not  been 
adequately performed in studies to date and it is possible that rates of resistance reported in 
the literature reflect a proportion of participants with poor therapy compliance. 
 
Aspirin is hydrolysed to inactive salicylate in the gut through the actions of esterases which 
may reduce its bioavailability and effect (297;298).  It is reported that use of proton pump 
inhibitors can increase mucosal hydrolysis of aspirin (299) which could cause apparent 
resistance but this is by no means proven (300). It is well known that concurrent intake of 
certain  non-steroidal  anti-inflammatory  drugs  (such  as  ibuprofen  and  naproxen)  can 
interfere with the anti-platelet effect of aspirin by preventing aspirin binding to COX-1 
(301) and thus prevent a reduction in inhibition of thromboxane production.  Interestingly, 
use of ibuprofen alongside aspirin has been shown to link with increased mortality during 
follow-up in comparison to aspirin alone and aspirin with diclofenac (302). 
 
Thromboxane  A2  may  be  produced  from  non-platelet  sources,  in  particular  in  pro-
inflammatory states where COX-2 activity is increased in monocytes and macrophages and 
can yield thromboxane A2 production. This may be relevant in atherosclerosis which is an 
inflammatory condition (303) and may explain why those with recurrent events or more 
severe  atherosclerosis  appear  more  likely  to  be  aspirin  resistant.  Renal  production  of 
thromboxane  may  also  contribute  to  platelet  activation  and  several  cardiovascular  risk 
factors can increase thromboxane synthesis via alternate pathways such as via isoprostane 
production (304).  Likewise, other pathways of platelet activation exist and include direct 
stimulation of platelet glycoprotein receptors and platelet shear stress and will be less likely 
to respond to aspirin; perhaps in this scenario alternative drugs such as clopidogrel will 
prove of use (305).   - 106 - 
 
Genetic polymorphisms may impact on the inter-individual variation in response to aspirin. 
A  variety  of  candidate  genes  have  been  suggested  (306).  Polymorphisms  in  the  COX 
enzymes,  platelet  receptors  and  factor  XIII  have  all  been  postulated  as  potential 
mechanisms  (307).  However,  the  overall  contribution  of  genetic  variation  to  aspirin 
resistance has not yet been clearly determined and in a recent systematic review, only the 
PIA1/A2 polymorphism in the GPIIIa platelet receptor linked with aspirin resistance (OR 
2.36, 95% CI 1.24 to 4.49) (308). 
 
Summary 
Thus, aspirin resistance appears to link with increased risk of cardiovascular events in those 
who take it. However, no firm evidence exists to suggest that routine screening for aspirin 
resistance and subsequent tailored anti-platelet regimens will improve outcome.  Also, the 
size  of  the  effect of  aspirin  resistance  is  unclear;  confidence  intervals  around  available 
estimates are wide and, given that aspirin prevents approximately 1/5 of recurrent strokes, it 
seems unlikely that resistance would lead to a three or four fold increase in event rate 
unless resistance reflected, at least in part more severe disease. 
 
There is also no consensus concerning its definition, disagreement as to the best means of 
measuring it and no clear answer as to its cause. These questions are likely to remain until 
large scale prospective clinical trials are conducted or until aspirin resistance is associated 
with a robust and easy to study surrogate marker. A link with asymptomatic microemboli in 
patients with carotid disease for example would prove useful in stimulating and allowing 
further study; they are a high risk group, MES are easy to measure and are anti-platelet 
therapy responsive.   - 107 - 
3.02  Chapter Aims / Hypothesis 
 
First, as recommended, a brief study was performed to establish the local reference range 
for normal platelet function using the PFA-100 device (study one). The chapter hypothesis 
was that aspirin resistance would be associated with the presence of microembolic signals 
in aspirin treated patients with carotid disease and that the prevalence of aspirin resistance 
in those who had proven recent aspirin ingestion would be lower than the rates reported in 
previous literature. The aim was thus to compare the rate of aspirin resistance in those with 
and without MES (study two) and to quantify the prevalence of aspirin resistance in those 
with cerebrovascular disease whilst addressing concerns surrounding patient compliance 
(study three).  
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3.03  Study One - Development of a Local Normal Range for Use of the PFA-100 
Device 
 
It is recommended by the manufacturer and expert guidelines that each institution clarifies 
its own reference range using healthy controls and establishes a control group for further 
quality control analyses prior to interpretation of results when using the PFA-100 device.  
The aim of this study was to establish this range. 
 
3.03.1  Study One Methods 
 
Forty  healthy  volunteers  were  recruited.  The  study  was  performed  in  the  University 
Division of Cardiovascular and Medical Sciences at the Western Infirmary, Glasgow and 
was approved by West Medical Research ethics committee.  Inclusion criteria for this study 
were presumed normal platelet function and age > 18 years. Exclusion criteria were any 
anti-platelet or anti-coagulant use (within past 1 month), known haematological disorder or 
family history of haematological disorder and recent non-steroidal anti-inflammatory drug 
ingestion (within past 2 days).  
 
Approximately 7 mls of blood was drawn using a 21 G needle.  With the PFA-100 device, a 
citrated  blood  mix  is  placed  into  the  analyser  and  platelet  adhesion,  activation  and 
aggregation is expressed as the ‘closure time’ – the time taken for a platelet plug to form 
and  occlude the  analyser  aperture  after  exposure  to  platelet  agonists.    Epinephrine  and 
collagen  cartridges  are  used and  are  pre-warmed  to room  temperature.      Those  with  a 
closure time of between 110-160 seconds were considered for inclusion in a donor control   - 109 - 
group and had testing performed in duplicate; if the repeat result was within a range of 
±15% of the first sample, they were asked to be part of the control group. 
The normal range was then expressed as the 95 % reference range of closure times in 
seconds.  When  performing  quality  control  measurements,  a  closure  time  within  the 
reference range was deemed satisfactory.  The coefficient of variation of closure times has 
been reported as 10% in the literature (309). 
 
3.03.2  Study One Results  
 
In total 40 participants  were recruited between  May  2005 and October 2008. All were 
healthy  with  no  past  medical  history,  no  family  or  personal  history  of  haematological 
disorders and were taking no regular medications. The majority (24, 60%) were female. 
Only  37  individuals  were  included  in  the  analyses.  Of  those  who  were  excluded,  one 
subsequently admitted to taking warfarin, one suffered factor V Leiden deficiency (both 
these individuals had abnormal results) and in one further case, no result could be obtained. 
 
The mean closure time was 134 seconds (standard deviation 22.8). The range of values was 
95 to 182 seconds and the 95% reference range was 89.4 to 178.9 seconds. Individual test 
results are shown in figure 3.1. Ten individuals had testing performed in duplicate and the 
mean coefficient of variation was 7.5%. A closure time below the upper limit of the 95% 
reference  range  in  the  context  of  recent  aspirin  ingestion  was  used  to  define  aspirin 
resistance (rounded up to a closure time < 179 seconds for analyses). 
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3.03.3  Study One Discussion 
 
The definition of aspirin resistance used here is consistent with that used in other studies 
(277;286;309-324) (table 3.1).  It is important to note the length of time taken to complete 
this study and develop the local reference range – this was done alongside other studies 
rather than before which is in retrospect the optimal approach. However, this did not affect 
conduct  of  the  other  studies  and  the  reference  was  developed  before  analyses  were 
performed. 
 
 
 
 
 
 
 
 
Figure 3.1 Distribution of Closure Times in 37 Healthy Volunteers Not Taking 
Regular Medication   - 111 - 
Authors  Reference  Definition of Aspirin Resistance 
Jilma et al  (309)  < 193 seconds 
Kundu et al  (310)  < 193 seconds 
Christiaens et al  (311;315)  < 186 seconds 
Cohen et al  (312)  <192 seconds 
Pamukcu et al  (321)  < 186 seconds 
Narvaez et al  (314)  < 173 seconds 
Gum et al  (286)  < 193 seconds 
Grundmann et al  (277)  < 165 seconds 
Wong et al  (316)  < 158 seconds 
Coma-Canella et al   (317)  <161 seconds 
Fateh-Moghadam et al  (320)  < 165 seconds 
Andersen et al  (318)  < 193 seconds 
Lordkipanidze et al  (319)  < 193 seconds 
Di Chiara et al  (322)  < 193 seconds 
Gurbel et al  (323)  < 193 seconds 
Angiolillo et al  (324)  < 193 seconds 
Table 3.1 Definition of Aspirin Resistance Employed in Previous Studies Using the 
PFA-100 Device 
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3.04  Study  Two  -  Microembolic  Signals  and  Aspirin  Resistance  in  Patients  with 
Carotid Stenosis 
 
The study hypothesis was that aspirin resistance would be associated with the presence of 
microembolic  signals  in  aspirin  treated  patients  with  carotid  disease.  An  observational 
cohort study was perfomed to test this. 
 
3.04.1  Study Two Methods 
 
The  study  was  performed  in  the  University  Division  of  Cardiovascular  and  Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the local research 
ethics committee.  
 
Patients aged > 18 years taking current aspirin therapy and who had significant carotid 
artery  disease  (defined  as  at  least  a  moderate  internal  carotid  artery  (ICA)  stenosis  or 
symptomatic  ulcerating  plaque  disease)  were  included.  Those  taking  clopidogrel, 
dipyridamole or anti-coagulant therapy and who had poor compliance with aspirin therapy 
were excluded. Further exclusion criteria included absence of a bony temporal window on 
TCD imaging, atrial fibrillation or other cardiac source of embolism (defined as valvular 
heart  disease,  recent  myocardial  infarction  or  known  patent  foramen  ovale)  and 
thrombolytic therapy within the past 2 weeks.  Compliance was assessed by questioning 
and, where the participant was an in-patient, from drug prescription charts and discussion 
with nursing staff. The presence of a temporal window for TCD imaging was assessed 
during carotid Doppler scanning as part of routine clinical care. Carotid ultrasound imaging 
utilised an Acuson Aspen 128 with a 5-Mhz linear transducer (Acuson, Mountain View,   - 113 - 
CA, USA). In the Doppler laboratory, a moderate ICA stenosis is defined as being present 
if peak systolic velocity (PSV) is >1.5 m/s and a severe stenosis if PSV is >2 m/s. 
 
Participants were identified during out-patient attendance at the hospital Fast Track TIA 
service or during an in-patient stay in the Acute Stroke Unit. All gave full written informed 
consent  to  participate  unless  hemiplegia  or visual  disturbance precluded  writing,  where 
witnessed oral consent was accepted. 
 
Study Assessments 
Patients were reviewed at baseline where TCD monitoring for MES and blood testing for 
platelet function analyses were performed.  Those who still met the eligibility criteria had 
repeat  TCD  monitoring  and  platelet  function  analysis  performed  as  near  to  7  days  as 
possible.  The  purpose  of  this  was  to  evaluate  whether  aspirin  resistance  was  a  stable 
phenomenon. At day 30, all patients were  contacted by  telephone or seen  at clinic (or 
reviewed on the ward if still an in-patient) to screen for any signs of recurrent TIA or stroke 
using a standardised set of clinical questions. This marked the end of their involvement in 
the  study.    Where  patients  could  not  be  contacted  by  telephone,  this  information  was 
gathered at the next scheduled clinic review. 
 
TCD recordings were made from the middle cerebral artery ipsilateral to the stenosis using 
a TCD 100M device (Spencer Technologies, Seattle, WA, USA) in–line with consensus 
guidelines  (325).  Recordings  lasted  one  hour  and  were  made  by  sonographers  with 
extensive  experience  in  TCD  techniques.    Where  there  was  bilateral  carotid  disease, 
simultaneous bilateral TCD recordings were made.  Recordings were monitored on-line by 
the sonographer and potential MES were also automatically identified using the emboli   - 114 - 
detection function. All recorded potential MES were reviewed and independently verified 
by the sonographer and one of the study investigators. Both were blinded to the aspirin 
responsiveness status. The presence of MES was defined as ≥1 MES on TCD scanning. 
 
Approximately 12 mls of blood was drawn using a vacutainer system and a 21 G needle 
into 3.8% citrate blood tubes. Well validated point of care cartridge based platelet analysers 
(PFA-100, Dade-Behring, Miami, FL (310;326) and Verify Now, Accumetrics (327;328)) 
were used to assess platelet function.  Samples were analysed at between 30 minutes and 4 
hours of being taken.  The PFA-100 device was used as described above. The coefficient of 
variation when using the PFA-100 device is typically 10% (309) and as described above, 
similar was seen in study one.  With the Verify Now device, a citrated blood mix and 
‘aspirin assay’ which contains fibrinogen coated beads and platelet agonists, are placed into 
the  analyser  and  platelet  induced  aggregation  is  measured  as  an  increase  in  light 
transmittance.    Results  are  expressed  as  the  number  of  aspirin  response  units.  The 
coefficient of variation when using the RPFA device is reported to range from 2.6 to 4.5% 
(information contained in Verify Now ASA product information sheet). 
 
Both devices are simple to use and give results within 10 minutes.  Using the PFA-100 
analyser, aspirin resistance was defined as a closure time below the in-house upper limit of 
the normal range for healthy non-aspirin treated individuals (<179s, as obtained in study 
one of this chapter).  Using the Verify Now system, aspirin resistance is defined as the 
presence  of  >550  aspirin  reaction  units  (329).  Participants  were  deemed  to  be  aspirin 
resistance if found to be so on either test.  Platelet function tests were performed blinded to 
results of TCD imaging and MES status. 
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Statistical Analysis 
The primary endpoint was the proportion of aspirin resistant patients in the MES and non-
MES group.  This was assessed using Fishers exact test. Pre-specified secondary endpoints 
were the number of aspirin resistant patients in the MES and non-MES group according to 
each individual test, agreement between the first and second visit aspirin resistance status, 
agreement between the two platelet function tests and the rate of stroke or TIA according to 
aspirin status.  Agreement between tests was assessed using attribute agreement analysis 
and  described  with  kappa  statistics.  It  was  estimated  that  the  prevalence  of  aspirin 
resistance would be 30% (274;275) in the whole study group and that the rate would be 
higher at approximately 40% in those with MES (277) (similar to the rate in patients with 
recurrent stroke in other studies) compared to a lower rate of approximately 10% in those 
without MES (277;278). A sample size of 31 patients in each group would allow detection 
of such a 30% difference in the rate of aspirin resistance between the MES and non-MES 
group with 80% power and a significance of 0.05.  It was estimated that at least 40% of 
screened patients would have MES (223;229;234) but in order to ensure blinding to MES 
status could be maintained, it was planned to recruit the first 62 eligible patients. 
 
P values of <0.05 were deemed to denote statistical significance and standard definitions of 
degree of agreement based on kappa statistics were used (330).  
 
3.04.2  Study Two Results  
 
Sixty-two patients between June 2006 and January 2008.  All had baseline MES and aspirin 
responsiveness status recorded.  In total, 37 patients (59.7%) remained eligible and had the 
day 7 visit performed.  Of those who did not, twelve had undergone carotid endarterectomy,   - 116 - 
one was commenced on clopidogrel, two went for scheduled cardiac surgery, two were 
moved to an off-site rehabilitation facility and could not attend, four did not attend and four 
withdrew consent for the second visit stating it was too soon after discharge. 
 
The mean age was 69.7 (± 11.8) years. The majority (53 patients, 85.5%) had symptomatic 
carotid disease and a severe stenosis (50 patients, 80%). Half (31 patients) were in-patients 
in the acute stroke unit; the remainder were out-patients attending the department. Of those 
who were symptomatic, 21 (39.6%) were  evaluated within 48 hours of onset, 9 (17%) 
within 7 days, 12 (22.6%) within one month and 11 (20.8%) within 6 months. Further 
baseline demographic details, including stroke subtype, drug therapy, risk factor burden, 
renal function and platelet levels are shown table 3.2. 
 
Baseline aspirin responsiveness and platelet function data are shown in table 3.3.  In total, 
16 patients (25.8%) exhibited evidence of aspirin resistance on one or more test. Of these 
patients, 13 (21%) were resistant on PFA-100 testing, 8 (12.9%) were resistant on RPFA 
testing and 5 (8.1%) were resistant on both. Sixteen (25.8%) had evidence of MES, with a 
range of 1-39 signals during monitoring. Only one patient (who was aspirin resistant on all 
modalities and at both visits) suffered a recurrent vascular event during follow up.  
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Variable  Value 
Age  69.7 (11.8) 
No Stroke Symptoms 
Total Anterior Circulation Stroke 
Partial  Anterior Circulation Stroke 
Lacunar Stroke 
Posterior Circulation Stroke 
Amaurosis Fugax only 
6 (9.7%) 
1 (1.6%) 
28 (45.2%) 
12 (19.4%) 
3 (4.8%) 
12 (19.4%) 
Symptomatic Carotid Disease  53 (85.5%) 
< 50% stenosis / plaque disease only 
>50% stenosis 
> 70% stenosis 
3 (4.8%) 
9 (14.5%) 
50 (81%) 
Smoker  20 (32.3%) 
Ischaemic Heart Disease  14 (22.6%) 
Diabetes Mellitus  9 (14.5%) 
Hyperlipidaemia  19 (30.7%) 
Hypertension  31 (50%) 
ACE I or ARB Therapy  24 (38.7%) 
Diuretic Therapy  23 (37.1%) 
Statin Therapy  43 (69.4%) 
Baseline Platelet Count  255.3 (101.7) *10
9/L 
Table  3.2  –  Study  Two  Baseline  Demographic  Variables.  Expressed  as  n  (%)  for 
categorical variables and mean (SD) for continuous variables. ACE I = ACE inhibitor, 
ARB = Angiotensin Receptor Blocker. 
 
MES and Aspirin Responsiveness Status 
Aspirin  resistance  on  at  least  one  test  was  present  in  8/16  (50%)  of  those  with 
microembolic signals and in 8/46 (17.4%) of those without MES (p=0.018 on  Fisher’s 
exact test). 
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PFA-100 CEPI-CT  254.2 (72.6) seconds 
Aspirin Resistance on PFA-100  13 (21%) 
RPFA  442.3 (90.3) ARU 
Aspirin Resistance on RPFA  8 (12.9%) 
Aspirin Resistance on Both Tests  5 (8.1%) 
Aspirin Resistance on ≥ 1 Test  16 (25.8%) 
Presence of MES  16 (25.8%) 
Number of MES (when present)  1-39 (range) 
Table 3.3 – Study Two Baseline Platelet Function Analysis Results 
PFA-100 = Platelet Function Analyser 100. RPFA = Rapid Platelet Function Analyser. 
ARU = Aspirin Responsive Units. MES = microembolic signals. Values expressed as n 
(%) for categorical variables and mean (SD) for continuous variables unless stated. 
 
Aspirin  resistance  was  present  in  5  (31.3%)  of  those  with  MES  on  PFA-100  testing 
compared to 8 (17.4%) without (p=0.29 on Fisher’s exact test). On RPFA testing, aspirin 
resistance was present in 5 (31.3%) of those with MES and 3 (6.5%) of those without 
(p=0.02 on Fisher’s exact test). 
 
Agreement between Platelet Function Tests 
Agreement between the aspirin responsiveness  status measured by the  different platelet 
function  tests  and  at  the  two  study  visits  is  shown  in  table  3.4.  At  the  baseline  visit, 
agreement between the two tests was moderate (ĸ=0.40). A scatter plot of the individual 
patient data is shown in figure 3.2. At the second study visit, agreement between the tests 
was also moderate (ĸ=0.41). Agreement between aspirin responsiveness status at the first 
and second visit was moderate on PFA-100 (ĸ=0.53) testing, moderate on RPFA testing 
(ĸ=0.44) but was fair for presence of resistance on one or more test (ĸ=0.36). At the second 
study visit, 11 (29.7%) of patients exhibited evidence of aspirin resistance on one or more   - 119 - 
test. All of these were resistant on PFA-100 testing and 4 (10.8%) were also resistant on 
RPFA testing. 
 
Visit 1 (PFA-100 vs RPFA)  ĸ= 0.4  P<0.001 
Visit 2 (PFA-100 vs RPFA)  ĸ= 0.41  p=0.006 
Aspirin Resistance on ≥ 1 Test (Visit 1 vs 
Visit 2) 
ĸ= 0.36  p=0.014 
PFA-100 (Visit 1 vs Visit 2)  ĸ= 0.53  P<0.001 
RPFA (Visit 1 vs Visit 2)  ĸ= 0.44  p=0.004 
Table 3.4. Measures of Agreement Between Tests and Study Visits in Study Two. 
PFA-100 = Platelet Function Analyser 100. RPFA = Rapid Platelet Function Analyser. 
ĸ= kappa statistic. p values shown are for test of ĸ > 0.  
 
 
 
 
 
Figure 3.2. Scatterplot of PFA-100 Measured versus RPFA Measured Aspirin 
Responsiveness in Study Two. Each data point represents one individual. Values 
to the right of the vertical reference line represent resistance on RPFA testing 
while values below the horizontal reference line represent resistance on PFA-100 
testing. ARU = Aspirin responsiveness units.   - 120 - 
3.04.3  Study Two Discussion 
 
Data from this study show that aspirin resistance is more common in those with significant 
carotid disease and MES compared to those with equivalent carotid disease and no MES. 
This  ties  increased  prevalence  of  aspirin  resistance  to  a  readily  measurable  and  robust 
marker  of  stroke  risk.  Importantly,  the  utility  of  MES  exceeds  their  predictive  value 
regarding future stroke risk; their presence and their response to treatment can be used to 
identify differences between anti-platelet strategies with small numbers (234). The findings 
from this study provide a useful model for further work which should aim to establish 
whether screening for aspirin responsiveness and subsequent changes to therapy reduces 
the rate of MES and stroke risk in those with carotid disease. For example, this strategy 
could be compared to other regimens such as unselected use of aspirin and clopidogrel 
(234). 
 
Aspirin remains the most widely prescribed anti-platelet agent after stroke and attempts to 
better target its use, especially in high risk groups, are valid. Resistance to aspirin effect has 
received much attention over the recent years and does appear to be associated with an 
increased risk of cardiovascular events (274;276). However, several issues beset the field: 
as yet no consensus exists concerning the definition of aspirin resistance or its mechanism 
and no evidence exists to suggest that its presence should guide therapy. The size of recent 
anti-platelet trials (140) suggests that clarifying these issues with clinical endpoint studies 
may be costly and impractical. A link between aspirin resistance and a readily measurable 
surrogate marker of stroke risk would therefore be useful to establish as it would allow 
(with relative ease) further study of tailored anti-platelet strategies. 
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Aspirin resistance can be defined either clinically (vascular events in patients taking aspirin, 
perhaps better termed treatment failure) or in terms of laboratory measures (such as failure 
to inhibit platelet aggregation or thromboxane A2 production).  Given the lack of consensus 
concerning the optimal definition two simple point of care analysers were used to assess 
aspirin responsiveness in this study. A wide definition of aspirin resistance (the presence of 
normal platelet function on one or more test) was also used; it was hoped that the simplicity 
of these methods will allow further research to proceed whilst ensuring any findings can be 
readily translated into routine clinical practice – the same could not be said for the more 
time consuming and cumbersome techniques of flow cytometry or traditional methods of 
platelet  aggregometry.  There  are  however  drawbacks  to  the  tests  used:  neither  is  truly 
specific  to  the  effect  of  aspirin  therapy  nor  do  they  do  directly  measure  platelet 
thromboxane A2 production; and agreement between them has previously been shown to be 
poor  (290).    Attempts  were  made  to  limit  the  lack  of  specificity  for  aspirin  action  by 
ensuring those taking alternative anti-thrombotic / anticoagulant therapy or those with a 
known haematological disorder were excluded. Also, as mentioned, it is important to note 
that approaches that directly measure thromboxane A2 production have other drawbacks: 
extra-platelet sources of thromboxane A2 may arise in those with recently symptomatic 
cardiovascular disease (283) and thus lead to false overestimates of resistance levels. 
  
The PFA-100 has been shown to be more sensitive than traditional optical aggregation 
techniques (286) and labels a higher proportion of individuals as resistant (274).  Similar 
supportive trends were seen in this study: 13 (21%) were resistant on PFA-100 testing 
compared to only 8 (12.9%) on RPFA testing. Interestingly, resistance on RPFA testing 
appeared  more closely  linked  to presence  of  MES  than  resistance  on PFA-100 testing, 
although the numbers resistant on each technique were small and a firm conclusion as to   - 122 - 
whether RPFA testing detects clinically more relevant aspirin resistance cannot be drawn.  
The prevalence of resistance using the combined definition in this study was 25.8% which 
is consistent with that seen in meta-analyses (274) and studies post stroke (275). 
 
Only  moderate  agreement  between  the  methods  used  to  define  resistance  and  between 
aspirin  responsiveness  status  at  the  first  and  second  visits  in  this  study.  While  the 
agreement seen between the different platelet function tests is superior to that seen in other 
studies (290) in the post stroke period, it remains too low to allow a patient to be deemed 
resistant on the results of a single test and the 95% CI for the estimate of agreement in this 
study  overlaps  with  previous  work  (290).  Until  the  optimal  technique  of  measuring 
resistance is clarified, it is likely that a battery of tests should be used.  Other authors have 
suggested that aspirin resistance may have a temporal component (331) and although the 
rates  of  aspirin  resistance  were  similar  at  the  first  and  second  visits  here,  agreement 
between visits was only moderate suggesting that the resistance status of some individuals 
changed. There are several potential explanations for this: compliance may have differed 
between  visits  in  some  individuals,  as  may  the degree  of  platelet  activation  which can 
change  following  acute  cardiovascular  events  (283).  Importantly,  it  is  unlikely  that 
compliance has influenced the main results of this study; all patients verbally confirmed 
compliance  and  half  were  in-patients  who  had  compliance  objectively  confirmed  from 
hospital prescription charts and discussion with nursing staff. 
 
Patients who were taking dipyridamole were excluded. The trial commenced before the 
ESPRIT  trial  (138)  revealed  incremental  reduction  in  recurrent  stroke  with  combined 
aspirin and dipyridamole therapy. Whether more widespread dipyridamole use will reduce 
early stroke risk or the likelihood of MES in those who are aspirin resistant is unclear.   - 123 - 
Available data suggest its addition does not alter the response to aspirin treatment measured 
by either the PFA-100 or RPFA (332) and it may be that the association seen would hold.  
Two patients toward the end of the study were commenced on dipyridamole prior to their 
second visit and neither had a change in their MES or aspirin resistance status. 
 
Only one patient in this study suffered a recurrent event, which, given the baseline risk of 
the group, appears low. This patient was aspirin resistant but no useful information can be 
drawn from this observation. The low recurrent stroke risk may in part reflect the number 
who proceeded to rapid carotid endarterectomy (7 of those with MES, 16 patients in total, 
12 of whom within one week of entering the study) or had aggressive anti-platelet therapy 
(3 with MES received aspirin and clopidogrel).  
 
A lower rate of MES than had been anticipated was seen. It was estimated that a rate of 
40% (223) would arise in the study group as a whole but MES were seen in only 25.8% 
(16) patients. Given that some patients in the study (9, 14.5%) had asymptomatic carotid 
disease, this probably is a representative figure. Furthermore, recent data (333) suggest that 
prevalence of MES falls with time after stroke (from 49% at 24 hours to 29% at 48 hours, 
although this was not a specific evaluation of subjects with carotid disease), and only ≈ 
40% of patients were recruited and assessed within 48 hours of symptoms.  
 
In conclusion, increased prevalence of aspirin resistance is linked to the presence of MES 
in patients with carotid disease. This provides a useful model to further study the benefits of 
guided  anti-platelet  strategies  and  further  work  should  establish  whether  screening  for 
aspirin responsiveness and subsequent adjustment to anti-platelet therapy reduces the rate 
of MES and stroke risk in those with carotid disease.    - 124 - 
3.05  Study Three - Aspirin Resistance and Cerebrovascular Events; the Importance 
of Participant Compliance with Aspirin 
 
The study hypothesis was that the aspirin resistance would remain a common phenomenon, 
even after compliance was adequately assessed but that the rate would be lower than the 
rates  previously  reported  in  the  literature.  A  prospective  case-controlled  study  was 
performed to test this. 
  
3.05.1  Study Three Methods 
 
The  study  was  performed  in  the  University  Division  of  Cardiovascular  and  Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the West Medical 
Research Ethics Committee. The study incorporated an analysis of all participants and a 
urine sub-study where only those who had evidence of aspirin metabolites in the urine were 
included.  
 
Cases 
Cases were aged > 18 years taking current aspirin therapy who had a clinical diagnosis of 
ischaemic stroke or transient ischaemic attack. It was required that recruitment and platelet 
function analysis be performed within 24 hours of onset of symptoms and that participants 
would be in theory able to submit a urine sample. Those with known poor compliance with 
aspirin therapy, those taking clopidogrel or anti-coagulant therapy or who had received 
thrombolytic therapy within the past 2 weeks and those with brain imaging which identified 
intracerebral haemorrhage were excluded. Compliance was assessed by questioning. 
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Cases were identified on admission to the  Acute Stroke Unit at the  Western  Infirmary 
Hospital.  Where  possible,  all  gave  full  written  informed  consent  to  participate  unless 
hemiplegia  or  visual  disturbance  precluded  writing,  where  witnessed  oral  consent  was 
accepted.  Where  potential  participants  were  unable  to  consent,  assent  from  the  nearest 
relative or welfare guardian was accepted. Ethical approval was given for this as exclusion 
of  those  unable  to  consent  because  of  their  stroke  would  bias  the  study  sample.  It  is 
important these patients are included as it is at least as relevant to establish the role of 
aspirin resistance in larger, more severe strokes. 
 
Controls 
Controls comprised individuals aged over 18 years of age taking current aspirin therapy for 
at least one year who had never suffered a cardiovascular event on aspirin. Those with 
known poor compliance with aspirin therapy, those taking clopidogrel or anti-coagulant 
therapy or who had received thrombolytic therapy within the past 2 weeks were excluded. 
Compliance was assessed by questioning. All gave full written informed consent. 
 
Controls were mostly identified during out-patient attendance at cardiovascular risk factor 
clinics at the Western Infirmary. 
 
Study Assessments 
Cases were reviewed at baseline and at 7 days or on discharge from depending on what was 
soonest. Controls only underwent baseline assessment. 
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Baseline Assessment 
Demographic and diagnostic data were gathered. A blood sample was drawn (ca 10 mls) 
for  platelet  function  analyses  and  attempts  were  made  to  obtain  a  urine  sample  for 
measurement of aspirin metabolites.   
 
Measurement of Platelet Function and Aspirin Responsiveness 
The same well validated cartridge based platelet analysers (PFA-100, Dade-Behring, Miami, 
FL (310;326) and Verify Now, Accumetrics (327;328)) were used as outlined above in 
study two. The definitions of as aspirin resistance were also the same as outlined previously 
(closure time of < 179 with the PFA-100 device and the presence of >550 “aspirin reaction 
units” when using the Verify Now 
TM system). Investigators were blinded as to levels of 
urinary aspirin metabolites when performing platelet function analysis (results were not 
available at the time of platelet function analysis). 
 
3.05.1.1  Measurement of Aspirin Metabolites (Detection of Urinary Salicylates) 
Where able, participants submitted a single urine sample (the next urine sample following 
recruitment). High performance liquid chromatography analysis was performed. All tests 
were performed at Divisional Labs at the Western Infirmary Hospital.  Other methods such 
as the method of Trinder (the principle of the test is a direct colour reaction on urine - a 
violet colour indicates the presence of salicylates) are available but relatively insensitive 
techniques (334); studies have revealed urinary concentrations in excess of the limit of 
detection for the Trinder method (20mg salicylate/L urine) 10 hours after a single 600 mg 
dose (335) but it is unclear whether this threshold will be reliably reached after a single 75 
mg aspirin dose, and for what period thereafter. 
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High performance liquid chromatography (HPLC) assays have been developed to identify 
aspirin and its salicylate metabolites in both plasma and urine (336-341).  HPLC involves a 
column which holds material (the stationary phase), a pump to inject and move the mobile 
phase, which acts as a carrier for the analysis sample, through the column and a detector 
which shows the retention times of the molecules. The retention times, or the time taken to 
elute from the column, depend upon the chemical interactions between the stationary phase 
and the mobile phase, and thus the properties of the analysis sample.  The stronger the 
interaction with the stationary phase, the longer the retention time.  There a variety of types 
of HPLC analysis but the most widely employed is reverse-phase HPLC, which utilizes a 
non-polar stationary phase and compounds are separated on the basis of hydrophilicity and 
lipophilicity.  There are also different types of mobile phase and the environment of the 
mobile  phase  can  be  manipulated  to  ensure  better  separation  of  the  sample.  Detector 
systems can also vary and can be based, for example, upon measurement of the refractive 
index, the ability of samples to absorb ultra-violet light, or a variety of other techniques. 
 
HPLC techniques are highly sensitive; detection of concentrations as low as 0.1 mg/l of 
aspirin metabolites are possible with some assays (339). Such methods have been used in 
many studies of aspirin pharmacokinetics and of salicylate levels in healthy volunteers and 
data suggest that salicylates can be detected several hours, and perhaps days, after low dose 
aspirin ingestion (summarized below). 
 
Aspirin and Measurable Metabolites 
Acetylsalicylic acid is hydrolyzed in the stomach and in blood to salicylic acid and acetic 
acid (342). Both acetylsalicylic acid and salicylic acid are rapidly absorbed. Several studies 
suggest that plasma concentrations of acetylsalicylic acid peak within one hour of ingestion   - 128 - 
(339;343;344) and that the elimination half life is approximately 20 to 40 minutes. Levels 
of approximately 1000 ng/ml are often seen (343). Plasma salicylate levels peak somewhat 
later at approximately 1 to 2 hours, are generally higher, and also have a longer elimination 
half-life of approximately 2 to 4.5 hours. Several studies confirm that salicylates can be 
detected  in  the  plasma  several,  and  up  to  10  hours  (339;345),  after  single  oral  dose 
ingestion. Following daily dosing of low dose aspirin, time – concentration curves suggest 
levels of acetylsalicylic acid and salicylic acid remain detectable for longer with high (near 
peak) levels of salicylic acid seen for approximately 6 hours after ingestion (343) on HPLC 
analysis. How long they remain detectable thereafter is unclear. 
 
Salicylates  are  predominantly  excreted  by  the  kidneys,  mostly  following  hepatic 
conjugation, as salicyluric acid (75%), free salicylate (10%), salicylic phenol (10%), acyl 
glucuronides (5%) and gentisic acid (<1%) (346).  Studies suggest that the salicylate load 
from low dose aspirin is mostly excreted in the urine within 24 hours (340;343), although 
others suggest that only 10% is excreted within 10 hours after a single dose (335).  Levels 
of salicylic acid of over 30 µg/ml have been seen in urine 10 hours after ingestion of a 
600mg dose (335), while some more sensitive techniques allow detection of salicylates up 
to 48 hours after ingestion of a single 80 mg dose of aspirin (347). Otherwise, little data 
exist to suggest actual concentrations of salicylate metabolites in the urine in the hours after 
ingestion of low dose aspirin. 
 
Importantly, salicylates are found in both the plasma and urine of those who do not take 
aspirin or other salicylate drugs. For example, in one study using HPLC analysis, salicylic 
acid was detected in the plasma of all 76 subjects studied with higher levels in vegetarians 
(0.11 µmol/l (range 0.04 to 2.47) compared to 0.07 µmol/l (range 0.02 to 0.2)) in non-  - 129 - 
vegetarians (348). However, levels were significantly, and approximately 100 times higher, 
in  those  taking  aspirin  (10.03  µmol/l  (range  0.23  to  25.4)).  There  was  however  some 
overlap with between vegetarians and those on aspirin; eight vegetarians had salicylic acid 
levels  above  the  lowest  level  seen  in  aspirin  treated  patients.  However,  this  level  was 
surprisingly  low  and  it  is  possible,  or  perhaps  probable,  that  this  individual  was  not 
compliant with aspirin therapy and that the vegetarian with very high levels had ingested 
some medicinal salicylate. In the urine, 24 hour excretion of salicyluric acid of 3.91 µmol 
per 24 hours (range 0.87 to 12.23) in non-vegetarians and 11.01 µmol per 24 hours in 
vegetarians (4.98 to 26.6) has been seen, compared to levels of 170.7 µmol per 24 hours 
(range 13.15 to 377.18) in those who have taken 75 mg of aspirin (349). Again there was 
some overlap between values seen in vegetarians and those on aspirin with a small number 
of vegetarians having levels above the lowest in the aspirin group. Interestingly, excretion 
of salicylic acid did not differ between vegetarian, non-vegetarians and those taking aspirin 
suggesting  that  salicyluric  acid  measurements  are  most  meaningful.    Levels  are  also 
increased following consumption of cranberry juice (350).  In a further study using HPLC 
analysis (341), the median urinary concentration of salicylic acid was 0.56 µmol/L (range 
0.07-0.89  µmol/L),  while  that  of  salicyluric  acid  was  3.20  µmol/L  (range  1.32-6.54 
µmol/L) in 10 individuals who did not take aspirin.  For salicyluric acid, a level of > 6.54 
µmol/L equates to > 1.3 µg/ml while for salicylic acid, a level of > 0.89 µmol/L equates to 
> 0.123 µg/ml. 
 
Thus, although salicylates are present in the plasma and urine of those who do not take 
aspirin, levels are significantly higher in those who take even low dose aspirin and remain 
detectable in both plasma and urine for several hours and may be detectable in the urine for 
up to 48 hours after a single 80 mg dose (347). This suggests that salicylate load due to   - 130 - 
aspirin  ingestion  can  readily  be  distinguished  from  that  of  the  normal  dietary  intake, 
particularly  in  non-vegetarians,  and  that  sensitive  techniques  that  measure  salicylate 
metabolites, and those in the urine in particular, can be used to confirm recent ingestion in 
those meant to be taking low dose aspirin. 
 
3.05.1.2  HPLC Analysis Used in This Study 
Urine concentrations of salicylic acid and salicyluric acid levels were determined using an 
established  reverse-phase  HPLC  method  (339).    The  materials  used  included  stock 
solutions (at a concentration of 1000 µg / ml) of salicylate and salicyluric acid in distilled 
H2O and 1.0M oxalic acid. The internal standard (IS) was 200ug m-hydroxybenzoic acid / 
ml distilled H2O. The mobile phase consisted of 25% H2O, 25% acetonitrile, and 50% 
phosphate buffer (0.2M pH 2.5). The solution was degassed by bubbling Helium through it 
for approximately 10 minutes.   
 
Standards comprised the stock solutions of salicylate and salicyluric acid. The standard 
curves for salicylate ranged from 3.125 to 25 µg / ml while those for salicyluric acid ranged 
from 25 to 200 µg / ml.  As salicylate and salicyluric acid are measured simultaneously, 
each  prepared  standard  contained both  metabolites  at  their  chosen  concentration.  There 
were seven prepared standards (table 3.5).  
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Std. No.  Conc. SA 
(µg/ml) 
Conc.  SU 
(µg/ml) 
Volume  Working 
Std. (µL) 
Volume  H2O 
(µl) 
1  0  0  0  1000 
2  3.125  25  125  875 
3  6.25  50  250  750 
4  9.375  75  375  625 
5  12.5  100  500  500 
6  18.75  150  750  250 
7  25  200  1000  0 
Table  3.5.  Prepared  Standards  Used  in  HPLC  Analysis.  SA  =  salicylic 
acid. SU = salicyluric acid. 
 
The urine sample for analysis was then prepared as outlined below; 
a)  Pipette 200µl of urine for analysis into 5ml round-bottomed tube. 
b)  Add 50µl internal standard (IS) and briefly vortex mix. 
c)  Add 200µl 1M oxalic acid. 
d)  Add 2ml hexane / diethyl ether mixture; ratio1:1. 
e)  Mix on rotator for approximately 5 minutes. 
f)  Centrifuge for 5 mins at 2000 rpm. 
g)  Remove as much hexane / diethyl ether mixture as possible into clean 12ml tube. 
h)  Evaporate  to  dryness  in  centrifugal  evaporator  at  minimum  temperature  setting 
(approximately 15 minutes). 
i)  Dissolve desiccant in 200µl Mobile Phase and briefly vortex mix. 
j)  Carefully transfer as much volume as possible to HPLC vial and cap. 
 
The HPLC system consisted of a Shimadzu SCl-10A VP system controller, Shimadzu Lc-
10AT VP pumps, a Shimadzu SIL-10AD VP sample injector, a Shimadzu SPD-6A variable   - 132 - 
wavelength UV detector and a computer with Jones JCL 6000 data acquisition software. 
The column used was a Phenomenex Synergi 4um Hydro-RP column (dimensions 15cm x 
4.6mm). The guard column is packed with Lichroprep RP-18, particle size 25-40um. The 
column and other system components are maintained at ambient temperature. 
 
HPLC conditions were a flow rate of 0.5 mls / min, a detector set at UV, λ 303 nm and 
absorbance 0.02 and the injection volume was 50 µl. Retention times were approx. 5.4 
minutes for IS, 6.9 minutes for salicyluric acid and 11.8 minutes for salicylic acid. 
 
Limits  of  detection  were  not  pre-specified.  Salicylate  metabolites  are  endogenous 
compounds with levels above the likely limit of detection seen in many individuals. 
 
Definition of Evidence of Recent Aspirin Ingestion Used 
Little data exist to inform levels of salicyluric acid or salicylic acid at differing times after 
aspirin ingestion and in those not taking aspirin. In a small sample in the local laboratory, 
levels of 0 to 5.25 µg/ml of salicyluric acid have been seen, with most values < 5 µg/ml in 
those taking no aspirin. Levels of  > 5 µg/ml were seen 24 hours after single dose aspirin 
ingestion. Although direct comparisons are not possible, this threshold is broadly similar to 
that outlined by others (341) and a salicyluric acid of > 5 µg/ml was therefore used to 
define evidence of recent aspirin ingestion. These individuals were included in the urine 
sub-study. Given that it is also know that aspirin metabolites are predominantly cleared 
from the urine within 24 hours, evidence of no recent aspirin ingestion was defined as 
stated  last  dose  of  aspirin  within  24  hours  from  submission  of  urine  sample  and  a 
salicyluric acid level of < 5 µg/ml. Importantly, given that the platelet mediated effects of 
aspirin last longer than 24 hours, it is expected that some participants whose urine sample   - 133 - 
was received after 24 hours would have evidence of aspirin mediated platelet dysfunction 
but a salicyluric acid level of < 5 µg/ml. 
 
Final Assessment - At the final assessment the final diagnosis and patient outcome were 
established for cases.  
 
Statistical Analysis 
It was planned to study 90 cases and 90 controls.  The primary endpoint was the proportion 
of individuals showing resistance to aspirin on any test. Secondary endpoints were defined 
as resistance to both tests, to the PFA-100 test and to the RPFA test. The rate of the primary 
(and secondary) endpoint(s) were compared between cases and controls.  It was estimated 
that the rate of aspirin resistance would be approximately 30% in the general population but 
that it would be higher, at approximately 40%, in cases (277;351) and lower in controls. It 
was estimated that approximately 20% in the control population would have no evidence of 
recent aspirin ingestion but there are little data to help estimate the rate in those with a 
vascular event.  Even after exclusion of these patients from the analyses (approximately 
20% of all subjects), 90 patients per group will allow detection of a ~ 20% difference in 
aspirin resistance rate between the two groups with 80% power and a significance of 0.05 
(for example 40% in cases vs 20% in controls).   
 
Differences between cases and controls were assessed by the Student's t test for means and 
the chi-square test for proportions or Fisher’s exact test. Agreement between the platelet 
function and salicylate detection testing was assessed using kappa statistics. A p value of 
<0.05 was used to determine statistical significance and standard definitions of degrees of   - 134 - 
agreement were used. Analyses were performed separately for each of the two methods of 
determining aspirin responsiveness. Cases and controls were not matched on a 1:1 basis. 
 
3.05.2  Study Three Results 
 
Ninety cases were recruited between the 19
th February 2007 and the 4
th November 2008. 
Ninety  controls  were  recruited  from  29
th  June  2007  to  4
th  November  2008.  Baseline 
characteristics are shown in table 3.6 and 3.7. There were several statistically significant 
differences  between  the  groups.  All  participants  verbally  confirmed  regular  compliance 
with aspirin. 
 
All cases (for the exception of one) and all controls were prescribed 75 mg per day of 
aspirin.  Baseline levels of routine biochemistry and haematology indices including platelet 
count  and  coagulation  parameters  are  shown  in  table  3.7.  There  were  no  significant 
differences.  Coagulation  screens  were  not  routinely  performed  in  controls  and  this 
comparison is thus based on a small number (n=7) of controls.  The time  from stroke 
symptoms to blood sampling was 16 (IQR  4.5 to 22.5) hours in cases.  
 
Variable  Cases  Controls  P Value  
Baseline Platelet Count  244.8 (8.1)  254.5 (14.1)  0.55 
Baseline Haemoglobin  13.4 (0.2)  13.7 (0.3)  0.39 
Baseline APTT  31.2 (0.5)  33.1 (1.9)  0.35 
Baseline PT  11.9 (0.16)  12.1 (0.6)  0.72 
Baseline Creatinine  96.8 (4.23)  97.7 (3.6)  0.99 
Table 3.6. Study Three Baseline levels of Blood Parameters in Cases and Controls. 
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Variable  Cases  Controls  P Value 
Age  71.1 (10.5)  66.7 (11)  0.007 
Male Sex  43 (47.8%)  47 (52.2%)  0.55 
Stroke 
TIA 
60 (66.7%) 
30 (33.3%) 
--- 
--- 
--- 
--- 
Total Anterior Circulation Stroke 
Partial  Anterior Circulation Stroke 
Lacunar Stroke 
Posterior Circulation Stroke 
Amaurosis 
11 (12.2%) 
44 (48.9%) 
22 (24.4%) 
11 (24.4%) 
2 (2.2%) 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
--- 
NIHSS Score  5.6 (5.4)  ---  --- 
Smoker  27 (30%)  10 (11.1%)  0.001 
Ischaemic Heart Disease  25 (27.8%)  27 (30%)  0.74 
Previous CVA  24 (26.7%)  1 (1.1%)  <0.001 
PVD  4 (4.4%)  4 (4.4%)  1 
Diabetes Mellitus  6 (6.67)  18 (20%)  0.015 
Hyperlipidaemia  22 (24.4%)  35 (38.9%)  0.054 
Hypertension  52 (57.8%)  80 (88.9%)  <0.001 
Atrial Fibrillation  13 (14.4%)  3 (3.3%)  0.008 
Dipyridamole Therapy  13 (14.4%)  1 (1.1%)  <0.001 
ACE I or ARB Therapy  45 (50%)  52 (57.8%)  0.37 
Diuretic Therapy  35 (38.9%)  51 (56.7%)  0.025 
Beta-blocker Therapy  32 (35.6%)  43 (47.7%)  0.13 
CCB Therapy  28 (31.1%)  41 (45.6%)  0.065 
Alpha-blocker Therapy  2 (2.2%)  20 (20.2%)  <0.001 
Statin Therapy  66 (73.3%)  67 (74.4%)  1 
NSAID Therapy  2 (2.2%)  4 (4.4%)  0.682 
Table 3.7. Study Three Baseline Characteristics 
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Aspirin Responsiveness Status in Cases 
In total , 55 (61.1 %) had blood sampling for platelet function testing performed within 24 
hours of last stated aspirin ingestion. PFA-100 and RPFA tests were not successful in three 
individuals. In total, 30 cases (33.7 %) exhibited evidence of aspirin resistance on one or 
more test. Of these, 28 (32.1 %) were resistant on PFA-100 testing, 16 (18.4 %) were 
resistant on RPFA testing and 12 (14 %) were resistant on both (table 3.8).  
 
  Cases  Controls  P Value   95  %  CI  for 
Difference  
PFA-100 CEPI-CT  272 (142 to 300)  293 (205 to 300)  0.068 
#  0.01 to 23.99 
# 
Aspirin  Resistance 
on PFA-100 * 
28 (32.1 %)  15 (18.1 %)  0.031  -27 to - 12.7 % 
RPFA  465 (396 to 530)  452 (399 to 481)  0.33
 #  -34.5 to 9.99
# 
Aspirin  Resistance 
on RPFA * 
16 (18.4 %)  12 (13.8 %)  0.54  -15.5 to 6.3 % 
Aspirin  Resistance 
on Both Tests 
12 (14 %)  5 (5.9 %)  0.07  -16.9 to 1 % 
Aspirin  Resistance 
on ≥ 1 Test 
30 (33.7 %)  21 (24.7 %)  0.19  -22.4 to 4.4 % 
Table 3.8. Study Three Platelet Function Analysis Results. * Only 87 participants had 
results available. P values and 95 % CI shown are for the difference between two 
proportions except for 
# where they are for the difference on Mann-Whitney testing.  
 
Aspirin Responsiveness in Controls 
All controls had blood sampling for platelet function testing performed within 24 hours of 
last stated aspirin ingestion. In total, 21 controls (24.7 %) who exhibited evidence of aspirin 
resistance on one or more test. Of these patients, 15 (18.1 %) were resistant on PFA-100   - 137 - 
testing, 12 (13.8 %) were resistant on RPFA testing and 5 (5.9 %) were resistant on both 
(table 3.8). 
 
Comparison Between Cases and Controls 
The rate of aspirin resistance as defined by resistance on PFA-100 testing or resistance on 
both modalities was significantly higher in cases than control (table 3.8). There were also 
trends towards higher rates of resistance on RPFA testing and on resistance defined as 
resistance on at least one modality. 
 
The Urine Sub-study - Cases 
A urine sample was submitted by 66 cases (73.3%).  The mean concentrations of salicyluric 
acid and salicylic acid seen in the urine were 50.1 (SD 64.5) µg/ml and 1.2 (SD 2.56) µg/ml 
respectively. In total 40 (60.1 %) had levels of salicyluric acid above the pre-specified level 
used to define evidence of recent aspirin ingestion (> 5 µg/ml). 
 
The median time from drawing of blood to submission of the urine sample was 20 minutes 
(IQR 0 to 60 minutes). However, only 24 (36.6%) submitted their urine sample on the same 
day as their last aspirin dose, while 37 (54.6%) submitted their urine sample within 24 
hours of their last stated aspirin dose.  In total 12 of these (32.4 %) had no evidence of 
recent aspirin ingestion (sample submitted within 24 hours of last stated aspirin dose and 
levels of salicyluric acid of < 5 µg/ml).   
 
When considering only those with evidence of recent aspirin ingestion, 10 (26.3 %) were 
aspirin resistant on at least one platelet function test. Of these, 9 (23.7 %) were resistant on   - 138 - 
PFA-100 testing, 5 (13.4 %) were resistant on RPFA testing and 4 (10.5 %) were resistant 
on both (table 3.9). 
 
Of those who submitted a urine sample within 24 hours of last ingestion and were aspirin 
resistant on at least one test, 5 of 10 (50 %) had salicyluric acid levels of < 5 µg/ml.  For 
PFA-100, RPFA testing or resistance on both tests, this figure was 5 of 9 (55.6 %), 4 of 6 
(66.7 %) and 4 of 5 (80 %) suggesting that poor compliance accounted for a significant 
number of the cases of resistance seen. 
 
  Cases (n=39)  Controls (n=32)  P Value  95  %  CI  for 
Difference 
PFA-100 CEPI-CT  283.5  (202.8  to 
300) 
276 (186 to 300)  0.89 
#  -8.01 to 14.98
 # 
Aspirin  Resistance 
on PFA-100 * 
9 (23.7 %)  6 (18.8 %)  0.77  -23.7 to 15.1 % 
RPFA  485  (404.5  to 
522.5) 
451  (395.3  to 
498.5) 
0.49
 #  -54.9 to 20
 # 
Aspirin  Resistance 
on RPFA * 
5 (13.5 %)  5 (15.6 %)  1  -14.6 to 18.8 % 
Aspirin  Resistance 
on Both Tests 
4 (10.5 %)   3 (9.7 %)  1   -15.1 to 13.4 % 
Aspirin  Resistance 
on ≥ 1 Test 
10 (26.3 %)  8 (25.5 %)  1  -21.3 to 20.3 % 
Table  3.9.  Platelet  Function  Analysis  Results  in  Those  With  Evidence  of  Recent 
Aspirin Ingestion. P values and 95 % CI shown are for the difference between two 
proportions except for 
# where they are for the difference on Mann-Whitney testing.  
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The Urine Sub-study - Controls 
A  urine  sample  was  submitted  by  37  controls  (41.1%).    The  mean  concentrations  of 
salicyluric acid and salicylic acid seen in the urine were 110.1 (SD 90.1) µg/ml and 1.6 (SD 
2.74) µg/ml respectively. In total 32 (86.5 %) had levels of salicyluric acid above the pre-
specified level used to define evidence of recent aspirin ingestion (> 5 µg/ml). 
 
All controls who submitted urine samples did so within the hour. All participants stated 
compliance with their aspirin up to the day of recruitment and thus all were assumed to 
have submitted their urine sample on the same day as their last aspirin dose. Thus, only 5 
individuals (13.5 %) had no evidence of recent aspirin ingestion (sample submitted within 
24 hours of last stated aspirin dose and levels of salicyluric acid of < 5 µg/ml).   
 
When considering only those with evidence of recent aspirin ingestion, 8 (25.8 %) were 
aspirin resistant on at least one platelet function test. Of these, 6 (18.8 %) were resistant on 
PFA-100 testing, 5 (15.6 %) were resistant on RPFA testing and 3 (9.7 %) were resistant on 
both (table 3.9). 
 
No individual with salicyluric acid levels of < 5 µg/ml had evidence of aspirin resistance. 
 
The Urine Sub-study - Comparison Between Cases and Controls 
The rate of aspirin resistance, regardless of definition used was similar in both cases and 
controls, although confidence intervals were wide because of the smaller sample size (table 
3.9). 
 
   - 140 - 
Agreement Between Platelet Function Tests 
Agreement between the aspirin responsiveness  status measured by the  different platelet 
function tests is shown in table 5.6. Overall, agreement between the two tests was fair 
(ĸ=0.35).  On sub analysis agreement was also fair in both the case and control population 
(table 3.10). A scatter plot of the individual patient data is shown in figure 3.3. 
 
  Kappa  P Value 
Cases (PFA-100 vs RPFA)  0.39  <0.001 
Controls (PFA-100 vs RPFA)  0.27  0.007 
Cases and Controls (PFA-100 vs RPFA)  0.35  <0.001 
Table 3.10. Measures of Agreement Between Platelet Function Tests in Study Three. 
PFA-100 = Platelet Function Analyser 100. RPFA = Rapid Platelet Function Analyser. 
ĸ= kappa statistic. p values shown are for test of ĸ > 0.  
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Figure 3.3. Scatterplot of PFA-100 Measured Aspirin Responsiveness versus 
RPFA Measured Aspirin Responsiveness in Study Three. Each data point 
represents one individual. Values to the right of the vertical reference line 
represent resistance on RPFA testing while values below the horizontal reference 
line represent resistance on PFA-100 testing. ARU = Aspirin responsiveness unit. 
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3.05.3  Study Three Discussion 
Data from this study revealed a prevalence of aspirin resistance of 34 % in cases with 
recent stroke or TIA compared to 25 % in controls where resistance on one or more test 
was used as evidence of resistance. This difference did not reach statistical significance 
although resistance defined by PFA-100 testing or resistance on both tests was significantly 
higher in  cases with recent stroke or TIA.  However, when only  those with objectively 
confirmed  evidence  of  recent  aspirin  resistance  were  considered,  the  prevalence  of 
resistance was similar in both groups.  A high proportion of cases who were resistant to 
aspirin  had  no  evidence  of  recent  aspirin  ingestion  despite  stating  they  regularly  took 
aspirin,  suggesting  that  compliance  accounts  for  some  of  the  apparent  difference  seen 
between cases and controls. 
 
The fact that aspirin resistance appeared higher in cases than controls would fit with recent 
data suggesting that aspirin resistance links with a higher rate of cardiovascular events 
(274;276).  However,  previous  case  control  studies  have  not  yielded  such  differences 
between groups (352-354), although this is the first such study to examine participants with 
stroke and is the largest case-control study to date. Although the rate of aspirin resistance 
was higher in cases than controls, both were compatible with previous figures given in the 
literature  (276-278)  and  in  particular  with  previous  studies  using  similar  techniques 
(318;355-361).  Thus, aspirin  resistance,  regardless  of  the  definition  used, is a  common 
finding. There were some significant differences between the case and control groups. For 
example cases were older which links with a higher prevalence of resistance (362) although 
fewer were female or diabetic which is also linked with increased resistance (286;363). 
These factors could confound this analysis as these are also risk factors for cerebrovascular 
disease.   - 142 - 
 
The majority of studies have attempted to assess participant compliance, including 17 of the 
20 studies in a recent meta-analysis (274). However, as well as the three studies which 
made  no  mention  of  compliance  assessment  (277;321;364),  3  relied  upon  verbal 
confirmation  of  compliance  (as  done  in  this  study)  (359;365;366)  and  the  remainder 
involved hospital in-patients or supervised ingestion of aspirin (278;355-357;360;367-373) 
at baseline. However, it is well know that verbal means of compliance assessment may not 
accurately reflect whether medication has actually been taken and an objective means of 
assessment is preferable (374) but few studies have employed such methods to date (354).  
 
The importance of participant compliance cannot be overestimated. Approximately 10-40% 
of patients do not take prescribed anti-platelet tablets in the secondary prevention setting 
(292-296). These individuals will be highly likely to appear aspirin resistant on testing. 
Poor compliance has also been shown to be a major cause of aspirin resistance in previous 
studies; for example, just over half (367;375) to all (291) of apparent aspirin resistance has 
previously been shown to be due to poor participant compliance with therapy. 
 
This study utilized direct measurement of aspirin metabolites in the urine as an objective 
means of ensuring recent aspirin ingestion in a secondary analysis. However, there are also 
difficulties with this approach; aspirin is rapidly metabolized and metabolites may be fully 
excreted in the urine at around 24 hours after a single dose, although this is less likely to 
occur  in  those  on  long  term  therapy.  Further,  salicylates  are  endogenous  compounds, 
although levels are much higher then normal following aspirin ingestion. A cut-off level of 
salicyluric acid of 5 µg/ml was used in this study with higher levels used to confirm recent 
ingestion and lower levels used to suggest poor compliance provided the urine sample was   - 143 - 
submitted within 24 hours of the last stated aspirin dose.  It is hoped, given that participants 
were approached and recruited during a single attendance at a clinic or on admission for an 
acute vascular event that their compliance status reflects their normal behaviour; they could 
not have expected to participate in the study before attendance.  The rate of non-compliance 
seen may be an overestimate as individuals who rapidly metabolise and excrete aspirin and 
its metabolites could have undetectable levels of salicyluric acid and salicylate before 24 
hours has elapsed since last aspirin ingestion. However, results were similar when analysis 
was restricted to those who claimed aspirin ingestion within 12 hours of submitting a urine 
sample  and  those  who  take  aspirin  regularly  (as  all  claimed  in  this  study)  excrete 
metabolites for longer in the urine.   
 
Despite the fact that all individuals in this study claimed compliance (and would thus have 
been recruited to many previous studies published in the literature), approximately 1/3 of 
cases met the definition of poor compliance with aspirin therapy. This further suggests that 
verbal statements of compliance are not reliable and that more objective measures should 
be mandatory in studies of aspirin resistance.  For example, in this study, over half of cases 
who submitted a urine sample within 24 hours of last ingestion and were aspirin resistant 
had  salicyluric  acid  levels  of  <  5  µg/ml.    This  suggests  that  poor  compliance  was  an 
important  cause  of  aspirin  resistance  in  this  group.    However,  even  when  this  was 
considered, resistance remained common and as in other studies, was highest with the PFA-
100 device at approximately 20%. 
 
Again in this study agreement between tests was only fair. This is in-line with work from 
other authors and has been discussed in chapter four.  
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In  conclusion,  data  from  this  study  suggests  that  aspirin  resistance  is  a  common 
phenomenon  that  merits  further  study  but  that  poor  compliance  may  contribute  in  a 
substantial number of cases of apparent resistance suggesting that objective measures to 
account for compliance should be mandatory in future studies of aspirin resistance. 
 
Chapter Summary 
The studies in this chapter have shown that the rate of aspirin resistance is higher in those 
with cerebrovascular microembolic signals (MES) and carotid disease compared to those 
with equivalent carotid disease and no MES. Approximately a quarter had MES and those 
with MES had a resistance rate of 50% compared to 17.4% in those without (p=0.018 on 
Fishers exact test). This provides a link to a well established and robust surrogate marker of 
outcome  and  thus  a  useful  model  to  further  study  the  benefits  of  guided  anti-platelet 
strategies. Aspirin resistance was present in 34% of those with recent stroke and in 18% of 
those with risk factors but no established disease in a case-controlled study. However, the 
role of poor compliance with therapy as a cause in a substantial number of individuals was 
established; it accounted for approximately half of those labelled resistant in the stroke 
group. Further, when only those with objective evidence of recent aspirin ingestion were 
considered, the prevalence of aspirin resistance was similar in both groups (at 26%) and it 
remained a common phenomenon. Objective measures to confirm compliance with aspirin 
therapy should be mandatory in future studies of aspirin resistance.  
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CHAPTER FOUR 
 
 
 
SERUM URIC ACID REDUCTION, XANTHINE OXIDASE 
INHIBITION AND RISK OF STROKE 
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4.01  Potential Novel Therapies – Lowering Serum Uric Acid 
 
The role of serum uric acid in the development of cardiovascular disease has been the 
subject of controversy for many years. Many studies concerning the association between 
increasing serum uric acid level and event rate and mortality in a variety of cardiovascular 
disease states have been published.  However, the presence of a causal relationship is less 
clear and elevated levels of uric acid may reflect a separate underlying disease process, 
atherosclerosis itself, or increased xanthine oxidase activity; all of which may influence 
vascular risk.   
 
4.01.1  Biochemistry of uric acid in man 
Uric acid is a breakdown product of ingested and endogenously synthesised purines (figure 
4.1).    DNA  and  RNA  are  degraded  into  purine  nucleotides  and  bases,  which  are  then 
metabolized, via the action of xanthine oxidase, to xanthine and uric acid.  These later steps 
are irreversible and generate superoxide anions.  Uric acid undergoes no further metabolism 
in humans and is excreted by the kidneys and intestinal tract.  In the kidney, it is filtered 
and  can  be  subsequently  reabsorbed  or  further  excreted  in  the  proximal  tubule, 
predominantly under the action of a urate transporter (URAT1) (376). 
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Serum levels are governed by the balance of production and excretion.  Production can be 
increased  by  several  mechanisms  including  rare  enzymatic  defects,  states  of  high  cell 
turnover  and  alcohol  ingestion  (partly  because  of  purines  contained  in  alcoholic drinks 
(377;378)).    However,  the  majority  of  cases  of  elevated  serum  uric  acid  result  from 
impaired renal excretion, possibly because of inter individual differences in function of the 
URAT1 transporter. 
 
4.01.2  Uric Acid as a Cardiovascular Risk Factor 
This has been evaluated in a number of studies. Studies have typically utilised data from 
randomised control trials or epidemiological databases and expressed results as change in 
relative risk per increment of uric acid or as relative risk across uric acid quintiles (379). 
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Cardiovascular Risk States 
In patients with diabetes, serum uric acid levels above the median (295µmol/l) have been 
associated with near double an increased risk of stroke (HR 1.91, 95 % CI 1.24-2.94) (380), 
while increasing uric acid levels were associated with increased prevalence of peripheral 
arterial disease in both a Taiwanese (381) and Australian cohort (382) (OR 1.004, 95% CI 
1.001-1.008
  and  1.03,  95%  CI  1-1.06,
  per  additional  0.1mmol/l  in  serum  uric  acid 
respectively). 
 
In patients with essential hypertension, serum urate in the highest quartile was associated 
with  increased  cardiovascular  event  rate  (HR  1.73,  95%  CI  1.01-3),      cardiovascular 
mortality and all cause mortality (HR 1.63, 95% CI 1.02-2.57) (383).  A similar positive 
association  was  seen  in  the  SHEP  trial,  where  serum  uric  acid  in  the  highest  quartile 
conveyed an increased risk of cardiovascular events (HR 1.32 95% CI 1.03-1.69) but not of 
all cause mortality or stroke (384). Other large studies have shown that small increments in 
serum uric acid are associated with increasing incidence of cardiovascular disease and with 
cardiovascular death (385;386).  These associations persist despite adequate adjustment for 
confounding factors and other risk factors.  However, in the Syst-Eur study of hypertensive 
patients, a trend but no association was seen with cardiovascular events or mortality (HR 
1.06, 95% CI 0.99-1.13 and HR 1.03, 95% CI 0.93-1.14 per 50µmol/L increment in serum 
urate respectively) (387).  While the event rate was similar to that in other studies, the 
proportion  of  females  was  far  greater,  meaning  it  is  possible  that  a  gender  effect  has 
attenuated the association. 
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Cardiovascular Disease 
In  patients  with  stroke,  increasing  serum  uric  acid  levels  have  been  associated  with  a 
reduced likelihood of a favourable outcome and an increased risk of recurrent vascular 
events  (OR  0.78,  95%  CI  0.67-0.91  and  RR  1.27,  95%  CI  1.18-1.36  per  additional 
0.1mmol/l in serum uric acid respectively) (388).  This association was more prominent in 
diabetic patients (389).  Elevated levels of serum uric acid in the early stages after acute 
stroke have also been associated with early clinical deterioration (390).  In patients with 
angiographically defined coronary artery disease, serum uric acid in the highest quintile 
(391) and quartile (392) has been shown to be predictive of all cause mortality (HR 1.5, 
95% CI 1.02-2.1 and HR 1.23, 95% CI 1.11-1.36 respectively). Increasing levels of serum 
uric acid have also been shown to strongly predict mortality, need for cardiac transplant and 
in-hospital mortality in those with cardiac failure (393;394).  Conversely, it has been shown 
that increased serum uric acid in the acute phase following stroke is associated with a good 
outcome (395); a finding that is addressed later.  
 
Healthy Populations 
The NHANES study (396) did show an association with each 59.5 µmol/l increment in 
serum uric acid leading to increased risk of cardiovascular events (HR 1.09, 95% CI 1.02-
1.18 in men) and cardiac mortality (HR 1.17, 95% CI 1.06-1.28 in men).  A yet more 
significant association was seen in women. However, a large analysis from the Framingham 
Heart study cohort found no association with cardiovascular mortality after adjustment for 
diuretic therapy (397) and a similar lack of association has been reported in other large 
studies of healthy individuals (398-400).  Lower event rates in such healthy populations 
may explain this inconsistency; larger sample sizes are required and some may have lacked 
power to detect an independent association   - 150 - 
 
For An Association 
Reference  Population  Change in Outcome Measure 
(380)  DM  HR  1.91 (1.24-2.94)  (serum  uric  acid  >295umol/l)  for 
risk of stroke 
(389)  DM / stroke  HR 1.49 (1.21-1.84)
 a  for recurrent CV event 
(388)  Acute stroke  RR 1.27 (1.18-1.36)
 a for recurrent CV events   
(390)  Acute stroke  Serum  uric  acid  ↑  in  those  with  early  clinical 
deterioration (p=0.001) 
(391)  CAD  HR 1.5 (1.02-2.1)
 b  for all cause mortality 
(392)  CAD  HR 1.23 (1.11-1.36)
c  for all cause mortality 
(384)  ↑ BP  HR 1.32 (1.03-1.69)
b, for CV events 
(401)  ↑ BP  HR 1.22 (1.11-1.35)
d for development of CV disease 
(386) 
 
↑ BP  HR 1.14 (1.02-1.27)
e  for CV mortality,  
HR 1.34(1.14-1.57)
e for fatal stroke 
(383)  ↑ BP  HR 1.73 (1.01-3)
 b for CV event rates 
Against An Association 
(395)  Acute stroke  OR 1.12, 95% CI 1-1.25 per additional mg/dl uric acid 
for good outcome 
(387) 
 
↑ BP  HR 1.03 (0.93-1.14)
e for CV mortality 
HR 1.06 (0.99-1.13)
e  for all CV events 
Results expressed as ratio and 95% CI. DM = Diabetes Mellitus, PVD = Peripheral 
Vascular Disease, CV = Cardiovascular, CAD = angiographic coronary disease, 
a = 
per  additional  0.1mmol/l  in  serum  uric  acid, 
b  =    for  highest  vs  lowest  quintile  / 
quartile, 
c,d = per additional 0.6 and 0.86mmol/l in serum uric acid respectively, 
 e = 
for each 50µmol/L increment in serum urate   
Table 4.1: Summary of Studies Examining Relationship Between Serum UA and 
Outcome 
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Summary / Gaps in the Epidemiological Evidence 
Most large, well-conducted epidemiological studies support the hypothesis that elevated 
serum uric acid is a powerful predictor of increased vascular event rate and mortality in 
patients with hypertension, diabetes and in those with known cardiovascular disease (table 
4.1).  The results in healthy populations are less consistent.  Despite this, the relationship 
with stroke rate and mortality is less clear; most studies have not specifically evaluated 
stroke mortality or have been limited by relatively low stroke rates (383;396).  Where it has 
been evaluated, only one Chinese study has shown a strong association (386) while others 
have not (384;387).  An association has been seen with stroke risk in patients with diabetes 
(380) and in a large observational cohort of patients aged > 55 years of age, although the 
association was less prominent in hypertensive individuals (402). The impact of serum uric 
acid on outcome in the acute period after stroke is also unclear. In a study of 2498 patients 
with acute stroke, increasing serum UA levels were associated with a reduced likelihood of 
favourable outcome at 90 days (OR 0.78, 95% CI 0.67-0.91 per additional 0.1 mmol/L UA) 
and an increased risk of recurrent vascular events (388), which were more prominent in 
those  with  diabetes  (389).  Some  have  suggested  increased  risk  of  early  clinical 
deterioration  following  ischaemic  stroke  (390).  However,  a  further  study  reported 
conflicting results: in 800 patients with acute ischaemic stroke, increasing UA levels were 
associated with a good outcome (OR 1.12, 95% CI 1-1.25 per additional mg/dl UA) at 
seven days (395). 
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4.01.3  An Innocent By-stander? 
Against a Direct Causal Association   
It  is  argued  that  elevated  serum  uric  acid  in  those  with  cardiovascular  disease  simply 
reflects  the  presence  of  other  risk  factors  such  as  hypertension  or  diabetes,  diuretic 
treatment, impaired renal function, atherosclerosis itself or increased oxidative stress. 
 
Worsening renal function is associated with increased serum uric acid levels and increased 
burden of cardiovascular disease.  Markers of oxidative stress are increased in patients with 
chronic renal disease and are predictive of increased cardiovascular mortality (403;404). 
Successful  renal  transplantation  (405-407)  improves  such  markers.    Therefore,  the 
association may simply reflect impaired renal function and the associated oxidative stress 
and cardiovascular risk.  While most studies have adequately adjusted for renal impairment, 
it cannot be excluded that raised uric acid levels reflect or contribute to sub clinical levels 
of renal impairment which contribute to the association in as yet undefined ways. 
 
Even in those with normal renal function, higher levels of uric acid may reflect higher 
levels of xanthine oxidase activity and oxidative stress.  This would also explain why serum 
uric acid levels rise after an ischaemic insult as discussed below. The action of xanthine 
oxidase leads to generation of superoxide anions, and is one of the principle sources of 
reactive oxygen species (ROS) in the human vasculature (408;409).  The molecular effects 
and importance of ROS in cardiovascular disease has already been extensively reviewed 
(410-413). In summary, once formed, superoxide anions can inactivate nitric oxide, leading 
to formation of peroxynitrite, which is also a strong oxidant.  This inhibits endothelium-
dependent  vasorelaxation,  limits  the  favourable  effects  of  nitric  oxide  on  platelet 
aggregation and vascular smooth muscle proliferation and causes oxidation of DNA and   - 153 - 
lipids;  all  factors  integral  to  development  of  atherosclerosis  (414).    Under  normal 
circumstances ROS production is usually countered by antioxidant defence mechanisms, 
including the action of superoxide dismutase (SOD) (415). 
 
As well as this putative role in atherosclerosis development, ROS production increases 
acutely following cerebral or cardiac ischaemia and may contribute to the degree and extent 
of tissue damage (416-418).  This hypothesis is supported by animal models of ischaemic 
stroke where SOD knockout mice exhibit greater lesion volumes after temporary middle 
cerebral artery occlusion (419-421), whereas SOD over expressing mice exhibit reduced 
lesion volume (422).  Infusion of SOD and catalase have led to a reduction in stroke lesion 
volume  in a  murine  stroke  model  (423).    Human  studies  have  also  shown  that  locally 
increased oxidative stress and reduced peripheral antioxidant activity are associated with 
increased stroke lesion volume and a greater neurological deficit (424;425).  Similar work 
in animal models of myocardial infarction has suggested oxidative stress is associated with 
increased development of heart failure (426;427).  It is also likely that oxidative stress 
predisposes to development of heart failure after acute myocardial infarction in humans 
(428;429).  Thus, increased uric acid levels may simply reflect increased xanthine oxidase 
activity which may directly contribute to the development of atherosclerotic disorders and 
predispose to more severe vascular events. 
 
There is evidence that uric acid has antioxidant activity and that levels may rise after an 
ischaemic insult.  This has led to an alternate hypothesis that elevated serum uric acid 
represents  a physiological,  and  perhaps  protective,  response  to the  oxidative  stress  that 
characterises many vascular disease states (430;431).  In a rat model of cerebral ischaemia, 
brain uric acid levels increased (432;433) and in a transient ischaemia model, infusion of   - 154 - 
uric acid led to a reduction of infarct volume and improved behavioural outcome (433). 
This is further supported by data from a rat model of traumatic brain injury and a mouse 
model of multiple sclerosis, where uric acid was found to reduce formation of peroxynitrite 
radicals (434;435). In healthy human volunteers, uric acid administration has been shown to 
increase serum antioxidant capacity (436).  In a study of 800 patients with ischaemic stroke, 
admission serum uric acid was higher in those with a good outcome and increasing levels 
associated with a good outcome (OR 1.12, 95% CI 1-1.25 per additional mg/dl uric acid) 
(395).  This finding is in direct contrast to those of other studies (388-390).   
 
While these findings warrant consideration, the potential antioxidant properties of uric acid 
in vitro or in vivo should not be over-interpreted. Increased local tissue levels in animal 
models of ischaemia and brain injury may simply reflect the levels of oxidative stress and 
xanthine oxidase activity, and not an innate protective response.  The substance itself may 
well  have  antioxidant  properties  but  its  generation  and  associated  superoxide  anion 
production  may  be  of  much  greater  significance  and  detriment.    Even  the  intriguing 
findings that uric acid infusion may be protective in animal models of brain ischaemia do 
not  imply  that  uric  acid  lowering  strategies,  and  particularly  those  involving  xanthine 
oxidase inhibition, could not have favourable effects in vivo. 
 
For a Causal Association 
Data from animal and in-vitro studies do raise the possibility of a direct causal mechanism 
for uric acid in cardiovascular disease which provides further support for the convincing 
epidemiological associations.  Monosodium urate crystals have been shown to stimulate 
release of the platelet constituents serotonin, ATP and ADP (437), while uric acid has been 
shown to stimulate rat vascular smooth muscle production in vitro (438).  Uric acid may   - 155 - 
also increase oxygenation of LDL (439) and may have a causative role in the development 
of hypertension (440-442). This is summarised in figure 4.2. 
 
 
 
4.01.4  Pharmacological intervention to Lower Uric Acid 
Several  drugs  are  known  to lower  uric  acid.   These  either increase  uric  acid  excretion 
(urosuric drugs), block the final step in uric acid production via xanthine oxidase inhibition 
or  lead  to  uric  acid  breakdown  (rasburicase).    The  most  effective  urosuric  drugs  are 
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probenecid  and  sulfinpyrazone,  while  fenofibrate  (a  fibrate)  (443)  and  losartan  (an 
angiotensin  II  antagonist)  (444;445)  also  have  urosuric  activity.    Rasburicase  is  a 
recombinant urate-oxidase  enzyme  which  converts  uric  acid to  allantoin.    It  is  used  in 
association with some anti-cancer treatments and is unsuitable for repeated dosing.  There 
are two commercially available xanthine oxidase inhibitors, allopurinol and oxypurinol.  
Allopurinol is rapidly metabolised to oxypurinol, which is an analogue of xanthine and 
preferentially binds to xanthine oxidase thereby inhibiting its activity (446).  Because of its 
action on both uric acid levels and xanthine oxidase activity, allopurinol is a logical drug to 
study in trials of cardiovascular risk reduction (figure 4.2).   
 
Allopurinol is generally well tolerated with few side effects.  Its major indication is in the 
prophylaxis  of  gout  (447).    Side-effects  typically  comprise  gastro-intestinal  upset  and 
rashes.  A rash develops in approximately 2 percent of patients and typically subsides after 
treatment is discontinued.  More serious side effects, such as generalised hypersensitivity, 
occur in less than
 1 in 1000 cases and include exfoliative dermatitis, often with vasculitis,
 
fever, liver dysfunction, eosinophilia, and acute interstitial
 nephritis (448).  The  rate of 
adverse reaction is highest in patients with renal dysfunction and rashes are more common 
with  concurrent  amoxicillin  therapy  (449;450).    There  is  a  known  interaction  with 
azathioprine and 6-mercaptopurine therapy and some rare reports of cytopenia. This side-
effect profile is comparable to that of commonly used secondary preventative agents such 
as  HMG-CoA  reductase  inhibitors  (451)  and  angiotensin  converting  enzyme  inhibitors 
(452;453). 
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4.01.5  Uric Acid Lowering Drugs and Cardiovascular Risk 
Three drugs known to reduce cardiovascular mortality have been shown to reduce serum 
uric acid.  This may explain some of their beneficial effect but changes in other risk factors 
such  as  renal  function  and  blood  pressure  may  explain  both  the  beneficial  effects  and 
changes in uric acid levels. 
 
Fenofibrate  is  a  fibric  acid  derivative  known  to  reduce  total  and  LDL  cholesterol  by 
approximately 15% with a similar increase in HDL cholesterol and with larger reductions 
in triglyceride levels (454).  Fibrates reduce incidence of cardiac events in dyslipidaemic 
patients (455) and in those with coronary disease (456).  These benefits may be greatest in 
type two diabetics (457) where they have been shown to reduce atherosclerosis progression 
(458)  and  total  vascular  events  (459).    Fenofibrate  reduces  serum  uric  acid  levels  (via 
increased  renal  excretion)  by  as  much  as  46%  in  healthy  volunteers,  hypertensive  and 
diabetic patients and those with gout on specific urate lowering therapy (460-462).  This 
may provide adjunctive efficacy in the treatment of gout when combined with allopurinol 
(463;464) and may contribute to the reduced vascular risk associated with fibrate therapy.  
This effect is not seen with other fibrates (465) and its mechanism is elusive although 
unlikely to be mediated by improvements in renal function (466). 
 
Losartan  is  an  angiotensin  II  receptor  antagonist  which  is  superior  to  atenolol  in  the 
prevention  of  cardiovascular  events  when  given  to  hypertensive  patients  with  left 
ventricular hypertrophy  (467).   Losartan is  known to increase  renal uric acid  excretion 
(468) (by as much as 30%), thereby causing significant reductions in serum uric acid (469).  
This mediated via effects on the urate/anion transport mechanism in the renal proximal 
tubule (470). This is not a class effect; other angiotensin II antagonists have little or no   - 158 - 
effect on serum uric acid excretion (471).  Up to 29% of the 13% relative risk reduction 
seen with losartan use in the LIFE study has been attributed to its effect on serum uric acid 
(472).  Serum uric acid increased with both atenolol and losartan use in the LIFE study, but 
the increase was significantly less with losartan.  Whether this does underpin much of the 
benefit of losartan and whether it can attenuate the possibly detrimental effects of diuretics 
on uric acid requires further clarification.  Although the effect was independent of measures 
of renal function, treatment with ACE blockade or angiotensin II antagonists do reduce 
levels of oxidative stress (473) which could itself account for this added benefit. 
 
Statin therapy has also  been shown to lower serum uric acid.   In the  GREACE study, 
atorvastatin was associated with a fall in serum uric acid (by 8.2%), whereas serum uric 
acid increased in those patients allocated to the placebo group (by 3.3%).  After extensive 
adjustment  of  several  risk  factors  including  change  in  renal  function,  each  60µmol/l 
reduction in serum uric acid was associated with a reduction in vascular event rates (HR 
0.76, 95% CI 0.62-0.89) (474).   A fall in serum uric acid has been mirrored in other studies 
of  statin  therapy  (149;475)  but  typically  in  association  with  improvements  in  serum 
creatinine.  Atorvastatin however, has repeatedly been shown to lower uric acid (by 6.4%) 
in  other  studies  (476)  even  after  adjustment  for  renal  function,  possibly  because  of 
decreased uric acid production (477).  As yet, this has not been adequately studied and 
cannot be assumed to explain some of atorvastatin’s effects, although it may represent a 
further beneficial effect. 
 
Specific Intervention to Lower Serum Uric Acid and Xanthine Oxidase Inhibition 
The effect of xanthine oxidase inhibition on measures of endothelial and cardiovascular 
function has also been tested in a number of small studies, performed in the context of   - 159 - 
diabetes, hypercholesterolaemia, hypertension, elevated 10 year cardiovascular risk, sleep 
apnoea, angiographically  confirmed  cardiovascular disease,  stroke  and  heart  failure.    A 
recent systematic review performed by myself has identified 22 such studies (478-498). A 
summary of the findings is given below and in table 4.2. 
 
Study design has varied using either oral or intravenous xanthine oxidase inhibition with 
differing  treatment  duration.  For  example,  seven  studies  (478;480;486-488;493;495) 
utilised a single dose of allopurinol or oxypurinol. In other studies duration of therapy was 
one  week  (480),  two  weeks  (491;492;498),  one  month  (481;483;484;490;494;497),  six 
weeks  (489), two  months  (479), three  months  (482;496)  and  six  months  (485).    Some 
studies were open label (478;480;486-488;493;496), others employed a cross over design 
(479-482;490;494;495;498)  and  the  remainder  were  randomised  controlled  trials  (483-
485;489;491;492;497).  
 
The  populations  studied  have  varied.  There  have  been  nine  studies  in  heart  failure  or 
cardiomyopathy (478-486), two in those with established cardiac disease (487;488), three 
in  those  with  diabetes  (490-492),  one  in  those  with  stroke  (489),  two  in  those  with 
hypercholesterolaemia (493;494), one in those with the metabolic syndrome (497), one in 
smokers (495), one in those with hyperuricaemia and elevated Framingham risk score (496) 
and one in those with sleep apnoea (498).  
 
The endpoints assessed also varied. Six studies reported changes in forearm blood flow 
responses following acetylcholine infusion (480;483;490;493-495) with similar measures 
of  limb  blood  flow  responses  assessed  in  a  further  four  studies  (480;496-498).  Three 
studies assessed changes in blood markers of oxidative stress (491;492) and inflammatory   - 160 - 
activity  (489)  while  further  studies  evaluated  change  in  BNP  levels  (482),  exercise 
tolerance  (482;484)  and  myocardial  efficiency,  contractility  and  function  (486) 
(478;484;488). Others reported effects on heart rate variability parameters (479), coronary 
vasoconstrictor activity (487) and in one study, a clinical endpoint of change in clinical 
status in those with chronic heart failure was assessed (485).  
 
Improvements in endothelial function following allopurinol have been shown in patients 
with  type  II  diabetes  and  mild  hypertension  (490).    Endothelial  function,  expressed  as 
percentage change in ratio of infused forearm blood flow (FBF) compared to non-infused 
arm FBF in response to intra-arterial acetylcholine infusion, was found to return to near 
normal  following  one  month  of  300mg  allopurinol  treatment.    No  effect  was  seen  on 
control patients. Using similar  methods, a single oral dose of allopurinol was found to 
improve peripheral endothelial function towards normal in smokers but had no effect in the 
non-smoking control group (495).  The rapidity of the improvement strongly suggests that 
xanthine  oxidase  is  a  key  contributor  to  the  endothelial  dysfunction  seen  in  smokers.  
Further study in those with diabetes has suggested improvement in markers of oxidative 
stress (491;492).  
 
Improvement  in  forearm  endothelial  function  has  also  been  seen  in  patients  with 
hypercholesterolaemia following intra-arterial administration of oxypurinol (493) but this 
was not replicated in a similar but smaller study of 4 weeks oral allopurinol treatment (494).  
It is possible this later study was underpowered; the power calculation was based upon the 
effect  size  seen  following  3  months  of  simvastatin  treatment  (499).    The  anticipated 
treatment effect was larger than that seen in other studies of allopurinol use, while the effect 
seen in this study at one month, was more similar and approximately half this.    - 161 - 
 
Forearm blood flow responses, expressed as ischaemia induced change in brachial artery 
diameter, were also improved by a three month course of allopurinol in a group of patients 
with elevated 10 year cardiovascular risk (496) and hyperuricaemia.  A recent study in 
patients with stable coronary artery disease (487) showed that intravenous administration of 
oxypurinol  improved  both  peripheral  endothelial  function  and  coronary  endothelial 
function (expressed as the coronary vasoconstrictor response to acetylcholine and changes 
in coronary blood flow) in those with impaired baseline function. A similar study showed 
an improvement in left ventricular function in those with IHD (488). 
 
Intra-coronary  infusion  of  oxypurinol  has  been  shown  to  reduce  myocardial  oxygen 
consumption, probably via preserved nitric oxide bioactivity, and to significantly increase 
myocardial efficiency measurements in those with heart failure (478). In a further study a 
single intravenous infusion (486) and a one month course of 600 mg allopurinol (484) 
improved left ventricular ejection fraction. Further, both an intravenous infusion (480), a 
one  month  300  mg  oral  course  (481)  and  a  six  month  600  mg  oral  course  (483)  of 
allopurinol have been shown to improve a variety of measures of peripheral endothelial 
function  in patients  with  heart  failure.    Recent  work  has shown  that  B-type  natriuretic 
peptide concentrations are reduced by a three month course of oral allopurinol (482) but no 
improvements in exercise tolerance were demonstrated, while in previous study no change 
in heart rate variability parameters was seen (479). 
 
Results from the largest study to date were disappointing. In the OPT-CHF trial (485), 405 
participants with heart failure were randomised to receive either oxypurinol 600 mg or 
placebo for 6 months. The primary endpoint was defined as a change in clinical status   - 162 - 
based  upon  changes  in  a  variety  of  parameters;  mortality,  heart  failure  related 
hospitalisations, need for therapy escalation, New York Heart Association functional class 
and Patient Global Heart Failure Clinical Status. There was no difference in the proportion 
of patients who improved or worsened between treatment groups (43.3% improved with 
allopurinol compared to 45%) with placebo while 32% and 35.6%) remained the same and 
24.6%  and  19.3%  worsened  (p  =  0.42)).  However,  post-hoc  analyses  suggested  that  in 
those  with  elevated  serum  uric  acid,  oxypurinol  improved  clinical  status,  whereas  the 
opposite occurred in those with lower uric acid levels. In the oxypurinol cohort as a whole, 
those who improved had significantly greater reductions in serum uric acid levels than 
those who worsened. These findings are difficult to interpret. On the one-hand the post-hoc 
analyses suggest benefit in those with high uric acid levels and that the greater the fall 
following oxypurinol in such patients, the better the outcome, they also raise the possibility 
that oxypurinol can cause harm in some. 
 
Potential Significance of These Studies 
Abnormalities  in  peripheral  and  coronary  arterial  responses  are  accepted  to  signify 
endothelial dysfunction and are associated with other markers of cardiovascular disease 
(500).  Improvements  in  these  parameters  have  been  shown  to  follow  treatment  with 
thiazolidinediones (501;502) and agents such as ACE inhibitors (503-505), HMG COA 
reductase inhibitors (502,505-509), and amlodipine (503).  Most of these agents have been 
shown to be effective in reducing cardiovascular event rates and mortality. While direct 
comparisons are flawed and difficult, the magnitude of the changes effected by xanthine 
oxidase inhibition seems comparable to those caused by these agents (bar the exception 
outlined  above)  (472;505;506;510).    Further,  the  reductions  in  BNP  levels  seen  were 
comparable to those induced by ACE inhibition, angiotensin II antagonists (511), beta-  - 163 - 
blockade (512) and spironolactone (513).  It is therefore possible, but entirely speculative, 
that allopurinol could have a similar impact on clinical outcomes as these agents.  The side 
effect  profile  of  allopurinol  is  also  comparable  to  other  treatments  but  the  cost  is  not; 
allopurinol is cheap making it an attractive preventative treatment. 
 
Data have shown that following stroke, each additional 0.1 mmol/l increase in serum uric 
acid is associated with a 27% increased relative risk of a recurrent cardiovascular event 
(388). Data also show that following stroke, 300 mg allopurinol causes a sustained  
reduction in serum uric acid from a mean of 0.35 mmol/L (SD 0.09) to 0.22 mmol/L (SD 
0.05) (unpublished data).  Using a secondary prevention stroke trial as an example, it would 
therefore be reasonable to expect a 27% relative risk reduction in cardiovascular event rate 
with this treatment.  With a predicted cardiovascular event rate of 6/100 patient years, or 
16%  over  3.5  years  (as  used  to  design  and  seen  in  the  recent  ESPRIT  trial  (138)), 
approximately 3000 patients would be required to be followed for a mean of 3 years to 
confirm this benefit.  It is important to remember that this figure may actually be less 
because the beneficial effects of allopurinol on endothelial function would be expected to 
contribute to the treatment effect regardless of changes in uric acid. For example, in those 
studies  involving  a single  dose  of allopurinol or  oxypurinol  which  showed  benefit,  the 
results presumably reflect xanthine oxidase inhibition rather than change in serum uric acid. 
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Ref.  Population  Intervention  Change Following Treatment 
(480)  CHF, ↑ uric acid  Intra-arterial  infusion 
of allopurinol 
Improvement in FEF  *  
(480)  CHF, ↑ uric acid  1  week  allopurinol 
300mg † 
Improvement  in  lower  limb 
endothelial function. 
(482)  CHF  3  months  allopurinol 
300mg † 
Fall  in  BNP  levels from  baseline.  
No change in exercise tolerance 
(481)  CHF  1  month  300mg 
allopurinol 
 † 
Improvement in FEF *  
(484)  CHF  1  month  oxypurinol 
600 mg 
Increase in LVEF 
(486)  CHF  Single  intra-venous 
oxypurinol infusion 
Increase in LVEF 
(485)  CHF  6  months  oxypurinol 
600 mg 
No change in functional status 
(479)  CHF  2  months  allopurinol 
300 mg 
No change in heart rate variability 
parameters 
(478)  Idiopathic DCM  Intra-coronary  infusion 
of allopurinol 
Reduction  in  MVO2.  Increase  in 
myocardial efficiency 
(488)  CHD and LVSD  Single  intra-venous 
oxypurinol infusion 
Increase in LVEF and reduction in 
end systolic ventricular volume 
(487)  Coronary  Heart 
Disease 
Single  intra-venous 
oxypurinol infusion 
Attenuation  of  coronary 
vasoconstrictor  response  *  and 
increase in coronary blood flow 
CHF  =  congestive  cardiac  failure.  FEF  =  forearm  endothelial  function.  BNP  =  brain 
natriuretic peptide. DCM = dilated cardiomyopathy. MVO2 = Myocardial O2 consumption. 
LVSD = left ventricular systolic dysfunction. * = in response to intra-arterial Ach infusion, 
† = cross over design, § =  control arm, || = ischaemia induced % change in BA diameter. 
Table 4.2. Studies of uric acid lowering therapy in those with or at risk of cardiovascular 
disease. 
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Ref.  Population  Intervention  Change Following Treatment 
(489)  Acute  ischaemic 
stroke 
6  weeks  allopurinol 
(300 or 100 mg) § 
Reduction  in  ICAM-1  levels 
following 300 mg allopurinol 
(490)   Type 2 DM  1  month  300mg  od 
allopurinol 
 †§ 
Improvement in FEF  * 
(491)  Type 1 DM  2  weeks    allopurinol 
300 mg 
Reduction in GSSG/GSH 
(492)  Type 2 DM  2 weeks allopurinol 100 
mg 
Reduction  of  lipid  peroxidation 
and  total  antioxidant  power  in 
blood / saliva 
(493)  ↑  cholesterol,  ↑ 
BP 
Single  infusion  of 
oxypurinol 
 § 
Improvement  in  FEF    *  in  ↑ 
cholesterol  patients  
(494)  ↑ cholesterol  4  weeks  300mg 
allopurinol † 
No change in FEF * 
(495)  Smokers  Single  600mg  po  dose 
allopurinol †§ 
Improvement in FEF  * 
(496)  ↑ uric acid, ↑ CV 
risk. 
3  months  300mg 
allopurinol § 
Improvement in FEF  || 
(497)  Metabolic 
Syndrome 
1  month  allopurinol 
300 mg 
Increase  in  FBF  ¥  respective  to 
baseline (3.8±0.1 %, p<0.01)  
(498)  OSA  2 weeks allopurinol 300 
mg 
Improvement in FEF *,‡ 
DM = diabetes mellitus. FEF = forearm endothelial function.* = in response to intra-
arterial Ach infusion, † = cross over design, FBF = forearm blood flow, § =  control arm, 
|| = ischaemia induced % change in BA diameter. OSA = obstructive sleep apnoea. 
Table  4.2  cont.  Studies  of  uric  acid  lowering  therapy  in  those  with  or  at  risk  of 
cardiovascular disease. 
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Gaps in the Clinical Trial Data 
 
There are no adequately powered clinical endpoint trials of uric acid lowering strategies 
such as xanthine oxidase inhibition and there are no small scale studies in patients with 
stroke or that examine markers of cerebrovascular health. 
 
Summary 
The  epidemiological  evidence  to  support  a  role  of  elevated  serum  uric  acid  in 
cardiovascular disease is cogent.  These associations are seen across healthy populations 
(albeit  less  consistently),  those  with  cardiovascular  risk  factors  and  in  those  with 
established cardiovascular disease.  While a clear pathophysiological role for uric acid in 
the development of cardiovascular disease has yet to be established, there are data to  
support detrimental and prothrombotic effects on platelet and endothelial function.  Post-
hoc  analyses  suggest  that  some  of  the  beneficial  effects  of  proven  treatments  for 
cardiovascular disease may be due to changes in serum uric acid level study. (458;472;474).  
Furthermore, xanthine oxidase mediated oxidative stress is likely to have a significant role 
in the development of atherosclerosis and several small studies have shown that xanthine 
oxidase  inhibition  improves  endothelial  function  and  markers  of  oxidative  stress  in  a 
variety of disease states (478;480-482;487;488;490;493-496), although not yet with regard 
to markers of stroke risk or in those with stroke.  Thus, even if serum uric acid is simply a 
marker of oxidative stress, there is a wealth of epidemiological, animal and now clinical 
data to suggest the benefits of strategies to lower uric acid and inhibit xanthine oxidase.  
Data from the OPT-CHF study raise the possibility that benefit may only be seen in those 
with elevated serum uric acid and that treatment may be detrimental in those with low 
serum  uric  acid.  Large  scale  trials  with  clinical  endpoints  are  justified  to  address  this   - 167 - 
important  question  in  the  context  of  heart  failure,  coronary  disease  and  in  broader 
categories of cardiovascular risk.  Despite being an old drug, allopurinol may prove to be a 
cheap, effective and novel preventative therapy for the 21
st century. 
 
4.02  Chapter Aims and Hypothesis 
 
The hypothesis was that elevated serum uric acid would be associated with a poor outcome 
following acute stroke; that it would be associated with increased stroke risk in those with 
hypertension;  and  that  use  of  allopurinol  would  improve  cerebrovascular  health  in  a 
primary and secondary prevention cohort. The aim was therefore to evaluate the association 
between  serum  uric  acid  and  functional  outcome  after  stroke  (study  one)  and  the 
association between serum uric acid and stroke risk in hypertensive patients (study two) 
and to test whether allopurinol, the most widely used uric acid lowering drug, improves 
cerebrovascular health in those with diabetes (study three) and recent subcortical stroke 
(study four).     - 168 - 
4.03  Study  One  -  Baseline  Serum  Uric  Acid  and  90-Day  Functional  Outcomes 
Following Acute Ischaemic Stroke 
 
The study hypothesis was that elevated serum uric acid would be associated with a poor 
outcome  following  acute  stroke.  A  retrospective  analysis  of  clinical  trial  data  was 
performed to test this. 
 
4.03.1  Study One Methods 
The relationship between serum uric acid measured early after stroke and 90-day outcome 
were evaluated using data from the Virtual International Stroke Trials Archive (VISTA) 
resource. Full details of the VISTA resource are described elsewhere (514). Briefly, VISTA 
represents an archive of either complete datasets or the placebo component from clinical 
trials in  acute  stroke.  The original  data  can be  searched  to  select  trials  and/or  patients 
fulfilling certain selection criteria or with fields containing certain information, such as 
serum uric acid level or functional outcome. Analyses on natural history are encouraged but 
exploration of treatment effects is prevented; in some cases trial datasets were donated 
under confidentiality rules that preclude identification of the trial in published analyses. 
The VISTA dataset continues to expand, but at the time of access for this study it contained 
data from 15 trials and over 15,000 patients. 
 
Data were extracted from the VISTA dataset, where serum uric acid had been measured 
during conduct of an acute stroke trial within 6 hours of symptom onset. Only a single trial 
in  VISTA  routinely  measured  baseline  uric  acid.    All  patients  had  ischaemic  stroke 
confirmed by brain imaging and baseline stroke severity (Scandinavian Stroke Scale (SSS)) 
(515) and demographic details were recorded. Follow up was for 3 months at which point   - 169 - 
functional outcome assessment (using the mRs and Barthel index) and repeat SSS scores 
were performed. 
 
Statistical Analysis 
Descriptive statistics were used to describe the population with mean (±SD) and or number 
(%) used. Poor outcome was defined as death or dependency at 90 days (modified Rankin 
scale (mRs) (516) score > 2 or death within 90 days). Uric acid levels were converted to 
mmol/l.  The  relationship  between  baseline  differences  (including  uric  acid)  and  poor 
outcome was assessed and univariate differences between groups were explored. The 
2 test 
(binary variables) and Student’s t test (continuous variables) were used. Univariate  and 
then  multivariate  logistic  regression  analysis  was  performed  to  assess  the
  relationship 
between  uric  acid  and  outcome  and  to  control  for  variables  that  differed  significantly 
between outcome groups or that are known to predict stroke outcome. Natural logarithmic 
transformations  of  data  were  employed  when  exploratory
 analyses  showed  these  to  be 
merited. The linearity assumption was verified using the Box-Tidwell test. 
 
Patients known to be alive at day 90 but for whom the mRs grading was unknown were 
excluded from the regression analyses. Sensitivity of the findings to this assumption was 
investigated by repeating the analyses twice, with missing scores entered as good and poor 
outcomes respectively. Mean values were imputed where data were missing for continuous 
variables.
 
 
All statistical analyses were performed using Minitab version 15 (Minitab inc. PA, USA).  
 
   - 170 - 
4.03.2  Study One Results 
 
In total, 852 patients were included. Mean age was 68 (±12) years and 524 participants 
(61.5%) were male. Mean baseline SSS was 27 (±9.2), mean systolic blood pressure was 
160 (±27) mmHg and mean diastolic blood pressure 88 (±15) mmHg. Mean baseline uric 
acid was 0.35 (±0.11) mmol/l. These and other baseline characteristics are shown in table 
4.3.  
 
Age, years  68.3 (12.1) 
Male  524 (61.5) 
SSS, units  27 (9.2) 
SBP, mmHg  160.5 (27) 
DBP, mmHg    88.4 (14.9) 
Creatinine (µmol/l)  92.7 (24.3) 
Cholesterol (mmol/l)  5.6 (1.2) 
Glucose (mmol/l)  7.57 (2.9) 
Uric Acid (mmol/l)  0.35 (0.11) 
Ischaemic Heart Disease  165 (19.4%) 
Diabetes Mellitus  164 (19.3%) 
Hypertension  467 (54.8%) 
Atrial Fibrillation  156 (18.3%) 
Congestive Cardiac Failure  74 (8.7%) 
Table  4.3  –  Study  One  Baseline  Demographic  Variables.  Expressed  as  n  (%)  for 
categorical variables and mean (SD) for continuous variables. 
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Outcomes 
Eleven patients could not be assigned to an outcome group as they were known to be alive 
but  had  no  day  90  mRs  score  recorded.  Four  patients  had  no  age  recorded,  8  had  no 
baseline measurement of heart rate and 2 had no baseline blood pressure measurement.  At 
90 days, 434 patients (51.6%) had suffered a poor outcome, 141 of whom had died. 
 
Univariate Analysis 
On univariate analyses (table 4.4), greater age, lower baseline SSS, higher systolic blood 
pressure,  higher  serum  glucose,  higher  serum  creatinine,  female  sex,  a  history  of 
hypertension, atrial fibrillation, diabetes mellitus and cardiac failure were associated with 
increased odds of a poor outcome, as were greater serum uric acid levels  (OR 1.57, 95% CI 
1.02-2.42). Natural logarithmic transformation of data was utilized for serum uric acid, 
creatinine and glucose levels. 
 
Variable  Coefficient  OR  CI  P 
Uric Acid *  0.451001  1.57  1.02-2.42  0.042 
Age  0.0381584  1.04  1.03-1.05  < 0.001 
Male  -0.307936  0.73  0.56-0.97  0.015 
BSSS  -0.136462  0.87  0.85-0.89  < 0.001 
Creatinine *  0.784949  2.19  1.26-3.82  0.006 
SBP  0.0065294  1.01  1-1.01  0.012 
Glucose *  1.03505  2.82  1.8-4.41  < 0.001 
Hypertension  0.309976  1.36  1.04-1.79  0.026 
AF  0.697322  2.01  1.4-2.89  < 0.001 
CHF  0.511970  1.67  1.02-2.74  0.04 
Table  4.4.  Relationship  Between  Baseline  Variables  and  Stroke  Outcome  on 
Univariate Analysis. * = natural logarithmic transformation employed.   - 172 - 
 
Multivariate Analysis 
Multivariate analysis revealed that only greater age, lower baseline SSS and higher serum 
glucose and systolic blood pressure were independently associated with a poor outcome 
(table 4.5). Uric acid level was not independently associated with poor outcome (OR 1.3, 
95% CI 0.73-2.31 (for log transformed data)). 
 
Variable  Coefficient  OR  CI  P 
Age  0.0273775  1.03  1.01-1.04  0.001 
Uric Acid *  0.234900    1.3  0.7-2.31  0.42 
Male  -0.215531  0.81  0.56-1.15  0.24 
BSSS  -0.135167  0.87  0.85-0.89  < 0.001 
Creatinine *  0.303908  1.36  0.65-2.84  0.42 
SBP  0.0084116  1.01  1-1.01  0.01 
Glucose *  0.775222  2.17  1.29-3.66  0.004 
Hypertension  -0.0091985  0.99  0.7-1.4  0.96 
AF  0.217369  1.24  0.8-1.92  0.33 
CHF  0.0750884  1.08  0.6-1.95  0.80 
Table  4.5.  Relationship  Between  Baseline  Variables  and  Stroke  Outcome  on 
Multivariate Analysis. * = natural logarithmic transformation employed. 
 
Results were similar whether the 11 missing mRs scores were substituted by good or poor 
outcomes on both univariate and multivariate analysis (table 4.6). 
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Variable  OR #  CI #  OR (*)  CI (*) 
Age  1.03  1.01-1.04  1.02  1.01-1.04 
Uric Acid *  1.41  0.8-2.49  1.28  0.73-2.26 
Male  0.84  0.59-1.19  0.79  0.56-1.13 
BSSS  0.88  0.86-0.9  0.87  0.85-0.89 
Creatinine *  1.19  0.57-2.48  1.45  0.69-3.02 
SBP  1.01  1-1.01  1.01  1-1.01 
Glucose *  1.10  1.04-1.16  1.95  1.18-3.24 
Hypertension  0.97  0.69-1.37  0.99  0.71-1.4 
AF  1.18  0.77-1.82  1.3  0.84-2 
CHF  1.09  0.61-1.96  1.08  0.6-1.94 
Table 4.6. Relationship With Poor Outcome (mRs > 2) – Multivariate Sensitivity 
Analysis. Missing outcome data assumed to represent poor (#) or good (*) outcome 
respectively. * = natural logarithmic transformation employed. 
 
 
4.03.3  Study One Discussion 
 
This study failed to demonstrate an independent association between serum uric acid and 
day 90 functional outcome after acute ischaemic stroke.  An association was seen between 
increasing uric acid levels and odds of poor outcome on univariate analyses but not on 
multivariate analysis. It is however possible given the upper limit of the 95% confidence 
intervals that such an association does exist. 
 
This study used a robust dataset from a large, rigorously monitored randomized controlled 
trial  with  near  complete  ascertainment  (98.7%)  of  90-day  functional  outcomes.    Data 
collection was restricted to studies where uric acid was measured acutely within a known 
time  frame  and  where  modified  Rankin  scale  scores  were  measured.  All  patients  were   - 174 - 
recruited and enrolled with a mean time of 4.5 hours from ictus and all those included in 
this analysis had baseline serum uric acid and stroke severity measured. The group included 
a  wide  range  of  ages  and  outcomes  similar  to  those  seen  in  other  large  trials  (517). 
Reassuringly, variables such as increasing age, blood pressure, serum creatinine and worse 
baseline stroke severity predicted poor outcome as has been shown previously. By using 
day 90 mRs as the outcome measure, results of this study can be readily interpreted in a 
fashion that is clinically relevant and meaningful. However, the fact this was a clinical trial 
population is also a potential weakness - the patients are naturally highly selected and thus 
not guaranteed to be truly representative of the wider population.  Log transformations of 
data were utilized because exploratory analyses suggested it appropriate and, while this 
makes direct comparison with other work difficult, it was appropriate.  A further potential 
weakness is that the analysis was based upon a single measurement of uric acid and small 
intra-individual variation in uric acid levels is known to occur (518). This will reduce the 
apparent strength of any association. However, in a study of the potential role of uric acid 
in the acute setting, a spot measurement is the most relevant. 
  
The literature to date overwhelmingly supports an association between elevated serum uric 
acid  and  increased  incidence  of  cardiovascular  events  and  mortality  (519).  More 
uncertainty  surrounds  the  relationship  between  levels  of  serum  uric  and  likelihood  of 
recovery after stroke. As mentioned, it has been previously demonstrated that higher uric 
acid measured early after stroke is independently associated with reduced likelihood of a 
favourable outcome, an increased risk of recurrent vascular events (388) and an increased 
risk  of  early  clinical  deterioration  (390).  Others  have  shown  increasing uric  acid to  be 
independently associated with increased odds of good outcome at 7 days (395). This study 
showed  an  association  between  increasing  serum  uric  acid  and  increased  odds  of  poor   - 175 - 
outcome on univariate analysis but,  given the results of  multivariate analysis, does not 
support any of the previous findings.  
 
These differences are intriguing. This and previous studies have used similar techniques, 
first exploring univariate differences between outcome groups then using multiple logistic 
regression  to  control  for  factors  known  to  influence  outcome.  There  were,  however, 
differences  in  trial  methodology  that  may  explain  this  apparent  discrepancy.  Previous 
studies  were  retrospective  analyses  of  registry  datasets  with  differing  endpoints.  For 
example, one previous analysis utilized placement at 90 days (alive, placed in own home or 
care or dead) as the outcome measure whereas work suggesting benefit of elevated uric acid 
utilized day 7 Mathew scale score. Both these have potential drawbacks; placement at 90 
days could be confounded by socioeconomic factors, while the Mathew scale is poorly 
validated and day 7 outcomes are less informative than those at day 90. The present study is 
the  first  analysis  from  a  clinical  trial  utilizing  the  most  widely  accepted  and  utilized 
measure  of  functional  outcome  available.  These  data  raise  the  possibility  that  no  such 
independent association exists, although the estimated odds ratio is similar to that found in 
previous work and the confidence intervals overlap; it may be that the study had limited 
statistical power to detect an independent effect of the magnitude found in previous studies. 
 
Regardless, these findings do not discount the possibility that uric acid reduction is a viable 
and promising strategy to reduce cardiovascular risk. Uric acid contributes to several key 
stages  of  the  atherosclerotic  process  and  may  have  detrimental  effects  on  platelet, 
endothelial and smooth muscle cell function (438;440;520;521) and may have a role in the 
development  of  MRI  detected  ischaemic  cerebral  white  matter  hyper-intensities  (522).  
These findings support the notion that elevated serum uric acid will increase cardiovascular   - 176 - 
event rate and could link with worse outcome after stroke. On the other hand, uric acid is 
widely accepted to have antioxidant activity and some speculate that elevated levels may be 
a beneficial response to the oxidative stress that characterises vascular disease states (430).  
This  may  apply  in  ischaemic  stroke:  brain  uric  acid  levels  increase  in  a  rat  model  of 
permanent cerebral ischemia (432;433) and infusion of uric acid reduces infarct volume and 
improves behavioural outcome in a rat transient ischemia model (434). Human data also 
support  the  antioxidant  properties,  where  uric  acid  administration  has  been  shown  to 
increase  serum  antioxidant  capacity  in  healthy  volunteers  (436)  and  reduce  markers  of 
oxidative stress in those treated with thrombolytic therapy for acute ischaemic stroke (523). 
Temporary iatrogenic hyperuricaemia may afford the beneficial antioxidant effects of uric 
acid without the detrimental effects of chronically elevated levels on the vasculature.  
 
In summary, this study found no significant independent association between serum uric 
acid level soon after ischaemic stroke onset and 90-day outcome. Prospective trials are 
needed  to  clarify  the  role  of  uric  acid  management  in  the  post  stroke  period  and  as  a 
preventative measure in cardiovascular disease.   - 177 - 
Study Two - Serum Uric Acid and Stroke Mortality in Patients with Hypertension 
 
The study hypothesis was that elevated serum uric acid would be associated with increased 
stroke risk in those with hypertension. A retrospective analysis of a large registry dataset 
was performed to test this. 
 
4.04.1  Study Two Methods 
 
The relationship between serum uric acid and mortality in a group of hypertensive patients 
domiciled in the West of Scotland was evaluated. Data from the Glasgow Blood Pressure 
Clinic were used. This is a secondary and tertiary referral centre for patients from the West 
of Scotland area.  Patients are reviewed at least annually.   Demographic and clinical data 
are routinely gathered on all patients and entered into a computer database, which currently 
holds  data  on  those  who  have  attended  since  November  1967.  The  study  design  was 
evaluated by  and  approved by  the  West  Medical  Research  Ethics  Committee,  who  felt 
formal application and review were unnecessary. 
  
Subjects are followed up by record linkage (524) to death records held and supplied by the 
Registrar General of Scotland, which provide accurate causes of death.  Causes of death are 
described  according  to  the  ninth  and  tenth  revisions  of  the  World  Health  Organisation 
International Classifications of Diseases (ICD-9 and ICD-10).  The primary outcome event 
was  defined  as  death  due  to  stroke  (ICD-9  430-438).  Secondary  outcomes  were  total 
mortality, coronary heart disease mortality (ICD-9 410-414.9) and total vascular mortality 
(stroke, coronary (defined above) and peripheral vascular disease deaths (440-447.6). 
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Statistical Analysis 
Descriptive statistics were used to describe the population with mean (±SD) or number (%) 
used.  Baseline demographic variables and outcomes were compared between those who 
had uric acid levels measured compared to those who did not. The relationship between 
baseline  differences  (including  uric  acid)  and  the  primary  outcome  was  assessed  and 
univariate differences between groups were explored. The 
2 test (binary variables) and 
Student’s t test (continuous variables) were used. The average serum uric acid throughout 
the  study  was  used  for  analyses.  Average  levels  of  blood  pressure  and  other  blood 
parameters were also used. 
 
A  Cox  proportional  hazards  model  was  used  to  assess  the  relationship  between  last 
measured  uric  acid  and  primary  outcome  after  adjustment  for  differences  between  the 
groups  or  other  factors  which  may  influence  occurrence  of  the  primary  outcome.  All 
statistical analyses were performed using SPSS software – version 11.5.  Results of the Cox 
proportionally  hazard  modeling  are  expressed  as  hazard  ratios  with  95%  confidence 
intervals. The same statistical procedures were followed for the secondary outcomes.  The 
risk between uric acid and stroke mortality appeared J-shaped so further analysis based 
upon uric acid quintiles was performed. 
 
4.04.2  Study Two Results 
 
Data  from  11,399  hypertensive  patients who  attended the  clinic  between  6
th  November 
1968 and 23
rd April 2003 were analysed. Uric acid results were available for 6202 patients 
(54.4%). The date of the last record linkage was 10
th July 2004. Mean follow up duration 
was 184 (SD 93.7) months with a median of 175 months. Baseline demographic variables   - 179 - 
are shown in table 4.7. Those who had serum uric acid levels measured were less likely to 
be smokers, more likely to be diabetic, hyperlipidaemic, have established vascular disease 
and to be taking anti-hypertensive therapy. Mean blood pressures and mean cholesterol 
levels were however lower.  
 
Variable  Whole Group 
n = 11399 
Uric  Acid 
Measured 
n = 6202 
No Uric Acid 
Measured 
n = 5197 
P Value 
Age; years  49.3 (13.7)  49.1 (13.4)  49.5 (14)  0.06 
Male Sex  5482 (48.1%)  2949 (47.5%)  2533 (48.7%)  0.21 
Smoker  3313 (29.1%)  1728 (27.9%)  1585 (30.4%)  0.002 
Cholesterol > 5 mmol/l  7444 (65.3%)  4355 (70.2%)  3089 (59.7%)  <0.0001 
Diabetes Mellitus  545 (4.8%)  363 (5.9%)  182 (3.5%)  <0.0001 
IHD  523 (4.6%)  301 (4.9%)  222 (4.3%)  0.14 
CVA  345 (3%)  204 (3.3%)  141 (2.7%)  0.07 
PVD  470 (4.1%)  273 (4.4%)  197 (3.8%)  0.10 
Any CVD  1191 (10.4%)  686 (11.1%)  505 (9.7%)  0.019 
Mean SBP; mmHg  157.8 (22.4)  156.5 (19.5)  159.3 (25.3)  <0.0001 
Mean DBP; mmHg  93.9 (11.2)  92.3 (9.7)  95.9 (12.5)  <0.0001 
BMI; kg/m
2  27.7 (5.4)  27.8 (5.4)  27.6 (5.5)  0.08 
Mean Cholesterol; mmol/l  6.04 (1.15)  6.1 (1.1)  5.9 (1.1)  <0.0001 
Mean Creatinine; µmol/l  99.1 (54.5)  98 (46.6)  102.5 (70.9)  <0.0001 
ACE Inhibitor  2648 (23.2%)  1796 (29%)  852 (16%)  <0.0001 
Beta Blocker  6104 (53.5%)  4071 (65.6%)  2033 (39.1%)  <0.0001 
Calcium Channel Blocker  3512 (30.8%)  2427 (39.1%)  1085 (20.9%)  <0.0001 
Diuretic  7120 (62.5%)  4250 (68.5%)  2870 (55%)  <0.0001 
P  values  represent  those  obtained  on  comparison  of  those  who  had  uric  acid  levels 
measured  compared  to  those  who  did  not.  Two  sample  t-tests  were  employed  for 
continuous variables, while chi-squared tests were used for binary variables. 
Table 4.7. Study Four Baseline Demographic Variables   - 180 - 
 
Uric Acid Data 
The mean first serum uric acid was 0.34 mmol/l (SD 0.14). The mean last serum UA was 
0.35 mmol/l (SD 0.18) while the mean average serum uric acid level during the study was 
0.35 mmol/l (SD 0.14). These data and uric acid quintiles are shown in table 4.8. In total, 
2431 (39.2%) of individuals had only one serum uric acid measured, 1039 (16.8%) had 
two, 660 (10.6%) had three and 2072 (33.4%) had four or more uric acid measurements.  
 
Uric Acid Data 
Whole Group  Mean (SD); mmol/l 
First Uric Acid  0.34 (0.14) 
Last Uric Acid  0.35 (0.18) 
Mean Uric Acid  0.35 (0.14) 
Uric Acid Quintiles  Range; mmol/l  N (%) 
1
st Uric Acid Quintile  0.01 to 0.25  1242 (20.1%) 
2
nd Uric Acid Quintile  0.26 to 0.30  1235 (19.9%) 
3
rd Uric Acid Quintile  0.31 to 0.35  1278 (20.6%) 
4
th Uric Acid Quintile  0.36 to 0.41  1207 (19.5%) 
5
th Uric Acid Quintile  0.42 to 5.5  1240 (19.9%) 
Table 4.8. Study Four Uric Acid Data. Uric acid quintiles are based upon mean 
serum uric acid levels. 
 
Higher serum uric acid was significantly associated with male sex, beta-blocker, diuretic 
and  calcium  channel  antagonist  therapy,  established  cardiovascular  disease  and 
hyperlipidaemia, and increases in age, serum creatinine concentration, blood pressure, total 
serum cholesterol concentration and body mass index (table 4.9). 
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Continuous Variables  Regression Coefficient  P value 
Age; years  0.001  <0.0001 
Mean SBP; mmHg  0.001  <0.0001 
Mean DBP; mmHg  0.001  <0.0001 
Mean Cholesterol; mmol/l  0.007  <0.0001 
Mean Creatinine; µmol/l  0.001  <0.0001 
BMI; kg/m
2  0.003  <0.0001 
Binary Variables  Present  Absent  P value 
Male Sex  0.39  0.31  <0.0001 
Smoker  0.34  0.35  0.55 
Cholesterol > 5 mmol/l  0.35  0.33  <0.0001 
Diabetes Mellitus  0.35  0.35  0.44 
IHD  0.36  0.35  0.07 
CVA  0.36  0.35  0.21 
PVD  0.36  0.35  0.19 
Any CVD  0.36  0.35  0.009 
ACE Inhibitor  0.35  0.35  0.87 
Beta Blocker  0.35  0.34  <0.0001 
Calcium Channel Blocker  0.35  0.34  0.007 
Diuretic  0.35  0.33  <0.0001 
For continuous variables linear regression analysis was employed and the regression 
coefficients refer to the increase in serum uric acid seen for each unit increase in the 
variable. For binary variables, the levels shown are the mean average serum uric acid 
according to whether the variable was present or absent and the p values refer to those 
obtained on 2 sample t testing. 
Table 4.9. Relationship Between Baseline Variables and Increasing Serum Uric Acid 
in Hypertensive Patients 
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Outcome Data 
In the total study group there were 713 (6.3% of patients) stroke deaths, 1462 (12.8%) IHD 
deaths, 2532 (22.7%) vascular deaths and 4137 (36.3%) deaths in total. In those who had 
serum uric acid measured, there were 354 stroke deaths (5.7%), 723 (11.7%) IHD deaths, 
1290 (20.8%) vascular deaths and 2124 (34.2%) deaths in total table 4.10). 
 
Outcome Data 
Variable  Whole Group 
n = 11399 
UA Measured 
n = 6202 
No  UA 
Measured 
n = 5197 
P Value 
Death  4137 (36.3%)  2124 (34.2%)  2013 (38.7%)  <0.0001 
IHD Death  1462 (12.8%)  723 (11.7%)  739 (14.2%)  <0.0001 
Stroke Death  713 (6.3%)  354 (5.7%)  359 (6.9%)  0.008 
Any  Vascular 
Death 
2532 (22.7%)  1290 (20.8%)  1302 (25.1%)  <0.0001 
Table  4.10.  Outcome  in  the  Whole  Hypertensive  Patients  Study  Group  and  Where 
Serum Uric Acid was Measured. P values refer to Chi-squared testing. 
 
4.04.2.1  Relationships with Stroke Mortality 
On univariate analysis male sex, smoking, diabetes, peripheral vascular disease, stroke, any 
established  vascular  disease,  diuretic  therapy  and  increases  in  age,  SBP,  DBP,  serum 
cholesterol  concentration,  serum  creatinine  concentration  and  serum  uric  acid  were 
associated with a significant increase in stroke mortality.  Increasing BMI was associated 
with a reduction in stroke mortality (table 4.11).  
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Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.093  1.081 to 1.104  <0.001 
Male Sex  1.273  1.033 to 1.568  0.024 
IHD  1.517  0.976 to 2.359  0.08 
CVA  5.093  3.663 to 7.082  <0.001 
PVD  2.386  1.611 to 3.534  <0.001 
Smoker  1.388  1.116 to 1.726  0.004 
Any CVD  2.939  2.287 to 3.776  <0.001 
Diabetes Mellitus  1.630  1.115 to 2.383  0.018 
BMI; kg/m
2  0.972  0.951 to 0.994  0.01 
Mean SBP; mmHg  1.029  1.026 to 1.033  <0.001 
Mean DBP; mmHg  1.032  1.023 to 1.041  <0.001 
Mean Creatinine; µmol/l  1.004  1.002 to 1.005  <0.001 
Mean Uric Acid; µmol/l  1.861  1.19 to 2.911  0.006 
Mean Cholesterol; mmol/l  1.413  1.042 to 1.254  0.005 
ACE Inhibitor  0.775  0.595 to 1.008  0.051 
Beta-Blocker  1.163  0.922 to 1.468  0.20 
Calcium Channel Blocker  0.984  0.789 to 1.227  0.89 
Diuretic  1.877  1.438 to 2.451  <0.001 
Table 4.11. Risk of Stroke Death (Unadjusted) in Hypertensive Patients. 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, stroke, and 
increases  in  age,  SBP,  DBP  and  serum  creatinine  were  associated  with  a  significant 
increase in stroke mortality. Serum uric was not associated with increased stroke risk (table 
4.12). 
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Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.086  1.071 to 1.101  <0.001 
Male Sex  1.552  1.21 to 1.99  0.001 
CVA  3.156  2.232 to 4.465  <0.001 
PVD  1.312  0.866 to 1.988  0.20 
Smoker  1.52  1.203 to 1.921  <0.001 
Diabetes Mellitus  1.623  1.085 to 2.426  0.018 
BMI  0.983  0.96 to 1.007  0.17 
Mean SBP  1.015  1.008 to 1.022  0.001 
Mean DBP  1.025  1.011 to 1.039  <0.001 
Mean Creatinine  1.002  1.001 to 1.004  0.006 
Mean Uric Acid  0.947  0.278 to 3.222  0.93 
Mean Cholesterol  1.015  0.919 to 1.120  0.77 
Diuretic  1.144  0.843 to 1.554  0.39 
Table 4.12. Risk of Stroke Death (Adjusted) in Hypertensive Patients. 
 
On exploratory analysis, the relationship between uric acid and stroke mortality appeared J-
shaped (figure 4.3) with risk lowest in the second quartile of serum uric acid levels (figure 
4.4).  Compared to those in the second quintile of uric acid levels, risk was significantly 
increased in those in the lowest quintile and increased from the third to the fifth quintile 
(table 4.13).  
 
Following  adjustment  for  other  significant  variables,  a  significant  J-shaped  relationship 
remained across the quintiles of uric acid with stroke mortality (table 4.14).   
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Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Mean Uric Acid  1.861  1.19 to 2.911  0.006 
Uric Acid First Quintile  1.652  1.135 to 2.404  0.009 
Uric Acid Second Quintile  1  -----  ----- 
Uric Acid Third Quintile  1.79  1.235 to 2.595  0.002 
Uric Acid Fourth Quintile  1.948  1.347 to 2.817  <0.001 
Uric Acid Fifth Quintile  2.207  1.531 to 3.181  <0.001 
Table 4.13. Risk of Stroke Death (Unadjusted for Other Variables) in Hypertensive 
Patients. 
 
Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.085  1.071 to 1.1  <0.001 
Male Sex  1.555  1.206 to 2.006  0.001 
CVA  3.192  2.253 to 4.522  <0.001 
PVD  1.285  0.848 to 1.948  0.24 
Smoker  1.519  1.202 to 1.920  <0.001 
Diabetes Mellitus  1.651  1.104 to 2.469  0.015 
BMI  0.984  0.96 to 1.008  0.19 
Mean SBP  1.015  1.008 to 1.022  <0.001 
Mean DBP  1.024  1.010 to 1.038  0.001 
Mean Creatinine  1.002  1.001 to 1.004  0.006 
Mean Cholesterol  1.016  0.920 to 1.122  0.76 
Diuretic  1.143  0.841 to 1.555  0.39 
UA First Quintile  1.777  1.186 to 2.661  0.005 
UA Second Quintile  1  ---  --- 
UA Third Quintile  1.468  0.993 to 2.169  0.054 
UA Fourth Quintile  1.521  1.028 to 2.251  0.036 
UA Fifth Quintile  1.434  0.953 to 2.159  0.08 
Table 4.14. Risk of Stroke Death (Adjusted) in Hypertensive Patients.   - 186 - 
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Figure 4.3. Risk of Death Across Serum Uric Acid Quintiles in 
Hypertensive Patients. 
Figure 4.4. Survival Free From Stroke Across Uric Acid 
Quintiles in Hypertensive Patients.   - 187 - 
4.04.2.2  Relationships with Total Mortality 
On univariate analysis  male sex, smoking, diabetes, ischaemic heart disease, peripheral 
vascular disease, stroke, any established vascular disease, beta-blocker, calcium channel 
and  diuretic  therapy  and  increases  in  age,  SBP,  DBP,  serum  cholesterol  concentration, 
serum  creatinine  concentration  and  serum  uric  acid  were  associated  with  a  significant 
increase  in  total  mortality.    Increasing  BMI  was  associated  with  a  reduction  in  total 
mortality (table 4.15). 
  
Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age; years  1.075  1.07 to 1.079  <0.001 
Male Sex  1.431  1.314 to 1.559  <0.001 
IHD  1.927  1.638 to 2.267  <0.001 
CVA  2.357  1.957 to 2.839  <0.001 
PVD  2.593  2.221 to 3.027  <0.001 
Smoker  1.589  1.456 to 1.734  <0.001 
Any CVD  2.306  2.065 to 2.574  <0.001 
Diabetes Mellitus  1.603  1.371 to 1.874  <0.001 
BMI; kg/m
2  0.987  0.979 to 0.996  0.004 
Mean SBP; mmHg  1.024  1.022 to 1.026  <0.001 
Mean DBP; mmHg  1.026  1.022 to 1.030  <0.001 
Mean Creatinine; µmol/l  1.004  1.003 to 1.004  <0.001 
Mean Uric Acid; µmol/l  2.052  1.759 to 2.394  <0.001 
Mean Cholesterol; mmol/l  1.138  1.096 to 1.183  <0.001 
ACE Inhibitor  0.904  0.815 to 1.002  0.05 
Beta-Blocker  1.236  1.123 to 1.361  <0.001 
Calcium Channel Blocker  1.14  1.044 to 1.245  0.004 
Diuretic  1.888  1.692 to 2.105  <0.001 
Table 4.15. Risk of Death (Unadjusted) in Hypertensive Patients.   - 188 - 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, ischaemic 
heart disease, peripheral vascular disease, stroke, and increases in age, SBP, DBP, serum 
cholesterol  concentration,  serum  creatinine  concentration  and  serum  uric  acid  were 
associated with a significant increase in total mortality.  Calcium channel antagonist use 
was associated with a reduction in total mortality (table 4.16). 
 
Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.075  1.069 to 1.081  <0.001 
Male Sex  1.574  1.424 to 1.740  <0.001 
IHD  1.248  1.049 to 1.486  0.012 
CVA  1.44  1.18 to 1.757  <0.001 
PVD  1.571  1.323 to 1.864  <0.001 
Smoker  1.721  1.564 to 1.893  <0.001 
Diabetes Mellitus  1.508  1.274 to 1.784  <0.001 
BMI  0.995  0.986 to 1.005  0.36 
Mean SBP  1.008  1.004 to 1.011  <0.001 
Mean DBP  1.019  1.013 to 1.025  <0.001 
Mean Creatinine  1.003  1.002 to 1.003  <0.001 
Mean Uric Acid  1.437  1.015 to 2.035  0.041 
Mean Cholesterol  1.05  1.008 to 1.094  0.019 
Beta-Blocker  1.04  0.933 to 1.158  0.48 
Calcium Channel Blocker  0.9  0.815 to 0.994  0.038 
Diuretic  1.069  0.942 to 1.212  0.30 
Table 4.16. Risk of Death (Adjusted) in Hypertensive Patients. 
 
There was no evidence that the relationship between serum uric acid and total mortality was 
J-shaped (figure 4.5).   - 189 - 
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4.04.2.3  Relationships with Vascular Mortality 
On univariate analysis  male sex, smoking, diabetes, ischaemic heart disease, peripheral 
vascular disease, stroke, any established vascular disease, beta-blocker and diuretic therapy 
and  increases  in  age,  SBP,  DBP,  serum  cholesterol  concentration,  serum  creatinine 
concentration and serum uric acid were associated with a significant increase in vascular 
mortality (table 4.17)  
 
 
 
 
 
Figure 4.5. Survival Free From Any Death Across Uric Acid 
Quintiles in Hypertensive Patients.   - 190 - 
 
Variable  Hazard Ratio (HR)  95%  Confidence 
Interval for HR 
p-value 
Age  1.077  1.071 to 1.082  <0.001 
Male Sex  1.494  1.339 to 1.668  <0.001 
IHD  2.251  1.852 to 2.735  <0.001 
CVA  2.688  2.149 to 3.363  <0.001 
PVD  2.701  2.223 to 3.282  <0.001 
Smoker  1.655  1.48 to 1.85  <0.001 
Any CVD  2.64  2.307 to 3.023  <0.001 
Diabetes Mellitus  1.715  1.412 to 2.084  <0.001 
BMI; kg/m
2  0.991  0.980 to 1.002  0.12 
Mean SBP; mmHg  1.027  1.025 to 1.029  <0.001 
Mean DBP; mmHg  1.033  1.028 to 1.037  <0.001 
Mean Creatinine; µmol/l  1.004  1.003 to 1.004  <0.001 
Mean Uric Acid; µmol/l  2.148  1.8 to 2.562  <0.001 
Mean Cholesterol; mmol/l  1.183  1.127 to 1.241  <0.001 
ACE Inhibitor  0.894  0.783 to 1.020  0.09 
Beta-Blocker  1.369  1.207 to 1.554  <0.001 
Calcium Channel Blocker  1.104  0.985 to 1.237  0.09 
Diuretic  2.114  1.829 to 2.443  <0.001 
4.17. Risk of Vascular Death (Unadjusted) in Hypertensive Patients. 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, ischaemic 
heart disease,  peripheral  vascular  disease,  stroke,  diuretic therapy  and  increases  in  age, 
SBP, DBP, serum cholesterol concentration, serum creatinine concentration and serum uric 
acid were associated with a significant increase in vascular mortality (table 4.18). 
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Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.077  1.069 to 1.084  <0.001 
Male Sex  1.702  1.496 to 1.935  <0.001 
IHD  1.465  1.190 to 1.803  <0.001 
CVA  1.636  1.287 to 2.079  <0.001 
PVD  1.585  1.277 to 1.967  <0.001 
Smoker  1.787  1.581 to 2.019  <0.001 
Diabetes Mellitus  1.566  1.27 to 1.931  <0.001 
BMI  1.001  0.989 to 1.014  0.85 
Mean SBP  1.011  1.007 to 1.015  0.001 
Mean DBP  1.025  1.017 to 1.033  <0.001 
Mean Creatinine  1.003  1.002 to 1.003  <0.001 
Mean Uric Acid  1.793  1.233 to 2.607  0.002 
Mean Cholesterol  1.091  1.036 to 1.149  0.001 
Beta-Blocker  1.111  0.965 to 1.280  0.14 
Diuretic  1.216  1.028 to 1.439  0.023 
Table 4.18. Risk of Vascular Death (Adjusted) in Hypertensive Patients. 
 
There was no evidence that the relationship between serum uric acid and vascular mortality 
was J-shaped (figure 4.6). 
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4.04.2.4  Relationship with Ischaemic Heart Disease Mortality  
On univariate analysis  male sex, smoking, diabetes, ischaemic heart disease, peripheral 
vascular disease, stroke, any established vascular disease, beta-blocker, calcium channel 
antagonist  and  diuretic  therapy  and  increases  in  age,  SBP,  DBP,  serum  cholesterol 
concentration, serum creatinine concentration and serum uric acid were associated with a 
significant increase in coronary mortality (table 4.19). 
 
 
 
 
 
Figure 4.6.  Survival Free From Vascular Death Across Uric 
Acid Quintiles in Hypertensive Patients.   - 193 - 
Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.066  1.059 to 1.073  <0.001 
Male Sex  1.692  1.459 to 1.961  <0.001 
IHD  2.847  2.248 to 3.607  <0.001 
CVA  1.709  1.186 to 2.464  0.008 
PVD  2.736  2.112 to 3.544  <0.001 
Smoker  1.778  1.533 to 2.063  <0.001 
Any CVD  2.591  2.161 to 3.107  <0.001 
Diabetes Mellitus  1.949  1.523 to 2.494  <0.001 
BMI; kg/m
2  1.002  0.988 to 1.017  0.767 
Mean SBP; mmHg  1.025  1.023 to 1.028  <0.001 
Mean DBP; mmHg  1.033  1.027 to 1.04  <0.001 
Mean Creatinine; µmol/l  1.004  1.003 to 1.004  <0.001 
Mean Uric Acid; µmol/l  2.146  1.696 to 2.714  <0.001 
Mean Cholesterol; mmol/l  1.227  1.151 to 1.309  <0.001 
ACE Inhibitor  0.958  0.806 to 1.140  0.63 
Beta-Blocker  1.607  1.348 to 1.916  <0.001 
Calcium Channel Blocker  1.206  1.038 to 1.401  0.015 
Diuretic  2.166  1.782 to 2.632  <0.001 
Table 4.19. Risk of IHD Death (Unadjusted) in Hypertensive Patients. 
 
Following adjustment for the predictive variables, male sex, smoking, diabetes, ischaemic  
heart disease, peripheral vascular disease, diuretic and beta-blocker therapy and increases in 
age, SBP, DBP, serum cholesterol, creatinine and uric acid concentrations were associated 
with a significant increase in coronary mortality (table 4.20). 
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Variable  Hazard  Ratio 
(HR) 
95%  Confidence 
Interval for HR 
p-value 
Age  1.066  1.056 to 1.077  <0.001 
Male Sex  1.896  1.594 to 2.257  <0.001 
IHD  1.996  1.55 to 2.57  0.012 
CVA  1.045  0.703 to 1.555  0.83 
PVD  1.693  1.269 to 2.259  <0.001 
Smoker  1.859  1.579 to 2.189  <0.001 
Diabetes Mellitus  1.746  1.339 to 2.276  <0.001 
BMI  1.012  0.996 to 1.029  0.15 
Mean SBP  1.01  1.004 to 1.015  0.001 
Mean DBP  1.022  1.012 to 1.033  <0.001 
Mean Creatinine  1.002  1.001 to 1.004  <0.001 
Mean Uric Acid  1.7  1.004 to 2.878  0.048 
Mean Cholesterol  1.159  1.082 to 1.241  <0.001 
Beta-Blocker  1.28  1.05 to 1.561  0.015 
Calcium Channel Blocker  0.9  0.76 to 1.067  0.22 
Diuretic  1.267  1.008 to 1.593  0.042 
Table 4.20. Risk of IHD Death (Adjusted) in Hypertensive Patients. 
 
There was no evidence that the relationship between serum uric acid and coronary mortality 
was J-shaped (figure 4.7). 
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4.04.2.5   Sex Specific Analysis 
 
Serum uric acid level was strongly associated with total mortality in females but not males 
on  exploratory  univariate  analysis.  Similar  was  found  for  CHD  mortality  and  vascular 
mortality and this sex difference remained apparent on multivariate analysis (table 4.21). 
 
With regard to stroke mortality a significant J shaped relationship was observed in females. 
This was not observed in males where only the lowest quintile of uric acid levels linked 
with increased risk (table 4.21). On multivariate analysis, only the highest quintile of uric 
acid linked with increased stroke risk in females, while the lowest linked with increased 
risk in males (table 4.22). 
Figure 4.7. Survival Free From Coronary Heart Disease Death 
Across Uric Acid Quintiles in Hypertensive Patients.   - 196 - 
 
Males  Females   
HR *  95% CI for 
HR 
p-
value 
HR *  95% CI for 
HR 
p-
value 
Total Mortality  1.16  0.77 to 1.74  0.48  8.84  6.06 to 12.91  <0.00
1 
CHD Mortality  1.20  0.64 to 2.256  0.58  10.31  5.64 to 18.87  <0.00
1 
Vascular 
Mortality 
1.25  0.79 to 1.97  0.36  10.71  6.97 to 16.46  <0.00
1 
Stroke Mortality  
1
st Quintile 
2
nd Quintile 
3 rd Quintile 
4
th Quintile 
5
th Quintile 
 
2.72 
1 
1.35 
1.34 
1.37 
 
1.48 to 4.99 
-- 
0.78 to 2.33 
0.79 to 2.29 
0.81- to 2.32 
 
0.001 
-- 
0.29 
0.28 
0.24 
 
1.61 
1 
2.11 
2.56 
3.74 
 
0.99 to 2.61 
-- 
1.27 to 3.51 
1.52 to 4.32 
2.21 to 6.34 
 
0.05 
-- 
0.04 
<0.00
1 
<0.00
1 
Table 4.21. Risk of Total, Vascular, Coronary and Stroke Death on Univariate Analysis 
According to Sex in Hypertensive Patients.. HR = hazard ratio. Hazard ratios shown are 
per mmol/l increase in serum uric acid, except for stroke where they are relative to the 
2
nd quartile. 
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Males  Females   
HR *  95%  CI  for 
HR 
p-
value 
HR *  95%  CI  for 
HR 
p-
value 
Stroke 
Mortality 
1
st Quintile 
2
nd Quintile 
3 rd Quintile 
4
th Quintile 
5
th Quintile 
 
 
2.64 
1 
1.43 
1.49 
1.22 
 
 
1.343 to 5.182 
-- 
0.78 to 2.61 
0.83 to 2.69 
0.67 to 2.24 
 
 
0.005 
-- 
0.25 
0.19 
0.51 
 
 
1.45 
1 
1.51 
1.68 
2.03 
 
 
0.87 to 2.40 
-- 
0.90 to 2.54 
0.98 to 2.90 
1.14 to 3.62 
 
 
0.15 
-- 
0.12 
0.060 
0.017 
Table  4.22.  Risk  of  Stroke  Mortality  on  Multivariate  Analysis  According  to  Sex  in 
Hypertensive Patients. Adjustment variables are as shown in table 4.14. HR = hazard 
ratio. Hazard ratios shown are relative to the 2
nd quartile. 
 
 
 
 
4.04.3  Study Two Discussion 
 
The results of this study suggest that increasing serum uric is associated with increased risk 
of stroke, total, vascular and coronary mortality in treated hypertensive patients but that the 
relationship between stroke mortality and serum uric acid appears J-shaped. Sex specific 
analyses also suggest that such a relationship with stroke risk is only apparent in females.   - 198 - 
 
The  relationship  between  uric  acid  and  cardiovascular  risk  is  well  documented  and 
increasingly accepted (521). However, many studies have not specifically evaluated stroke 
mortality (383;396;525;526) and, in studies where this has been examined, there has often 
been little evidence of an association, even when it was apparent for all cardiovascular 
endpoints.  It is important to note however that all studies to date have been limited by 
relatively low stroke rates.  For example, in an analysis of data from the SHEP trial (384), 
there were only 243 strokes. In an analysis from the Syst-Eur trial (387), there were only 
128 strokes, of which only 36 of these were fatal. In the Syst-China trial (386), there were 
only 87 strokes, although these did make up the majority of cardiovascular endpoints. In 
analysis of data from the NHANES study (396) there were only 111 strokes and in the 
PIUMA study analysis, there were only 48 strokes (383).  
 
The population studied here (those with treated hypertension) represent a group where the 
relationship between stroke rate and mortality is particularly unclear. Some studies have 
shown an association (380;386;402) while others have not (384;387).  In the Syst-China 
study (386), a 50 µmol/l increase in serum uric acid afforded a relative hazard ratio of 1.28 
(95% CI 1.1 to 1.5) for stroke mortality, although there was no significant association with 
all stroke events. Whether results from a Chinese population with a disproportionately high 
haemorrhagic  stroke  risk  and  low  serum  cholesterol  can  be  widely  generalised  is 
questionable. An association has been seen with stroke risk in patients with diabetes (380), 
where serum uric acid levels above the median were associated with increased stroke risk 
(HR 1.91, 95% CI 1.24 to 2.94) although the number of strokes was again small (114 in 
total). In a large observational cohort of patients aged > 55 years of age (Rotterdam study 
data (402)) an association was seen with stroke incidence (HR 1.18, 95% CI 1.06 to 1.3). In   - 199 - 
total, there were 381 stroke events; the largest number to date. However, subgroup analysis 
suggested  this  association  was  only  present  in  females  and  in  those  with  no  previous 
hypertension.  
 
There were 354 stroke deaths in this study; the highest number in any study to date, and the 
largest  study  of  those  with  hypertension.  This  allows  thorough  analysis  of  any 
relationships. The impact of sex in many studies is difficult to assess but those who have 
addressed it suggest the association exists only in females, or is at least more prominent 
(402;525;526), although other studies show no such difference (387).  In the Rotterdam 
study for example, no association was seen in males but an association was present in 
females.  This study showed similar with a highly significant relationship was present in 
females but not males. There are known differences in uric acid metabolism between the 
sexes;  women  have  a  lower  total  body  uric  acid  pool,  presumably  due  to  oestrogen 
mediated  differences  in  renal  excretion  (527).    Despite  uric  acid  being  higher  in  post 
menopausal women (528), menopausal status has little effect on the association between 
uric acid and cardiovascular disease (396).  It is therefore possible, but speculative, that 
raised serum uric acid in females reflects a different mechanism than in males; perhaps 
increased xanthine oxidase activity and the associated superoxide anion production.  It is 
also possible that changes in uric acid have less impact on those with higher baseline risk 
and higher rates of traditional risk factors; such as the males studied here. The possibility of 
a sex specific effect of uric acid lowering strategies on cardiovascular outcomes should be 
considered in the design of future clinical trials, although because of higher baseline risk, 
measures such as allopurinol use may prove most effective in males because of ancillary 
effects such as xanthine oxidase inhibition. 
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A J-shaped relationship between serum uric acid and cardiovascular risk has also been seen 
in many previous studies (383;385;396;525) and also with regard to stroke risk (380;386).  
This  study  found  similar  with  regard  to  stroke  risk  but  not  total,  vascular  or  coronary 
mortality. Why these differences exist is unclear.  There are plausible explanations. It has 
been speculated that this J-shaped relationship reflects the putative detrimental effects of 
elevated uric acid on endothelial and platelet function and vascular smooth muscle and the 
association between lower serum uric acid and low plasma antioxidant activity.  It is also 
possible that some of the increased risk seen with lower uric acid is due to poor nutrition or 
other  illnesses  which  may  contribute  to  cardiovascular  risk  -  hypouricaemia  is  more 
common in  hospitalised  patients,  with  concomitant  medications  and  in those with  liver 
disease or neoplasia (529).  Why this should be particular to stroke risk here is not clear. 
 
There  are  strengths  to  this  study  including  its  size,  the  prospective  nature  of  the  data 
collection and the large number of fatal strokes. There are however, some weaknesses. The 
long  study  period  means  several  of  these  events  may  have  occurred  before  aggressive 
preventative strategies became commonplace and treatment regimens for hypertension have 
changed  over  the  years.  For  example,  there  is  now  less  emphasis placed  upon  diuretic 
therapy  which  increases  serum  uric  acid.  Whether  this  impacts  upon  the  contemporary 
relevance of the results is unclear but possible. 
 
In summary, data from this study suggest that serum uric acid is associated with increased 
stroke mortality and that this relationship is J-shaped, unlike that between uric acid and 
total, vascular and coronary mortality.   - 201 - 
4.05  Study Three - Allopurinol and Basal Nitric Oxide Production in the Cerebral 
Circulation of those with Diabetes; a Randomised Trial 
 
The study hypothesis was that the XO inhibitor allopurinol would enhance nitric oxide 
bioavailability in the cerebral circulation of patients with type 2 diabetes. This would be 
reflected by enhancement of the effects of L-NMMA, which produces transient reductions 
in cerebral blood flow (CBF).  A randomized, double blind, placebo controlled crossover 
study was performed to test this.  
 
4.05.1  Study Three Methods 
 
The  study  was  performed  in  the  University  Division  of  Cardiovascular  and  Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the local research 
ethics committee and was registered in the ISRCTN database (ISRCTN 68849312). 
 
Male patients aged over 40 years old with type 2 diabetes of duration less than 5 years and 
stable glycaemic control (HbA1c below 9.0%) were studied. Oral biguanide therapy was 
permitted,  although  those  on  insulin  or  sulphonylurea  therapy  were  excluded.  Further 
exclusion criteria were: greater than 70% extra-cranial internal carotid artery (ICA) stenosis, 
known coronary arterial disease, significant co-morbidity or frailty likely to cause either 
death or difficulty with protocol adherence within 3 months, significant renal impairment 
(defined as serum creatinine concentration over 250 µmol/L) and contra-indication to or 
indication  for  administration  of  allopurinol.  Patients  taking  sulphonylurea  therapy  were 
later included following a protocol amendment. Exclusion criteria were chosen to minimise 
the  theoretical  risks  of  sub-endocardial  myocardial  ischaemia  following  L-NMMA,  to   - 202 - 
minimise potential risks of allopurinol treatment and to ensure carotid flow readings were 
not falsely elevated because of intrinsic carotid disease. 
 
Patients were identified during out-patient attendance at hospital clinics. All participants 
gave written informed consent to participate and underwent full Bruce protocol exercise 
tolerance testing prior to randomisation to exclude sub-clinical coronary arterial disease. If 
evidence of this was found, further participation was not permitted. All drug treatments 
remained unchanged throughout the study period. 
 
Study Assessment 
Study visits took place in the Investigations Ward of the Acute Stroke Unit in the Western 
Infirmary and were supervised by one of the study investigators.  The participant schedule 
is shown in figure 4.8. 
 
2 Week
Washout Period END
Repeat of:
BP
Bloods
TCD
Arterial Stiffness
Day 14
Repeat of:
BP
Bloods
TCD
Arterial Stiffness
Day 14
Repeat of:
BP
Bloods
TCD
Arterial Stiffness
Day 42
Repeat of:
BP
Bloods
TCD
Arterial Stiffness
Day 42
Measurement of:
BP
Bloods
TCD
Arterial Stiffness
Day 28
Measurement of:
BP
Bloods
TCD
Arterial Stiffness
Day 1
Allopurinol
Allopurinol Placebo
Placebo
 
  Figure 4.8. Study Three Participant Study Schedule   - 203 - 
Baseline assessment of mean flow velocity in the ICA and middle cerebral artery (MCA) 
was performed, along with measures of ICA diameter and area. Peripheral (radial) pulse 
wave analysis (PWA) and (carotid-radial) pulse wave velocity (PWV) measurements were 
also  performed.    On  completion  of  these  measurements,  a  45  ml  infusion  of  0.8 
µmol/kg/min of  L-NMMA dissolved in normal saline was  given intravenously over 15 
minutes. L-NMMA was obtained from Clinalfa. Assessment of ICA and MCA parameters 
was repeated upon cessation of infusion and at 10, 20 and 30 minutes thereafter. PWA and 
PWV measurements were repeated upon cessation of infusion and at 15 and 30 minutes 
thereafter.  Carotid insonation was performed using an Acuson Aspen 128 with a 5-Mhz 
linear transducer (Acuson, Mountain View, CA, USA) and measurements were taken 1 cm 
distal  to  the  carotid  bifurcation.  MCA  insonation  was  performed  using  a  TCD  100M 
(Spencer  Technologies,  Seattle,  WA,  USA)  and  readings  were  taken  at,  or  as  near  as 
possible to, a depth of 50 cm. Ultrasound examinations were performed by a sonographer 
with several years’ experience of neurovascular ultrasound. PWA and PWV measurements 
were made using a SphygmoCor device (Atcor Medical, Sydney, Australia) by operators 
with several years experience.  
 
Following baseline assessment, participants were randomised to receive either 300 mg of 
allopurinol or matching placebo orally once daily. Dosing began on the day of baseline 
assessment  and  continued  for  two  weeks  after  which  participants  returned  for  further 
assessment as described above. A two-week washout period then ensued after which repeat 
assessment,  a  two  week  dose  of  the  other  agent  (placebo  or  allopurinol)  and  the  final 
assessment  occurred.  All  haemodynamic  studies  were  conducted  as  near  to  midday  as 
feasible and subjects were asked to refrain from caffeine for 24 hours prior to each study. 
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At each study visit, blood was drawn to allow measurement of routine biochemistry and 
haematology  parameters  and  circulating  markers  of  endothelial/inflammatory  function 
(VEGF, sICAM, eSelectin and CRP).  For these tests, serum was frozen and stored for 
subsequent analysis using ELISA techniques. 
  
Randomisation and Treatment Allocation 
Allopurinol tablets were manufactured by Alpharma. Placebo tablets were manufactured by 
Penn  Pharmaceuticals.  Both  were  encapsulated  to  appear  identical,  in  the  Pharmacy 
Production Unit at the Western Infirmary Hospital. Study treatments were collected by one 
of  the  investigators  on  the  day  of  the  baseline  and  the  first  post-washout  study  visit. 
Concordance with therapy was assessed by questioning and pill counts where available. 
Investigators remained blinded to serum uric acid data until the end of the study to prevent 
unmasking  of  treatment  allocation.    Randomisation  was  performed  by  the  pharmacy 
department and the randomisation code was held by an independent study pharmacist. The 
code  was  not  broken  until  all  follow  up  was  complete  and  all  data  were  prepared  for 
analysis.  
 
Statistical measures 
The  primary  endpoint  was  change  in  ICA  flow  induced  by  the  L-NMMA  infusion 
expressed as area under flow / time curve (AUC) measured from the start of infusion to 20 
minutes  after  its  completion  (530;531).    Based  on  previous  pilot  data  (530),  it  was 
calculated that a sample size of 20 patients would enable detection of a clinically significant 
improvement  in  L-NMMA  responsiveness  (to  approximately  75%  of  that  seen  in  non-
diabetic individuals), with 90% power (alpha = 5%). Secondary endpoints were the intra-
individual percentage change in ICA flow following L-NMMA infusion (from baseline to   - 205 - 
10 minutes post infusion), change in systolic and diastolic blood pressure (SBP and DBP) 
and  middle  cerebral  artery  flow  velocity  (MCAv)  induced  by  the  L-NMMA  infusion 
(expressed as AUC), change in augmentation index (AI, measured during PWA) and PWV, 
and change in circulating markers of endothelial/inflammatory function.   
 
AUCs were calculated using the trapezoidal method with the aid of NCSS software (Utah 
USA).  A  negative  AUC  signifies  a  reduction  in  flow  (or  blood  pressure  for  example) 
following L-NMMA infusion and a positive area under the curve indicates an elevation in 
flow.    The  difference  between  the  AUCs  pre  and  post  each  intervention  period  were 
calculated  and  compared  (allopurinol  minus  placebo)  using  paired  non-parametric  tests 
(Wilcoxon signed rank test). A positive difference in AUCs represents an improvement in 
basal  NO  activity  during  that  study  phase  and  a  positive  difference  between  the  study 
periods represents improvement in favour of allopurinol. For the AI and PWV, pre infusion 
values  and  the  change  immediately  following  infusion  were  compared  between  study 
periods using the same approach as taken for AUCs. The difference between pre and post 
treatment  values  was  compared  for  the  circulating  markers  of  endothelial/inflammatory 
function. As a sensitivity analysis, a mixed effects model was generated to adjust for any 
effect  of  treatment  ordering  and  to  incorporate  information  from  patients  who  did  not 
complete all of the study visits. 
 
4.05.1.1  Rationale  for  Use  of  L-NMMA  Responsiveness  a  Measure  of 
Cerebrovascular Function 
Endothelial  dysfunction  is  key  to  the  development  of  cardiovascular  disease  with 
maintenance of normal endothelial function dependant upon production of endothelial nitric 
oxide (NO). Studies have also shown this to be involved in maintenance of resting cerebral   - 206 - 
blood flow (CBF) (532) and a dynamic effect of NO on cerebral autoregulation has been 
demonstrated via studies of infusion of NG-monomethyl-L-arginine (531) (L-NMMA). L-
NMMA is an analogue inhibitor of endothelial nitric oxide synthase (eNOS) and thus basal 
NO activity; in healthy volunteers, L-NMMA lowers CBF (531) and has also been shown 
to reduce forearm blood flow (533), to increase large artery stiffness (534) and to increase 
blood pressure (535). The magnitude of the response is dependent upon basal NO activity 
and thus endothelial health; for example, the bigger the fall in CBF following L-NMMA, 
the better the cerebrovascular endothelial function. 
 
This CBF response is reduced in those with established type 2 diabetes, where little effect 
of  L-NMMA  is  seen  (530)  and  this  may  predispose  them  to  hypoxic  or  ischaemic 
cerebrovascular  insult.  In  a  recent  prospective  case-controlled  study  (530),  L-NMMA 
produced a mean reduction in ICA flow (expressed as the area under the flow-time curve) 
of 12.8% (SD 17.8) in healthy volunteers compared to only 2.1% (SD 21.7) in those with 
diabetes. The response to  L-NMMA is therefore a valid measure and improvements in 
peripheral responses have been shown following treatment with agents proven to impact on 
cardiovascular  morbidity  and  mortality,  such  as  statins  and  ACE  inhibitors  (536;537). 
Whether therapy can improve the impaired response of the cerebrovasculature to L-NMMA 
in diabetes or other conditions is as yet untested.  
 
The mechanism of the impaired response seen in diabetes is unclear. Superoxide anions 
(·O2
-)
 inactivate  NO  (538),  inhibit  endothelium-dependent  vasorelaxation  (539)  and  are 
implicated in diabetes related endothelial dysfunction. While many sources of ·O2
- exist in 
the vascular endothelium, xanthine oxidase (XO) activity has been shown to be important 
(408) and, as outlined, inhibition of this enzyme (with allopurinol) improves peripheral and   - 207 - 
cardiac  endothelial  function  in  many  cardiovascular  disease  states  (521).  If 
pharmacological attenuation of XO activity improved cerebrovascular NO bioavailability in 
patients with diabetes, this would suggest a role for XO activity in the pathogenesis of 
diabetic  cerebrovascular  disease  and  provide  a  potential  means  to  improve  stroke 
prevention. 
 
4.05.1.2  Rationale for Use of Pulse Wave Analysis and Pulse Wave Velocity as 
Measures of Arterial Function and Health 
The relationship between brachial cuff blood pressure and risk of cardiovascular disease 
(and in particular of stroke) is clear and could be described as one of the few certainties in 
medicine. At all ages and across the range of blood pressure down to at least 115/75mmHg, 
the risk of death from stroke and cardiac disease increases in a log-linear fashion (155). In a 
recent meta-analysis of data from over 1 million adults, a doubling of rate of death from 
stroke and cardiac disease was seen with each 20mmHg higher systolic blood pressure (or 
10 mmHg higher diastolic blood pressure).  The simplicity of measurement of cuff brachial 
blood pressure and the legion of evidence (157) showing that a reduction in these values 
leads to reduction in morbidity and mortality means this will likely remain a cornerstone of 
cardiovascular risk prediction and in particular for stroke where the evidence for a link 
between other risk factors such as cholesterol and incidence is less compelling. 
 
However, evidence has emerged that measures of central blood pressure parameters, which 
are the values to which target organs are exposed, and measures of stiffness of arteries are 
also  important  and  linked,  independently  of  brachial  cuff  blood  pressure,  to  risk  of 
cardiovascular disease (540;541).  Some support for the use of these parameters can be 
gained from brachial cuff measurements; analysis of Framingham data suggest that cardiac   - 208 - 
events  are  more  closely  related  to  systolic  brachial  cuff  pressure  and  that  events  may 
actually be inversely related to diastolic pressure for any given systolic level (542). This 
suggests that pulse pressure, and thus increasing stiffness of large arteries, is in important 
factor in the development of cardiovascular disease. 
  
It is important to note that in normal healthy individuals the central and peripheral pulse 
pressures  differ  with  pulse  pressure  rising  more  peripherally  because  of  an  increase  in 
systolic pressure (543). This however alters with age; in young adults, the brachial pulse 
pressure pulse may be 50% greater than in the ascending aorta while they are similar in the 
elderly. This presumably reflects increasing vascular stiffness and is not best quantified by 
brachial  cuff  measures.  Measures  to  directly  quantify  central  pressure  parameters  and 
arterial stiffness are naturally invasive but non-invasive estimation of central pressures can 
now be achieved. 
 
The most widely employed methods are those of pulse wave analysis and measurement of 
pulse  wave  velocity  which  employ  the  use  of  arterial  applanation  tonometry.  Such  an 
example is the Sphygmocor system which incorporates a thin probe with a high-fidelity 
strain  gauge  transducer  with  a  small  pressure-sensitive  ceramic  sensor  area  linked  to  a 
computer and software to aid automated calculation of indices.   The probe is held over the 
skin at the point of maximal arterial pulsation. For PWA, this is done at a single site, most 
readily the radial artery at the wrist, and at two sites during measurement of PWV (for 
example at the radial and carotid artery or carotid and femoral artery).  In all individuals the 
aortic pulse wave is augmented by the reflection of blood at arterial bifurcation points, so 
called points of impedance discontinuity. The sum of all these reflected waves will behave 
like one single wave at each large artery origin in the aorta. In the young, or those with   - 209 - 
highly elastic aortas, this wave returns during late systole or diastole, whereas in the elderly, 
it arrives in early systole and augments the pulse pressure. The augmentation index is a 
measure of the degree to which the reflected wave contributes to the pulse pressure and is 
defined as the magnitude of this augmented pressure divided by the pulse pressure. A rise 
in the augmentation index and thus early arrival of the reflected wave should therefore 
reflect the increasing arterial stiffness that occurs with age and cardiovascular risk factor 
states. Ideally, this would also be measured directly in the aorta but measures from the 
radial site have been shown to correlate well with aortic and carotid values (544;545) when 
a transfer function is employed to allow their approximation. The transfer function is also 
utilized to estimate the central systolic, diastolic blood and pulse pressures; all from the 
radial site. 
 
A variety of studies have linked these parameters to cardiovascular risk factor states. For 
example, a recent study of over 12000 individuals in England and Wales (546) found that 
the pulse pressure ratio (aortic pulse pressure : peripheral pulse pressure, increases in which 
should link to increased arterial stiffness) and augmentation index were higher in those with 
hypertension, hypercholesterolaemia, diabetes and in smokers and in those with established 
cardiovascular  disease  in  comparison  to  healthy  controls.    These  findings  remained 
consistent across the age range.  Studies have also linked increasing augmentation index to 
increases in cardiovascular mortality and morbidity in those with end-stage renal disease 
(547) and in those undergoing percutaneous coronary intervention (548;549) although only 
one of these utilized transfer function based measurements from the radial site (551) and 
not all studies yielded positive associations, including a study of nearly 500 individuals 
with hypertension (550).  Date also exist to suggest that transfer function based estimation   - 210 - 
of central blood pressure values can better predict outcomes in comparison to peripheral 
measures (551), although again data conflict (552). 
 
It is therefore of interest to ask whether differences in central parameters explain observed 
differences in cardiovascular event reduction between drug classes which do not appear 
explained  by  differences  in  brachial  blood  pressure  level.  Also,  it  would  provide 
encouraging evidence of benefit if any new or novel therapy, not aimed directly at lowering 
blood pressure, improved some of these measures of arterial stiffness. The CAFÉ study 
investigators addressed the first question.  The CAFÉ study (553) was a sub-study of the 
ASCOT  trial  (554),  where  an  amlodipine  ±  perindopril  based  regimen  led  to  fewer 
cardiovascular events or procedures in comparison to an atenolol ± bendrofluazide based 
regimen (HR 0.84, 95 % CI 0.78 to 0.9, p <0.0001). This was not completely accounted for 
by differences in blood pressure in a post-hoc analysis (555). In the CAFÉ study, which 
included 2199 participants from 5 ASCOT centres, there was little difference in brachial 
systolic  BP  (0.7  mmHg,  95%  CI  -0.4  to  1.7,  p=0.2)  but  substantial  reductions  in  the 
amlodipine arm were seen regarding central aortic systolic (4.3 mmHg, 95% CI 3.3 to 5.4 
mmHg, p<0.0001) and pulse (3 mmHg, 95% CI 2.1 to 3.9 mmHg, p<0.0001) pressures. 
These  indices  also  linked  to  clinically  relevant  endpoints  with  10mmHg  increments  in 
central pulse pressure associated with an 11% increase in risk of events (HR 1.11, 95% CI 1 
to 1.23 per 10 mmHg increment). 
 
The pulse wave velocity is the measurement of speed of the pressure waves traveling along 
an  arterial  segment,  usually  calculated  from  measurements  at  a  proximal  (for  example 
carotid) and distal (for example radial) site.  The distance between these sites is measured 
with a tape measure and using ECG gating, the time taken for the arterial pulse to transmit   - 211 - 
this distance between can be determined allowing the velocity of the pulse wave to be 
calculated.  A  higher  pulse  wave  velocity  suggests  increased  arterial  stiffness  has  been 
shown  to  link  with  increased  mortality  in  a  cohort  with  severe  renal  disease  (556), 
hypertension (557), established cardiac disease (558) and in a healthy cohort (559).  For 
example, in a cohort from the Rotterdam study revealed a hazard ratio of 2.45 (95% CI 1.29 
to 4.66) for development of coronary disease and 2.28 (95% CI 1.05 to 4.96) for stroke in 
those in the highest tertile of pulse wave velocity compared to those in the lowest.  The 
mean PWV in the whole cohort was 13.3 (SD 2.9), although individual tertile ranges were 
not given. In a hypertensive cohort (557), mean PWV in those who suffered a coronary 
event was significantly higher at 12.8 (SD 3.2) compared to 11.4 (SD 3.1) in those who did 
not (p<0.0001) and each SD increment (3.5 m/s) conveyed a RR of 1.39 (95% CI 1.08 to 
1.79, p=0.01) for coronary events. As yet, there is no data to confirm that reductions in 
PWV lead to reductions in cardiovascular events. 
 
It is also of interest that an increase in both the AI and PWV has been seen following L-
NMMA seen in a previous study of healthy volunteers (534). This study incorporated a 
range of doses of L-NMMA (from 0.1 to 3 mg/kg/minute) and effect was only seen with 
the  higher  doses,  which  were  higher  than  used  here.  This  response  has  not  yet  been 
evaluated in those with diabetes and this is important to establish as it is possible that there 
are regional differences in basal NO production between different vascular beds and that 
responses to treatment may similarly differ (560). 
 
Thus, it is relevant and rational to measure these parameters in studies of putative new 
preventative strategies in those at risk of stroke. However, there is an important note of 
caution  when  interpreting  the  results  of  such  studies;  if  an  agent  were  to  yield  similar   - 212 - 
benefits to those seen in the CAFÉ study in terms of the AI or to give a 50% improvement 
toward values in healthy controls in those with diabetes, 135 and 388 participants per group 
respectively  would  need  to  be  recruited  to  ensure  90%  power  (alpha  0.05).  Benefit  is 
therefore unlikely to be seen in small pilot studies, or at least good statistical power is 
unlikely. 
 
4.05.2  Study Three Results 
 
Fourteen  patients  were  recruited  between  September  2006  and  August  2007.  Nineteen 
suitable patients were identified and approached and 5 declined participation. Eleven of 
those recruited completed follow up. One patient was deemed unsafe to continue as he had 
significant ST segment shift on his exercise tolerance test, one failed to attend for further 
assessment after visit one and one withdrew consent after attendance for exercise tolerance 
testing. One patient was unable to receive L-NMMA during his last study visit (because of 
lack of supply) leaving 10 who completed the study protocol. Data from this participant 
were included in analyses of blood markers and non L-NMMA dependent parameters. No 
other adverse event occurred during the study. The study was terminated early due to a 
national lack of availability of L-NMMA.  
 
Of these recruited, mean age (SD) was 53.1 (10.8) years. Demographic details, including 
baseline drug therapy, risk factor burden, renal function and uric acid levels are shown table 
4.23.  
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Smoker  4 (28.6) 
Hyperlipidaemia  5 (35.7) 
Hypertension  12 (85.7) 
Oral Hypoglycaemic Agent  11 (78.6) 
Anti-platelet Therapy  9 (64.3) 
ACE Inhibitor or ARB Therapy  11 (78.6) 
Diuretic Therapy  5 (35.7) 
Lipid Lowering Therapy  13 (92.3) 
Calcium Channel Antagonist Therapy  6 (42.9) 
Baseline Serum Creatinine  88 (16.9) µmol/l * 
Baseline Serum Glucose  9.9 (4.5) mmol/l * 
Baseline Serum Uric Acid  0.33 (0.07) mmol/l * 
Baseline Internal Carotid Artery (ICA) Flow  619 (SD 162) ml/min * 
Baseline Change in ICA Flow (ml)  -789 (IQR -4194 to 7233) ml † 
Baseline SBP  154 (SD 11) mmHg * 
Baseline Change in SBP (mmHg*min)  -133 (IQR -205 to 94) † 
Baseline DBP  85 (SD 6.8) mmHg * 
Baseline Change in DBP (mmHg*min)  66 (IQR -60 to 276) † 
Baseline MCAv  39.8 (SD 4.4) * 
Baseline Change in MCAv (m/s*min)  14 (IQR -29 to 53)  † 
Baseline Augmentation Index (AI)  23.9% (SD 6.86) * 
Baseline Change in AI  1.7% (SD 10.6) * 
Baseline Pulse Wave Velocity (PWV)  8.3 (SD 2.25) m/s * 
Baseline Change in PWV  -0.025 (0.89) m/s * 
Table 4.23. – Study Three Baseline Variables (at first study visit). Expressed as n 
(%) for categorical variables and mean (SD) for continuous variables * except 
for  area  under  curve  measurements  where  median  values  and  interquartile 
ranges (IQR) are given †. These values (†) refer to changes following L-NMMA 
infusion. ARB = angiotensin receptor blocker. MCAv = middle cerebral artery 
flow velocity. 
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Baseline Visit Response to L-NMMA Infusion 
Mean (SD) ICA flow rate pre L-NMMA infusion was 619 (162) ml / min. The median area 
under the change in ICA flow/time curve following L-NMMA infusion was -789 ml (IQR -
4194 to 735) (p=0.16 for test of median difference less than zero). ICA flow fell by a 
median of 4.8% (95% CI -17.3 to 9.4, p=0.25) following L-NMMA infusion. This, and 
baseline values for the other parameters, are shown in table 4.24. There was no change in 
blood pressure parameters where AUCs were considered, although systolic and diastolic 
blood pressures were raised immediately post infusion (by 3.6 mmHg, 95% CI -0.8 to 8.0 
mmHg and 5.6 mmHg, 95% CI 1.2 to 9.9 mmHg respectively). No change was seen in 
PWA or PWV parameters following LNMMA. 
 
Effect of Allopurinol on Response to L-NMMA Infusion 
Allopurinol  treatment  significantly  augmented  the  reduction  in  ICA  (expressed  as  area 
under the flow time curve) following L-NMMA infusion (p=0.032, median improvement in 
ICA flow reduction following LNMMA of 3144 (95% CI 375 to 7143) mls). Allopurinol 
did not significantly influence response of other measured parameters to L-NMMA (4.24). 
ICA flow fell by a median of 11.9% (95% CI -2.5 to 23.3, p=0.04) following LNMMA 
after treatment with allopurinol, The effect of allopurinol on the group and intra-individual 
changes in ICA flow following LNMMA are shown in figures 4.9 and 4.10. 
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Variable  Following 
Placebo 
Allopurinol  Difference  Between 
Periods * 
P value † 
Change  in  ICA 
Flow (ml) 
-1314  (-3359  to 
419) 
1134  (-964  to 
7872) 
3144 (375 to 7143)  0.032 
Change  in  SBP 
(mmHg*min) 
20 (-260 to 158)   116  (-248  to 
501) 
14 (-461 to 588)  0.92 
Change  in  DBP 
(mmHg*min) 
-55 (-220 to 86)   -162  (-206  to 
94) 
-56 (-218 to 90)  0.48 
Change  in  MCA 
MFV (m/s*min) 
-41 (-112 to 108)   -38 (-146 to -9)  -35 (-174 to 45)   0.36 
Table 4.24 – Change in Haemodynamic Parameters / Response to L-NMMA During 
Study Three. N = 10 included. All values refer to the change in area under the time 
curve. * = estimated difference in medians and the 95% CI on Wilcoxon signed rank 
test. † = for paired Wilcoxon signed rank test. 
 
A  mixed  effects  model  sensitivity  analysis  adjusted  for the  order  in  which  participants 
received  allopurinol  and  placebo.    The  results  were  consistent  with  the  main  analysis 
(p=0.046 for allopurinol versus placebo) and found no significant order effect (p=0.51). 
Baseline  ICA  flow  level  also  did  not  explain  the  reduction  in  ICA  flow  following  L-
NMMA infusion. 
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Figure 4.9. Intra-patient Change in ICA Flow Following L-NMMA Infusion in Study 
Three. Each data point represents the difference in response to LNMMA between 
study  periods  for  one  individual  (in  mls).    For  each  study  phase,  values  were 
calculated as the difference between the pre and post intervention area under the 
flow-time  curve.  The  difference  between  study  phases  was  then  calculated 
(allopurinol minus placebo) and positive values (to the right) represent improvement 
in  response  following  allopurinol  and  negative  values  improvement  following 
placebo. 
 
Figure 4.10. Change in ICA Flow Following L-NMMA Infusion in Study Three. 
The values shown represent the median (± 1 SE) change in ICA flow following 
intervention with allopurinol or placebo. The p value refers to between group 
comparisons on non-parametric testing (Wilcoxon signed rank test). A greater 
reduction in ICA flow following L-NMMA represents an improved response.   - 217 - 
Effect of Allopurinol on Peripheral Vascular Reactivity 
The pre-infusion AI or PWV did not differ significantly between the treatment periods 
(estimated median difference between placebo and treatment periods of -4.3% (95% CI -11 
to 7%, p=0.56) and -0.32 m/s(95% CI -2.1 to 7.8, p=0.39) respectively).  The response to 
L-NMMA  did  not  differ  significantly  between  the  treatment  periods  for  both  the  AI 
(estimated median difference between placebo and treatment periods of 7%, 95% CI -11.5 
to 23%, p=0.54) and PWV (estimated median difference of -0.7 m/s, 95% CI –7.6 to 1.85, 
p=0.68) (table 4.25). 
 
Variable  Baseline 
Visit ‡  
Change Post 
Placebo‡  
Change Post 
Allopurinol 
‡ 
Difference 
Between 
Periods § 
P value || 
AI (%)†   23.5 (18.5 to 
29.5) 
-3  (-14.5  to 
4.5) 
2  (-6.00  to  
10) 
-4.3  (-11  to 
7)  
0.56 
PWV (m/s) †  9  (7.6  to  
9.6) 
0.8  (0.1  to 
10.2) 
0.75  (-0.85 
to 2.3) 
-0.32 (-2.1 to 
7.8) 
0.39 
Table 4.25. Change in Measures of Peripheral Vascular Reactivity During Study Three. 
† = values refer to difference between pre-infusion values. ‡ = values shown are median 
and interquartile range.   § = values shown are estimated difference in medians and the 
95% CI on Wilcoxon signed rank test.  || = for paired Wilcoxon signed rank test. 
 
Effect of Allopurinol on Circulating Markers of Inflammation/Endothelial Function 
No significant differences were seen in any marker  (table 4.26).  The  VEGF level  rose 
during allopurinol treatment, although this did not reach statistical significance and s-ICAM 
levels seemed to be lower following allopurinol treatment. However, with all blood markers, 
the confidence intervals for the differences between study periods were large. 
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Variable  Placebo  Allopurinol  Difference 
Between 
Periods * 
P value † 
VEGF (pg/ml)  -14 (-67 to 59.1)  66.9  (5.9  to 
119.6) 
91 (-53 to 151)  0.08 
s-ICAM (ng/ml)  73.6  (-85.3  to 
96.5) 
9 (-7.8 to 65.3)  -51.7  (-81  to 
91.9) 
0.69 
e-Selectin 
(ng/ml) 
0.01  (-14.6  to 
10.3) 
2.4  (-12.9  to 
17.1) 
16 (-19 to 26)  0.45 
CRP (mg/l)  0.09  (-0.3  to 
0.75) 
0.195  (-0.01  to 
1) 
0.33  (-0.48  to 
1.29)  
0.40 
Table 4.26.  Change in Markers of Endothelial Function During Study Three. N = 11 
included. Median values (interquartile range) are given for each study period. A negative 
difference in medians represents improvement in favour of allopurinol. * = estimated 
difference in medians. † = for paired Wilcoxon signed rank test. 
 
4.05.3  Study Three Discussion 
 
L-NMMA can be used as a pharmacological tool to assess the extent of underlying NO 
activity.  In the cerebral vasculature, L-NMMA reduces CBF through restriction of NO 
activity and the higher the basal NO activity, the larger the effect.  In this study, treatment 
with allopurinol enhanced this effect implying that it improves basal levels of NO activity 
and raises the possibility that use of allopurinol could improve cerebrovascular health. The 
response to L-NMMA improve toward the previously published (530) 12.8% (95% CI 3.29 
to 22.31%) fall in ICA flow seen in healthy volunteers (from a non-significant 4.8% (95% 
CI -17.3 to 9.4) reduction at baseline to an 11.9% (95% CI -23.3 to 2.5) fall following 
allopurinol treatment). 
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The potential beneficial effects of allopurinol on the vasculature are two fold; it reduces XO 
mediated ·O2
-. production and serum uric acid. The XO system has been shown to be an 
important source of ·O2
-. in the vasculature (408) but this is the first human study to show 
that inhibition of XO improves cerebral NO bioavailability. Most large, well-conducted 
epidemiological studies suggest that increasing serum uric acid is associated with increased 
cardiovascular event rate and mortality (519), possibly via detrimental effects on platelet, 
smooth muscle and endothelial function (521), and UA reduction may impact favourably 
on cardiovascular risk (472). 
 
Previous studies, typically also utilising cross over design and brief treatment duration, 
have  shown  a  beneficial  effect  of  XO  inhibition  on  measures  of  forearm  or  coronary 
endothelial function in patients with or at high risk of vascular disease (521) - including in 
patients with diabetes. One previous small study (492) failed to show benefit of allopurinol 
on  markers  of  oxidative  stress  (such  as  the  lipid  peroxidation  assay)  in  patients  with 
diabetes, although there were large differences in the levels of baseline HbA1c and cardiac 
risk factors such as smoking with levels worse in those randomised to allopurinol. This 
study is the first to show benefit of allopurinol on cerebrovascular endothelial function.  
Whether these improvements are driven by change in uric acid or XO activity is unclear but 
previous work suggests the later (483), although as mentioned, uric acid reduction may 
bring other benefits in the longer term.  
 
There  are  strengths  to  this  study;  it  utilised  a  rigorous  protocol,  with  which  there  is 
considerable experience, and a similar baseline response to L-NMMA was found compared 
to that seen in previous work (530). The response to L-NMMA is a valid measure; it is an 
analogue inhibitor of eNOS and infusion has previously been shown to reduce both CBF   - 220 - 
(531) and forearm blood flow (533), to increase large artery stiffness (534) and to increase 
blood pressure (535). Also, improvements in these responses have been shown following 
treatment with other agents proven to impact on cardiovascular morbidity and mortality 
(536;537).  
 
There are limitations to the study and areas that require further study. Fewer patients were 
included than intended because of the lack of ongoing availability of L-NMMA, reducing 
the statistical power of the study. The unfortunate supply problem affected several centres 
in the UK. Even so, the consistency of effect seen is reassuring; 8 of 10 patients who 
completed the protocol  experienced an improvement in cerebrovascular NO availability 
during the allopurinol phase. The dosing period was short (a limitation of many previous 
studies) and it is possible that any changes in vascular function afforded by a reduction in 
XO activity and ·O2
-. production may be short lived and soon by-passed by other sources of 
·O2
-.  The effect of more prolonged XO inhibition requires clarification. Also, while it is an 
appropriate measure to study, this study has only examined the effect on eNOS activity and 
other forms of NO and ·O2
-. production may be important in both disease and health. 
 
No improvement was seen in blood markers or measures of peripheral arterial stiffness in 
this study. Pre-infusion measures of arterial stiffness did not differ significantly between 
the study periods and neither did the response to L-NMMA. These results contrast with a 
previous study where forearm blood flow responses were improved following allopurinol 
(490)  but  a  different  technique  was  employed  here  and  the  study  was  not  specifically 
powered to detect differences in these parameters. Also, at the baseline visit, the increase in 
AI or PWV following L-NMMA seen in previous studies of healthy volunteers (534) was 
not replicated. This is perhaps because the response is impaired in those with diabetes or   - 221 - 
because of the comparatively low dose of L-NMMA used. Study to further evaluate this 
response in those with diabetes would be of use. Importantly, it is possible that there are 
regional  differences  in  basal  NO  production  between  different  vascular  beds  and  that 
responses to treatment may similarly differ (560). 
 
In summary, this study showed that XO inhibition with allopurinol improves cerebral NO 
bioavailability  and  suggest  a  beneficial  effect  of  allopurinol  on  cerebrovascular  health. 
Further investigation to establish the use of allopurinol in stroke prevention is required.     - 222 - 
4.06  Study Four - The Effect of Allopurinol on the Cerebral Vasculature of Patients 
with Subcortical Stroke 
 
The hypothesis was that allopurinol would improve cerebrovascular reactivity in a cohort of 
patients with recent subcortical stroke. A randomised, blinded, placebo controlled trial was 
performed to test this hypothesis.   
 
4.06.1  Study Four Methods 
The  study  was  performed  in  the  University  Division  of  Cardiovascular  and  Medical 
Sciences at the Western Infirmary, Glasgow. The study was approved by the West Medical 
research ethics committee and was registered in the ISRCTN database (ISRCTN 06452574). 
 
Patients aged over 18 years old with subcortical stroke between two weeks and six months 
prior to randomisation were studied. Exclusion criteria were: >70% extra-cranial internal 
carotid artery stenosis, known coronary arterial disease, significant co-morbidity or frailty 
likely to cause death within 3 months or likely to make adherence to study protocol difficult 
for patient, contra-indication to or indication for administration of allopurinol (as detailed 
in  summary  of  medicinal  product  characteristics),  concurrent  azathioprine  or  6-
mercaptopurine  therapy,  contra-indication  to  administration  of  acetazolamide,  serum 
creatinine > 250 mmol/l, enrolment in another clinical trial and women of childbearing 
potential.  Exclusion  criteria  were  chosen  to  minimise  the  potential  risks  of  allopurinol 
treatment and acetazolamide infusion and to ensure carotid flow readings were not falsely 
elevated because of intrinsic carotid disease. 
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Patients were identified during admission to the Acute Stroke Unit at the Western Infirmary 
and  out-patient  attendance  at  hospital  clinics.  All  participants  gave  written  informed 
consent to participate. All drug treatments remained unchanged throughout the study period, 
except in one participant who was commenced on dipyridamole and perindopril during the 
study. 
 
Study Assessment 
Study visits took place in the Investigations Ward of the Acute Stroke Unit in the Western 
Infirmary and were supervised by one of the study investigators.  The participant schedule 
is shown in figure 4.11. 
 
Assessment  of  mean  flow  velocity  in  the  ICA  and  middle  cerebral  artery  (MCA)  was 
performed, along with measures of ICA diameter and area. Peripheral (radial) pulse wave 
analysis (PWA) and (carotid-radial) pulse wave velocity (PWV) measurements were also 
performed.    On  completion  of  these  measurements,  a  15  mg/kg  ml  infusion  of 
acetazolamide  was  given  intravenously  over  3  minutes.  Assessment  of  ICA  and  MCA 
parameters and PWA and PWV  measurements were repeated at 15 thereafter.  Carotid 
insonation  was  performed  using  an  Acuson  Aspen  128  with  a 5-Mhz  linear  transducer 
(Acuson,  Mountain View, CA, USA)  and  measurements were taken 1  cm distal to the 
carotid  bifurcation.  MCA  insonation  was  performed  using  a  TCD  100M  (Spencer 
Technologies, Seattle, WA, USA) and readings were taken at, or as near as possible to, a 
depth of 50 cm. Ultrasound examinations were performed by a sonographer with several 
years’ experience of neurovascular ultrasound. PWA and PWV measurements were made 
using a SphygmoCor device (Atcor Medical, Sydney, Australia) by operators with several 
years experience.    - 224 - 
 
Following baseline assessment, participants were randomised to receive either 300 mg of 
allopurinol  or  placebo  orally  once  daily  (on  a  1:1  basis).  Dosing  began  on  the  day  of 
baseline assessment and continued for 90 days after which participants returned for further 
assessment  as  described  above.  All  haemodynamic  studies  were  conducted  as  near  to 
midday as feasible and subjects were asked to refrain from caffeine for 24 hours prior to 
each study. 
 
At each study visit, blood was drawn to allow measurement of routine biochemistry and 
haematology  parameters  and  circulating  markers  of  endothelial/inflammatory  function 
(VEGF, sICAM, eSelectin and CRP).  For these tests, serum was frozen and stored for 
subsequent analysis using ELISA techniques. 
 
END
Clinical
Assessment and 
and Blood Tests
Day 14
Clinical
Assessment and 
and Blood Tests
Day 14
Measurement of:
BP
Bloods
TCD
Day 1
Allopurinol
Placebo
Measurement of:
BP
Bloods
TCD
3 MONTHS
Measurement of:
BP
Bloods
TCD
3 MONTHS
 
 
 
 
Figure 4.11. Study Four Participant Study Schedule.   - 225 - 
 
4.06.1.1  Rationale  for  Use  of  Response  to  Acetazolamide  as  a  Measure  of 
Cerebrovascular Function 
Impaired regulation of the subcortical microvasculature has been proposed as a pathogenic 
mechanism in first and recurrent lacunar cerebral infarction and in vascular dementia (561). 
This impaired regulation can be assessed using a standard non-invasive ultrasound protocol 
which measures cerebral vasomotor reactivity (CVR), the compensatory dilatatory capacity 
of cerebral resistance vessels in response to increased arterial carbon dioxide concentration, 
which can be manipulated by an acetazolamide infusion (562-564). The magnitude of the 
change in cerebral blood flow is the measure of CVR and is a functional assessment of the 
cerebral vasculature (562).
  Impaired CVR occurs in a variety of cardiovascular risk states 
(565;566), correlates with the severity of leucoencephalopathy seen on magnetic resonance 
imaging (567) and confers an increased risk of ischaemic stroke, possibly due to increased 
rigidity in the arteriolar wall and to failure of the cerebral vasculature to compensate for 
fluctuations in perfusion pressure (566;568). Importantly, CVR can be improved with statin 
(569) and ACE inhibitor (562) therapy, both strategies known to reduce incidence of stroke 
in  high-risk  individuals  and  is  thus  a  useful  therapeutic  target  upon  which  to  test  new 
treatments. 
 
CVR as measured by response to acetazolamide is thus a valid measure and a 15mg/kg or 
1g dose of acetazolamide leads to maximal vasodilatory effect (570) with a peak effect at 
approximately 15 minutes (571).  Acetazolamide is a reversible inhibitor of the enzyme 
carbonic anhydrase which catalyses the reaction; 
CO2 + H20 = H2CO3 = H
+ + HCO3
-. 
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It is presumed that the effect of acetazolamide on cerebral blood flow is mediated by the 
increase in extracellular pCO2 and decrease in extracellular pH it affords. Both of these 
changes lead to dilatation of small cerebral blood vessels (572). However, it is important to 
note that acetazolamide may have a direct effect on smooth muscle of the blood vessel wall 
(573) and thus acts through both endothelium dependent and independent mechanisms. It is 
possible  therefore  that  changes  in  CVR  assessed  by  this  means  may  not  truly  reflect 
benefits  or  otherwise  of  a  treatment  such  as  allopurinol,  whose  vascular  effects  are 
mediated by a reduction in oxidative stress and improved endothelial function. Assessment 
of effect on measures such as L-arginine reactivity or infusion on L-NMMA may have thus 
be  a  more  appropriate  measure  (574;575)  but  is  unsuitable  in  this  population  due  to 
concerns with its administration in those with established cardiovascular disease. 
 
Randomisation and Treatment Allocation 
Allopurinol tablets were manufactured by Alpharma. Placebo tablets were manufactured by 
Penn Pharmaceuticals. Both were packaged in identical fashion in the Pharmacy Production 
Unit at the  Western Infirmary Hospital.  Study  treatments were  collected by one of the 
investigators on the day of the baseline and the first post-washout study visit. Concordance 
with therapy was assessed by questioning and pill counts where available. Investigators 
remained blinded to serum uric acid data until the end of the study to prevent unmasking of 
treatment allocation.  Randomisation was performed by the pharmacy department and the 
randomisation code was held by an independent study pharmacist. The code was not broken 
until all follow up was complete and all data were prepared for analysis.  
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Statistical measures 
The primary endpoint was the change in MCA flow velocity induced by the acetazolamide 
expressed as the percentage change measured at 15 minutes after the infusion compared to 
the 0 minute value (termed CVR). Based on previous data (562), it was calculated that a 
sample size of 25 patients per group would enable detection of a clinically meaningful 10% 
improvement  in  CVR  following  allopurinol  treatment  with  90%  power  (alpha  =  5%, 
assumed standard deviation 10%). Secondary endpoints were change in augmentation index 
(AI,  measured  during  PWA)  and  PWV,  and  change  in  uric  acid  levels  and  circulating 
markers of endothelial/inflammatory function during the study. Approval was sought and 
obtained to recruit 80 participants, which would allow detection of a smaller yet potentially 
significant 3.7% improvement in CVR with 90% power. 
 
The difference in CVR values between the follow-up and baseline visits were compared 
between treatment groups. For the AI and PWV, 0 minute values at the baseline visit and 
follow-up visit were compared. The difference between pre and post treatment values was 
compared for the circulating markers of endothelial/inflammatory function. As data were 
non-normally  distributed,  the  Mann-Whitney  test  was  used  for  all  between  group 
comparisons. Minitab Software (version 15, California USA). 
 
4.06.2  Study Four Results 
 
Fifty participants were recruited between March 2006 and May 2008. Forty-five of those 
recruited completed the protocol. Two participants withdrew consent prior to the baseline 
visit, one felt unwell following acetazolamide infusion so did not wish to continue, one had 
an unreliable TCD window so that MCA velocities could not be reproducibly measured and   - 228 - 
one participant (who had stopped study medication) did not attend on two occasions for the 
follow-up visit. Data from this latter participant were included in analyses of baseline levels 
of blood markers and CVR. All these participants were randomised to the allopurinol group. 
There were two serious adverse events, both of which occurred in the allopurinol group but 
were  deemed  unrelated  to  treatment;  one  participant  developed  tonsillitis  and  required 
hospital  admission  while  another  developed  acute  appendicitis.  One  participant  in  the 
placebo group suffered gout. The study was terminated after recruitment of 50 participants. 
 
Of  these  recruited,  mean  age  (SD)  was  58.3  years  (SD  10.4).  Demographic  details, 
including baseline drug therapy, risk factor burden, renal function and uric acid levels are 
shown  table  4.27.  Baseline  variables  were  broadly  similar  although  the  proportion 
established  on  diuretic  and  ACE  inhibitor  or  angiotensin  receptor  blocker  therapy  was 
higher in the placebo group.  
 
Baseline Response to Acetazolamide Infusion 
At the baseline visit, MCAv increased by a mean of 15.5 m/s (SD, 12) and by 36.3% (SD 
26) following acetazolamide infusion in the whole  group and by 36.5% (SD 27.9) and 
36.2% (SD 4.9) in the allopurinol and placebo groups respectively. The AI and PWV did 
not alter following acetazolamide infusion. 
 
Change in CVR Following Allopurinol Treatment 
CVR did not change following treatment with allopurinol (median change in CVR 0.89% 
in the allopurinol group and -0.68% in the placebo group, p=0.64, (95% CI for estimated 
difference in medians -13.4 to 25.5%)) (figure 4.12). 
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Variable  Allopurinol 
Group 
Placebo 
Group 
All 
Participants 
Completed Protocol  20 (80%)  25 (100%)  45 (90%) 
Age  59.4 (9.3)  57.3 (11.5)  58.3 (10.4) 
Smoker  9 (37.5%)  13 (52%)  22 (44.9%) 
Hyperlipidaemia  8 (33.3%)  7 (28%)  15 (30.6%) 
Hypertension  13 (54.2%)  16 (64%)  29 (59.1%) 
Previous CVA  4 (16.7%)  0  4 (8%) 
Diabetes  2 (8.3%)  3 (12%)  5 (10.2%) 
Anti-platelet Therapy  23 (95.8%)  24 (96%)  47 (95.9%) 
ACE Inhibitor or ARB Therapy  7 (29.2%)  20 (80%)  27 (55.1%) 
Diuretic Therapy  6 (25%)  11 (44%)  17 (34.7%) 
Calcium  Channel  Antagonist 
Therapy 
1 (0.04%)  3 (12%)  4 (8.2%) 
Beta-Blocker Therapy  5 (20.1%)  2 (8%)  7 (14.3%) 
Lipid Lowering Therapy  23 (95.8%)  23 (92%)  46 (93.9%) 
Oral Hypoglycaemic Agent  2 (8.3%)  3 (12%)  5 (10.2%) 
Serum Creatinine (µmol/l)  91.1 (19.2)  90.4 (21.8)  90.8 (20.4) 
Serum Glucose (mmol/l)  6 (1.8)  6.6 (2.4)  6.3 (2.2) 
Serum Uric Acid (mmol/l)  0.35 (0.1)  0.33 (0.09)  0.34 (0.09) 
SBP (mmHg)  133.9 (17.1)  142.9 (24.1)  138.6 (21.3) 
DBP (mmHg)  74.4 (11.8)  78.8 (11.4)  76.7 (11.7) 
MCAv (m/s)  42.6 (10.8)  44.6 (12.5)  43.7 (11.6) 
Augmentation Index (AI, %)  24.4 (12.3)  22.4 (11.5)  23.4 (11.8) 
Pulse  Wave  Velocity  (PWV, 
m/s) 
7.6 (1.6)  8.1 (1.6)  7.8 (1.6) 
Any Serious Adverse Event  2 (8.3%)  0  2 (4%) 
Table 4.27 – Study Four Baseline Variables 
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Secondary Endpoints 
The AI did not change following treatment with allopurinol (median change 0% in the 
allopurinol group and 2 % in the placebo group, p=0.51). There was also no change in 
PWV (median change -0.3 m/s in allopurinol group compared to -0.35 m/s in the placebo 
group,  p=0.42)  (table  4.28).  Uric  acid  level  was  significantly  reduced  by  allopurinol 
treatment but there were no significant changes in the other blood parameters or markers of 
endothelial function (table 4.29). 
 
 
 
Figure 4.12. Percentage Change in Cerebrovascular Reactivity  
(CVR) Following Treatment in Study Four   - 231 - 
Variable  First Visit ‡   Change Post 
Placebo‡  
Change  Post 
Allopurinol ‡ 
Difference 
Between 
Groups § 
P  Value 
|| 
AI (%)   23.35  (14.25 
to 52) 
2  (-3.75  to 
35) 
0 (-6 to 6)  -1.5 (-7 to 4)   0.5 
PWV (m/s)  7.82  (6.6  to 
8.9) 
-0.35  (-1.35 
to 0.35) 
-0.3 ( -1.25 to 
1.4) 
0.35  (-0.5  to 
1.5) 
0.42 
Table 4.28 - Measures of Peripheral Arterial Stiffness in Study Four. All values refer 
to the baseline pre-infusion values. ‡ = values shown are median and interquartile 
range.   § = values shown are estimated difference in medians and the 95% CI on 
Mann-Whitney testing.  || = for Mann-Whitney testing. 
 
 
Variable  Placebo  Allopurinol  Difference  Between 
Periods * 
P value † 
Uric  Acid 
(mmol/l) 
0.02  (-0.02  to 
0.06) 
-0.12  (-0.2  to  -
.05) 
-0.15 (-0.2 to -0.09)  <0.0001 
VEGF (pg/ml)  11.8  (-60.6  to 
157.4) 
-11.4  (-50  to 
10.8) 
-27.3 (-12.5 to 42)  0.23 
s-ICAM 
(ng/ml) 
12.8  (-13.3  to 
93.7) 
10 (-68 to 56.7)  -32.7 (-142.4 to 25.1)  0.3 
e-Selectin 
(ng/ml) 
-4.71 (-13.35 to 
11.72) 
-6.43 (-21.51 to 
8.06) 
-2.85 (-19.64 to 11)  0.72 
CRP (mg/l)  0.29  (-2.12  to 
0.76) 
0.03  (-0.41  to 
0.93) 
0.09 (-0.72 to 1.44)  0.87 
Table  4.29  –  Change  in  Blood  Parameters  and  Markers  of  Endothelial  Function 
During Study Four 
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4.06.3  Discussion 
 
This study found no effect of allopurinol treatment on CVR, as measured by response to 
acetazolamide infusion in patients with recent subcortical stroke. 
 
The lack of effect of allopurinol on CVR is not in-keeping with data which support the 
beneficial effect of allopurinol on the vasculature. The effect of XO inhibitors on measures 
of endothelial and cardiovascular function has been tested in many small studies (521). 
Trials have variously used oral or intravenous drug and typically involved a cross over 
design, with changes in arterial responsiveness  as outcome measures,  which have been 
shown to improve following treatment with CV risk-modifying drugs (510). Improvements 
following  XO  inhibition  are  seen  in  patients  with  type  II  diabetes  and  hypertension, 
hypercholesterolaemia,  smokers,  in  those  with  elevated  10  year  CV  risk  and 
hyperuricaemia,  in  stable  coronary  disease  and  in  the  context  of  heart  failure  (521), 
although  beneficial  effects  were  not  seen  in  some  studies  in  heart  failure  and 
hyperlipidaemia.  This  is  the  first  study  of  the  effect  of  allopurinol  on  a  measure  of 
cerebrovascular health in patients with previous stroke. Previous work from this unit has 
shown that allopurinol use is associated with a potentially beneficial attenuation of the rise 
in ICAM-1 levels after stroke (489) and improvements in cerebrovascular function in those 
with  type  2  diabetes  (576)  hence  the  wish  to  evaluate  whether  allopurinol  improves 
cerebrovascular health after stroke.  
 
This study employed a rigorous protocol, with which there is considerable local experience, 
and CVR measured in this fashion has previously been shown by this group and others to 
improve following treatment with statins and ACE inhibitors (561;569).  This study may   - 233 - 
have failed to see benefit for several reasons. Firstly, the study size would allow detection 
of a 10% improvement in CVR with 90% power. This is the same magnitude of benefit that 
was previously seen with perindopril use but this study has limited power to detect smaller 
yet potentially beneficial improvements. This is compounded by the large variability seen 
in the change and measures of CVR. Also, by chance, all patients who withdrew before or 
early after starting medication had been randomised to the allopurinol group. Further, in 
this study, 94% of patients were established on statin therapy, compared to only 30% in 
similar studies of ACE inhibition (562), and over half were receiving ACE inhibition or 
ARB therapy, while 70% were on some form of anti-hypertensive therapy. The rate of 
concurrent ACE I / ARB therapy was more than double in the placebo group compared to 
those who received allopurinol. It may be that, in such a well treated cohort, the potential 
beneficial effect of allopurinol is less than originally anticipated.  The potential limitations 
of CVR measured in this way have already been discussed. It remains, however, a valid 
measure given the concerns surrounding other measures such as response to L-NMMA in 
those with established cardiovascular disease. 
 
Further, while the baseline levels of CVR in this study are comparable to previous studies 
in this patient group, there is considerable overlap in the literature between values reported 
in healthy volunteers (577), those with elevated cardiovascular risk, previous stroke and 
occlusive carotid disease (563). It is therefore difficult to estimate to what degree baseline 
CVR was impaired in this group and thus the degree of improvement that one would expect 
to see from effective therapy. 
 
Many previous studies have investigated the effect of a short treatment duration, and even 
single dose, of allopurinol treatment and have consistently revealed benefit on measures of   - 234 - 
vascular function (521). It is of interest that 2 of the 3 published studies (487) (482;496) 
testing a longer treatment duration have failed to yield benefit. Any beneficial effects of 
xanthine oxidase inhibition on the vasculature may be short lived and by-passed by other 
sources of oxidative stress. It may also be that up-regulation of xanthine oxidase occurs 
with time, meaning any improvements may not be sustained for a prolonged period.  Uric 
acid levels were not elevated in this population and studies in the setting of heart failure 
suggest  that  the  vascular  effects  of  allopurinol  are  demonstrable  only  where  xanthine 
oxidase activity is up-regulated and uric acid levels are increased (578), although the effects 
may not be mediated by uric acid reduction per se (483). 
 
In summary, this study did not confirm a beneficial effect of allopurinol on cerebrovascular 
reactivity.  It  may  therefore  be  that  previous  encouraging  findings  will  not  therefore 
translate into important clinical benefits. Further study is required and results of this trial 
suggest this should focus on those with increased serum uric acid levels and aim to clarify 
whether the previous positive effects of allopurinol are sustained over a prolonged period. 
 
Chapter Summary 
 
These studies suggest uric acid is an important risk factor for adverse vascular outcome. 
Allopurinol may also be a promising preventative strategy.  Serum uric acid predicts poor 
functional outcome following acute stroke but not in an independent fashion. There was no 
evidence of an association with favourable outcome as other groups have found. Increasing 
serum uric acid was also shown to be predictive of increased risk of stroke, total, vascular 
and coronary mortality in treated hypertensive patients but interestingly, the relationship   - 235 - 
between  stroke  mortality  and  serum  uric  acid  appears  J-shaped  and  most  apparent  in 
females. 
 
Allopurinol  was  shown  to  improve  cerebral  nitric  oxide  bioavailability  suggesting  a 
beneficial  effect  of  allopurinol  on  cerebrovascular  health.  However,  allopurinol  did  not 
improve cerebrovascular reactivity (as measured by response to acetazolamide infusion) in 
a  group  of  patients  with  recent  subcortical  stroke.  This  raises  interesting  questions 
regarding the longevity of any positive effect of allopurinol as this, and other studies of 3 
month duration, have revealed no benefit. Further, subjects in this neutral study did not, on 
balance, have elevated serum uric acid and it has recently been suggested that only those 
with  significantly  elevated  levels  benefit  in  the  setting  of  congestive  cardiac  failure.  
Further  work  should  establish  whether  this  is  also  true  in  those  with  regard  to  stroke 
prevention.   - 236 - 
 
 
 
 
 
CHAPTER FIVE 
 
 
 
FUTURE DIRECTIONS 
 
    - 237 - 
Stroke is a common disorder with dire consequences for the patient and for society and will 
increase  in  prevalence  over  the  coming  years.  Following  stroke,  many  patients 
unfortunately suffer a further stroke, and recurrent strokes account for approximately 25% 
of the total. Considerable scope therefore exists to improve both primary and secondary 
stroke prevention.  This thesis has addressed several areas at key stages in the prevention of 
stroke by developing strategies to better identify those at highest risk, attempting to better 
target pre-existing anti-platelet therapy and by beginning the evaluation of xanthine oxidase 
reduction and uric acid lowering therapy in the prevention of stroke. 
 
A clinical scoring system to aid diagnostic recognition in those with suspected transient 
ischaemic attack (TIA) was successfully developed and has the ability to reduce the referral 
of those without cerebrovascular disease to busy TIA clinics. This would have a substantial 
effect on waiting times  for assessment; a key  aim  given the recent evidence that rapid 
assessment and treatment of those with TIA greatly reduces stroke risk. Further work to 
evaluate and introduce the score to routine clinical practice is required.  It is planned to 
incorporate use of the scoring system into the referral process to our TIA clinic. It will be 
established whether, when used by General Practitioners, the scoring system can identify 
those without TIA whilst safely identifying those with true TIA. The potential impact on 
services will also be assessed.  
 
Aspirin resistance was confirmed to be a common phenomenon, although the role of poor 
compliance with therapy as a cause in a substantial number of cases was established. This 
suggests that objective measures to confirm aspirin ingestion should be mandatory in future 
studies  of  aspirin  resistance.    Aspirin  resistance  was  also  higher  in  those  with 
cerebrovascular microembolic signals (MES) and carotid disease compared to those with   - 238 - 
equivalent carotid disease and no  MES. This provides a link to  a well established and 
robust surrogate marker of outcome and thus a useful model to further study the benefits of 
guided  anti-platelet  strategies.  An  interventional  clinical  anti-platelet  trial  based  upon 
individual aspirin responsiveness in high risk individuals such as those with MES is now 
warranted and funding will be sought for this in the near future. 
 
Increasing  serum  uric  acid  was  found  to  be  a  predictor  of  poor  functional  outcome 
following acute stroke but not in an independent fashion. However, there was no evidence 
of an association with favourable outcome as other groups have found. Increasing serum 
uric acid was also shown to be predictive of increased risk of stroke, total, vascular and 
coronary  mortality  in  treated  hypertensive  patients  but  interestingly,  the  relationship 
between  stroke  mortality  and  serum  uric  acid  appears  J-shaped  and  most  apparent  in 
females.  A study of the use of allopurinol in those with diabetes showed that XO inhibition 
improves  cerebral  NO  bioavailability  suggesting  a  beneficial  effect  of  allopurinol  on 
cerebrovascular  health.  However,  a  study  of  the  effect  of  allopurinol  treatment  on 
cerebrovascular reactivity (as measured by response to acetazolamide infusion) in a group 
of patients with recent subcortical stroke revealed no positive effect.  This raises interesting 
questions  regarding  the  longevity  of  any  positive  effect  of  allopurinol  as  it,  and  other 
studies of 3 month duration, have revealed no benefit. Further, subjects in this study did not 
on balance have elevated serum uric acid and it has recently been suggested that only those 
with  significantly  elevated  levels  benefit  in  the  setting  of  congestive  cardiac  failure.  
Whether this is also true in those with stroke also requires to be clarified. A large study of 
the effect of allopurinol on carotid intima-media thickness, a robust and modifiable marker 
of vascular risk, in those with recent stroke is planned to address these questions. 
   - 239 - 
The  planned  study  is  a  randomised,  double-blind  placebo  controlled  pilot  study  to 
investigate  benefit  of  2  years  allopurinol  300  mg  on  change  in  carotid  intima-media 
thickness in those with recent stroke. Levels of endothelial progenitor cells and circulating 
markers of endothelial function and safety and clinical endpoint data will also be gathered 
assessed.  The trial will require approximately 500 participants to be followed for a two 
year period to ensure adequate power. The study hypothesis is that allopurinol will reduce 
IMT progression rate, increase levels of EPCs and reduce levels of circulating endothelial 
markers with no increase in serious adverse events. The study will begin in May 2009 and 
take five years to complete.   - 240 - 
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